checkAd

    DNAG: Hass oder Liebe - dazwischen geht nichts! - 500 Beiträge pro Seite

    eröffnet am 27.07.05 15:54:39 von
    neuester Beitrag 12.02.07 16:30:17 von
    Beiträge: 232
    ID: 996.013
    Aufrufe heute: 0
    Gesamt: 7.235
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 27.07.05 15:54:39
      Beitrag Nr. 1 ()
      Auf speziellen Wunsch von hvs1, der ja ein besonderes „Händchen“ dafür hat, andere Board-Teilnehmer zu Eröffnung eines Threads zu „überreden“, und da der Titel des Vorgängerthreads – wann, wenn nicht 2004? – auch nicht mehr so richtig aktuell ist, hier also eine Zusammenfassung meiner jetzigen Sicht der Dinge:

      DNAG hieß bis vor kurzem noch DNAP und war unter diesem Symbol nicht so ganz unbekannt.
      Im Juli 05 wurde ein Resplit im Verhältnis 1:20 durchgeführt; seitdem ist das Symbol DNAG und die WKN ist A0ETWM.

      Hass oder Liebe? Es sprechen starke Argumente für beide Gefühle!

      Ich fange mit der negativen Seite an: : Die große Gefahr einer Dilution (Verwässerung)
      Vor dem Resplit hatte DNAP (jetzt DNAG) 1,5 Milliarden Aktien genehmigt (authorized shares a/s), davon ca. 1,4 Milliarden ausgegeben (outstanding o/s).
      Durch den Split 1:20 halten die Alt-Aktionäre jetzt nur noch 70 Millionen Aktien. Da sich aber an der Gesamtzahl der autorisierten (genehmigten) Aktien nichts geändert hat, hält die Firma jetzt die restlichen ca. 1,43 Milliarden Aktien und kann diese im Prinzip auf den Markt bringen.
      500 Millionen davon sind schon vorsorglich angekündigt worden.
      Und da die Firma nur unwesentliche Einkünfte (revenues) erzielt im Vergleich zu den laufenden Ausgaben (Gehälter, Mieten, Geräte usw.), ist sie zum Überleben darauf angewiesen, ihre Kosten durch den Verkauf eigener Aktien zu bestreiten. Und das tut sie auch!
      Ergebnis: Es werden ständig neue Aktien auf den Markt gedrückt, der pps (price per share, Kurs) zeigt im Langfrist-Bereich eine starke Tendenz Richtung Süden.
      Die Alt-Aktionäre, die früher einmal aus welchen Gründen auch immer eingestiegen sind und der Firma das Start-Kapital gegeben haben, sind im Moment absolut die Ge@rschten! Die Firma weiß das, aber sie kümmert sich nicht drum! Kann sie auch nicht, denn sie will ja überleben.
      Und das Schlimmste: Es gibt momentan keinerlei konkreten Hinweis darauf, dass sich diese Situation in absehbarer Zeit ändern könnte.

      Also: Hände weg von dieser Aktie; bestenfalls beobachten und ein wenig Mitleid mit den Longs empfinden. Im Moment kann man zu einem absoluten Tiefstpreis rein (splitbereinigt).

      Wenn es keine positiven Seiten gäbe, hätte ich diesen Thread nicht eröffnet: The cutting edge, die technologische Spitzenposition!
      Und jetzt wird’s kompliziert. Denn was eine technologische Spitzenposition ist, lässt sich einem Laien nur schwer vermitteln.
      Einige Sachen sind ziemlich klar:

      1) Ancestry by DNA, das Angebot zur Klärung der genetisch/rassischen Herkunft

      2) DNAWitness, welches bei einem Verbrechen Hinweise auf den möglichen Täter geben kann. Hier gibt es schon ein wenig Geheimnistuerei, denn die Strafverfolgungsbehörden (z.B. FBI) wollen die Kriminellen möglichst im Unklaren lassen, mit welchen Methoden sie arbeiten.

      Diese beiden Punkte beinhalten das Brot- und Buttergeschäft von DNAG, bringen aber längst nicht die notwendigen Einkünfte für den ganzen Betrieb.

      Viel wichtiger sind die Zukunfts-Aussichten im Bereich der personalisierten Medizin.
      Zum Beispiel die Vorhersage der Wirkung (oder Nichtwirkung) eines speziellen Medikaments auf eine spezielle Person aufgrund deren spezieller DNA.
      Wenn in dieser Richtung – evtl. in Zusammenarbeit mit Forschungsinstituten oder Pharmakonzernen - der Durchbruch erzielt werden könnte, könnte der Kurs gewaltig explodieren.
      Apropos Zusammenarbeit: DNAG hat einen 18%-Anteil an der deutschen Biofrontera AG erworben und evtl. die Möglichkeit, diesen Anteil am Jahresende noch erheblich auszuweiten.
      DNAG arbeitet mit dem Lee Moffitt-Center zusammen, einem renommierten Krebs-Forschungsinstitut.
      DNAG hat vom Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) die Exklusiv-Lizenz erworben eine besser und länger wirkende Version ihres Anämie-Medikaments EPO zu entwickeln (Super-EPO).

      Hier noch eine Zusammenfassung der Dinge, die DNAG momentan in der Röhre hat (einschließlich Forschungsprojekte und klinische Tests. Diese Zusammenstellung (Stand Juli 2005) habe ich mit Erlaubnis ihres Autors aus einem amerikanischen Board (I-Hub) kopiert:

      MILESTONES FOR FORENSICS AND CONSUMER MARKETS

      ANCESTRYbyDNA 2.0….R/D 2000-01… 4Q 2002 market… Mar2004*replaced w/ V2.5
      ANCESTRYbyDNA 2.5….R/D 2003….Feb2004 market….Feb2005 Portable Microarray System
      ANCESTRYbyDNA 3.0…………………………… ………R/D 2005………2006 market?
      EURO-DNA 1.0…………………………R/D 2003……….......4Q 2004 market
      DNAWitness 2.0….R/D 2002…………….2003 market……...2004*replaced w/ V2.5
      DNAWitness 2.5 …R/D 2003...July 2004 market…Test kit - late 2005 ...global sales 2006
      DNAWitness 3.0………………………………...............R/D 2005 (3.0 to include eye color)
      EURO Witness 1.0………………………………R/D 2004………….Feb2005 market
      RETINOME 1.0 Eyecolor. …R/D 2003....4Q 2004 market…Test kit - late 2005…global sales 2006
      RETINOME HA Haircolor…….R/D 2004….2005-06 validate…..2007 beta test……..2008 market?
      SKIN SHADE………………………………….R/D 2005-07……2008 market?
      AMERIND 1.0…………………………………R/D 2005-06……2007 market?
      Genetic Family Tree DB………….………………………………R/D 2004………….online 2005
      Searchable Ancestry Genealogy DB…………...R/D 2003…….online 2004……….expand 2005
      Searchable PhotoAncestryDB (Forensics)……R/D 2003……..online 2004………..expand 2005
      DNA Database for Native Americans…develop 2003/2004….expand 2005
      DNA Database for African-Americans….develop 2005

      * NEW– Forensics – 3D BIOMETRICS Imaging System for fuzzy photo ………Jun 2005 develop…

      * NEW – ACQUISITION– Trace Genetics - genealogy, forensics, and molecular diagnostics ……..Jun 2005…

      MILESTONES FOR PHARMACOGENOMICS AND THERANOSTICS

      Drugs and Predictive Drug Classifier Test Combinations

      1) Ovanome - Taxol/Carboplatin efficacy
      * R/D 1998…Announce Mar 2000…Validation Studies 2002-2004…Clinical Study May 2005…FDA IND late 2006….

      2) Statinome - Lipitor, Zocor, efficacy, liver, muscle adverse myalgia response
      * R/D 1998….Clinical Studies late 2004/early 2005…FDA IND 2007?...Market?...

      3) Acenome - Enalapril, Lisinopril efficacy, muscle, adverse cough
      * R/D 1998….Clinical Studies late 2004/early 2005…FDA IND 2007?...Market?...

      4) BC-LOH – Breast Cancer (DNAP/Moffitt)
      * R/D 2003…………………Clinical Studies 2005/2006…..FDA IND 2007-8?...Market?

      5) Ondansetron – Chemo-nausea (DNAP/Moffitt)
      * R/D 2003…………………Clinical Studies 2005/2006…..FDA IND 2007-8?...Market?

      6) Melphalan/Topotecan – Multiple Myeloma (DNAP/Moffitt)
      * R/D 2003…………………Clinical Studies 2005/2006…..FDA IND 2007-8?...Market?

      7) Xeliri/Xelox – Colon Cancer (DNAP/Moffitt)
      * R/D 2003…………………Clinical Studies 2005/2006…..FDA IND 2007-8?...Market?

      8) Immunosuppressants - Sirolimus, Tacrolimus, Mycophenolate
      * R/D 2001…NYU Open R/D?….

      9) Acute Lymphocyte Leukemia (ALL)
      * R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?…..

      10) Cervical Cancer and Environmental Tobacco Smoke
      * FAMRI Grant Feb 2003….2 year grant….Publication 2006?....

      11) Super EPO Anemia Drug
      * License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA IND late 2006/early 2007….
      * DNAP exclusive worldwide license to develop a Super EPO drug with a $10 billion dollar market potential.
      * NEW - Jun 2005
      – Consulting contract with inventor/patent-holder to help DNAP develop super EPO drug
      – Contract for CRO to manufacture super EPO drug for pre-clinical testing, ready Fall 2005

      * Latest News – Another New Acquisition (July 13, 2005)

      DNAPrint Genomics Acquires 18% Interest In Biofrontera, A Small German Pharmaceutical Company With 3 Drugs Already In Pipeline

      Biofrontera’s Drug Pipeline (now Biofrontera/DNAG) :

      12) BF-Derm1 - for antihistamine-refractory urticaria – in Clinical Phase II Trials….2006/2007 market

      13) 5-aminolevulinic acid (ALA) - for actinic keratosis – in Clinical Phase II Trails….2007/2008 market

      14) 5-HT2B receptor antagonist - for migraine prophylaxis - in Preclinical Development…2010 market

      * Biofrontera milestone note: Biofrontera stated its intentions to do an IPO stock offering in Europe, which of course if it happens, it will bring additional value to DNAG investors.

      --------------------------------------------------------------------------------------
      Hinweis: Die obigen Angaben sind nachzulesen in Pressemitteilungen, Newsletters oder Filings für die SEC.


      Ergänzungen, Hinweise, evtl. Berichtigungen sind herzlich willkommen bzw. werden von mir von Zeit zu Zeit geliefert.

      Gruß an alle Investierten und (noch) nicht Investierten

      Michi
      Avatar
      schrieb am 27.07.05 22:28:26
      Beitrag Nr. 2 ()
      Thankx Michi,

      100000 Fleiss-Punkte ...

      Aber wo wäre der Kurs jetzt ohne Split ?

      Das Problem :

      Wenn er (Tony) denn wirklich evtl. vielleicht usw. die Stecknadel findet...

      Das was dann kommt sprengt alle Vorstellungen...

      Deshalb bleibe ich bei meinem strong buy ganz unten am A....

      Ich warte bis 5 cent - aber rein gehts wieder !!!

      >>> Come to da moon with DNAP <<<



      cu - Croko
      Avatar
      schrieb am 27.07.05 23:29:24
      Beitrag Nr. 3 ()
      croco

      Life is live!

      . . . und meinen croco lese ich immer wieder gerne!

      forever
      Michi
      Avatar
      schrieb am 28.07.05 10:11:28
      Beitrag Nr. 4 ()
      Ja, schreiben wir denn jetzt hier weiter?
      Habt Ihr schon mal einen nackten Mann gesehen?
      Soll ich noch was nachkaufen?
      Wart Ihr schon mal in einem türkischen Gefägnis?

      Fragen, Fragen, Fragen ...... :confused:

      g4
      Avatar
      schrieb am 28.07.05 12:44:16
      Beitrag Nr. 5 ()
      g4, einige Antworten:

      Ja, schreiben wir denn jetzt hier weiter? - Dafür gibt es weder Regeln noch Zuständigkeiten!
      Habt Ihr schon mal einen nackten Mann gesehen? - Ja!
      Soll ich noch was nachkaufen? - Ja!
      Wart Ihr schon mal in einem türkischen Gefägnis? - Nein!

      Gruß
      Michi :laugh:

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 28.07.05 20:01:54
      Beitrag Nr. 6 ()
      Moin Michi,

      hab mir gerade überlegt bis zu den Kaufkursen bei DNAP nochg ein wenig Vogelfutter zu verstreuen...

      Dabei habe ich gedacht das Fieber ist wech - nun kommt es (nach fast 2 Jahren)langsam zurück......

      Croko
      Avatar
      schrieb am 28.07.05 22:06:48
      Beitrag Nr. 7 ()
      Moin croco,

      ährlich gesacht: Im Moment hab ich mich auf 0 shares runtergearbeitet (in Worten: Null).
      Ich habe einen ziemlichen :mad: auf das, was da managementmäßig im Moment abgeht und denke, dass der downtrend voll intakt ist :cry:.
      Hat aber nix mit der Eröffnung dieses Threads zu tun, das war mal wieder an der Zeit.

      Ich mach etz erstmal zwei Wochen Urlaub in der Schweiz (Cariocca holladihööhhh!), halte mein bißchen Pülverchen trocken und dann schaugn mer mal.

      Wenn`s in der Zwischenzeit explodieren tut, hab ich halt Pech gehabt.
      Aber das mit dem Explodieren ist vermutlich nicht so dringend.

      Gruß
      Michi
      Avatar
      schrieb am 28.07.05 22:09:27
      Beitrag Nr. 8 ()
      dept to equity
      Und gearscht sind die Altaktionäre ...
      That`s life ;-)))
      Avatar
      schrieb am 10.08.05 17:35:53
      Beitrag Nr. 9 ()
      eieieieieiei .......... :(
      Avatar
      schrieb am 10.08.05 17:50:06
      Beitrag Nr. 10 ()
      Ups - da sind ja meine 5 cent

      Warte aber die Woche noch ab - eigentlich wollte ich wieder Spazen kaufen - aber für 5 cent gabs in F nix... :look:

      Nu habe ich die Kohle erstmal in Knight und Patriot gesteckt...

      Mal sehen...

      Croko
      Avatar
      schrieb am 15.08.05 17:41:30
      Beitrag Nr. 11 ()
      Hello and back again in Germany.

      Ist ja genau das eingetreten, was ich vor meinem Urlaub vorausgesagt/befürchtet habe.
      Ein Down-move nach dem Resplit.

      Aber nicht ganz so weit, wie ich erwartet habe.

      Wie auch immer, ich steige mal wieder mit einem begrenzten Betrag ein: Kauf zu 0,07.

      Let`s see. Croko, was erwartest Du??

      Michi
      Avatar
      schrieb am 15.08.05 19:33:26
      Beitrag Nr. 12 ()
      Avatar
      schrieb am 16.08.05 18:03:46
      Beitrag Nr. 13 ()
      Hi Michi,

      wo warst Du denn?

      Wenn ich so überlege,dass meine Euro 85.000,-
      nur noch etwa $ 10.000,- wert sind,fällt es mir nicht leicht nachzulegen.:mad::mad::mad:
      Ich warte noch etwas ab.
      Meine ICGE laufen ganz ordentlich.

      hvs1
      Avatar
      schrieb am 17.08.05 08:57:29
      Beitrag Nr. 14 ()
      Hi Michi,

      habe mal weiter vorn gelesen.Du warst also in der Schweiz.
      Ich hoffe,Dein Urlaub war schön.Hast Du denn Cariocca ge-
      troffen?
      DNAG geht noch weiter abwärts,schöne Scheisse.:mad::mad:

      hvs1
      Avatar
      schrieb am 17.08.05 09:11:29
      Beitrag Nr. 15 ()
      Hi hvs1

      Schön war`s wieder mal in der Schweiz!
      Zu Cariocca habe ich keinen Bezug mehr, ich wüsste nicht, warum wir uns also treffen sollten.
      Meine Entscheidung, aus DNAG komplett rauszugehen, war im Nachhinein richtig; ich hätte es nur schon viel früher tun sollen.
      Cariocca hatte früher mal geäußert: "Wenn ich auch nur von Ferne etwas von einem Resplit höre, laufe ich weg, so schnell ich kann." Recht hat er!

      Jetzt bin ich wieder mal vorsichtig mit 3.000 Dollar bei 0,07 eingestiegen. Vielleicht noch zu früh, aber man weiß ja nie. Wenn sie noch weiter fallen, kaufe ich vielleicht noch mal nach, aber immer vorsichtig.

      Glückwunsch zu Deinen ICGE

      Gruß

      Michi
      Avatar
      schrieb am 17.08.05 18:08:53
      Beitrag Nr. 16 ()
      . . . und warum ging der Kurs heute hoch?

      Deshalb: http://www.usatoday.com/news/nation/2005-08-16-dna_x.htm

      US today ist eine weit verbreitete Zeitschrift in den USA.
      Will heißen: DNAG ist jetzt bekannt.
      Und wenn jetzt eine gute PR draufgesetzt wird, . . .

      Michi
      Avatar
      schrieb am 17.08.05 18:26:08
      Beitrag Nr. 17 ()
      Ist aber wieder mal nur das übliche Strohfeuer.

      Wer rechtzeitig dabei ist, kann einige Doller bei so einem kurzfristigen Upmove gutmachen.
      Die Longs gucken wie immer unentschieden aus der Wäsche und warten weiter ab.
      So do I!

      Michi
      Avatar
      schrieb am 17.08.05 18:41:30
      Beitrag Nr. 18 ()
      WEIAH!!

      2,25 Millionen shares Umsatz bis jetzt!
      Das entspricht 45 Millionen vor dem RS!! :eek: :eek:
      Avatar
      schrieb am 23.08.05 01:15:22
      Beitrag Nr. 19 ()
      Hi Michi,

      bin wieder rein - zu 5 cent ;)

      Die Order stand schon seit Wochen....

      Jetzt nehme ich noch die Spazen mit und dann ist die Mischung komplett ;)

      cu Croko
      Avatar
      schrieb am 23.08.05 23:20:28
      Beitrag Nr. 20 ()
      Here is a letter from the CEO:

      August 22, 2005
      Dear Shareholder,

      Many of you may have read the USATODAY news article (8-16-2005 http://www.usatoday.com/news/nation/2005-08-16-dna_x.htm?POE… published August 16, 2005 concerning the successful application of DNAPrint`s forensic technology to a criminal investigation surrounding the unidentified, decapitated body of a three year old girl found in Kansas City, Missouri. Based on the evidence analyzed by DNAPrint, authorities now believe the victim, dubbed "Precious Doe," was beaten to death by her parents. This tragic case offers compelling and tangible support to DNAPrint`s ongoing efforts in the field of forensic DNA research and technology is DNA evidence of the type analyzed successfully in the Precious Doe case is relatively new. But it is clear to DNAPrint and too many of our customers and supporters, that this technology offers a valuable tool to criminal investigators and law enforcement. DNAPrint has assisted criminal investigations in other notable cases listed below. If you like, you may, do a "google` search for them on the Internet and learn more about them. Additionally, our DNAWITNESS™ web site will be up and running soon. This site will also discuss ongoing criminal cases, news and media links relevant to our forensic products and technology.

      We hope that high profile news coverage of cases like "Precious Doe" encourage more detectives, forensic scientists and medical examiners to utilize the benefits offered by our DNAWitness technology. We are constantly seeking ways to expand the market and educate potential consumers for our products. But federal funding for this type of service is sorely lacking and the technology is still relatively new. We appreciate the courage and persistence of our customers and look forward to assisting other criminal investigations in the future

      The DNAWITNESS™ product suite now includes:

      DNAWITNESS 2.5 -- Assists detectives, forensic scientists and medical examiners in constructing a physical portrait from crime scene DNA, which can be used to corroborate eyewitness reports and/or provide direction for a criminal investigation. DNAWITNESS 2.5 provides a BioGeographical Ancestry report that includes a photo database for reference samples of individuals. Reported ancestral origins are Sub-Saharan African, Native American, East Asian and Indo-European.

      EUROWITNESS™ 1.0 -- Tests crime scene DNA to determine more specific geographic origins if the test sample ancestry is 50% or more Indo-European. In some cases this may enable a more specific physical portrait for the DNA donor. EUROWITNESS 1.0 provides a BioGeographical Ancestry report that includes relative percentages of Northwest European, Southeastern European, Middle Eastern or South Asian.

      RETINOMES™ -- A predictive test for individual eye color from DNA. Retinome predicts eye color if the sample is 50% or greater European ancestry. Prediction classes include blue, mostly blue, brown or mostly brown. Representative materials from an eye photo database that match the sample are provided for visual reference.

      STR-Witness™ -- A genetic "matching" used as a bar code to track and report the samples. STR is the same test used for determining an individual`s identity of an available DNA sample. Crime labs run this test to screen the Federal Bureau of Investigation`s Combined DNA Index System (CODIS) database for possible matches.

      DNAWitness-Y -- A new Y-chromosome test that determines the direct paternal ancestral lineage from the male sex chromosome. DNAWitness-Y can be used as an identification tool in cases where a mixture of male and female samples exists.

      The following is a short list of cases that we have been involved with. A few are more notorious than others and for some have resulted in a very large press following for DNAPrint. We would like to see more of that coverage as the public, the police, the detectives, medical examiners and forensic scientists need to be informed that DNAWITNESS™ exists, and it can help them solve their cases.

      Louisiana Serial Killer-The Louisiana Serial Killer case came to our attention after a presentation to the forensic community in late 2002. Nearly 2,200 Caucasian males had been screened in Louisiana, based mostly on eyewitness reports that cited a "white male in a white pickup truck" spotted near the scene of two murders. A woman had also reported breaking away from a "white male in a white truck" who tried to accost her. Our report to the task force concluded that the DNA sample came from a person who was 85% sub-Saharan African and 15% Native American, clearly not a Caucasian male. Within six weeks of our report, a DNA sample was obtained from an individual was matched with the crime scene DNA. The suspect promptly fled but was later apprehended in Atlanta, Ga., and extradited to Baton Rouge. The man, Derrick Todd Lee, has since been convicted for two counts of murder. He remains a suspect in at least six other cases.

      Boulder, Colorado Case- A young woman left her boyfriend`s home after an argument. She was found the next day beaten to death and raped. Despite DNA screening of a significant number of potential suspects, there were no matches and the investigation went cold. The crime scene DNA was loaded into the CODIS database system and in 10+ years there have been no additional hits. Upon analyzing the DNA that was sent to us, we concluded that the genetic ancestry of the sample donor was a mixture of Native American, East Asian and Caucasian, and that from our patent-pending database matching method, these results indicated that this individual was not from the Caucasian community. Up until this time, only white males were considered as possible suspects. The investigation has been re-opened as a result of our findings.

      Concord, Calif. Case- A working mother never returned from a walk in the park on her lunch break. Her body was discovered later beaten to death and raped. Asian and Hispanic gangs reportedly had been operating in the park and according to several eyewitness reports members were seen in the vicinity of the crime. Crime scene evidence analyzed by DNAPrint, however, revealed that the suspect was 95% Indo-European or Caucasian. Based on the DNAPrint testing results, the investigation`s focus shifted to a small number of Caucasian individuals who were in the park and had been interviewed previously by police. One of these suspects immediately fled the area after providing a DNA sample. He was later apprehended in another state and has now been charged with rape and murder.

      Mammoth Lakes Case- In May 2003 the remains of a body were unearthed in a shallow grave near the resort town of Mammoth Lakes, California. The remains were sent to the San Francisco Medical Examiner`s office, which determined that the victim was a woman, 30 to 40 years old, of Southeast Asian ancestry. The medical examiner`s findings were corroborated by eyewitness reports of a short possibly Asian woman in the area complaining about an abusive spouse or significant other. In August 2004, however, investigators shifted the focus of their investigation after a DNA sample sent to DNAPrint for analysis determined that the victim was 100% Native American.

      The Minstead Case -- We were contacted by Scotland Yard and the London Metropolitan Police to evaluate a DNA sample obtained from an individual believed to be responsible for nearly 90 incidents of reported breaking and entering, theft, assault and rape of elderly women in London. We were asked to determine, if possible, the suspect`s ancestry. Based on the fact his sample contained a minor component of Native American ancestry, we believed he was from the Caribbean Islands and not from continental Africa. The pool of potential African male suspects in London between the ages of 30 and 45 number in the 50,000+ range. To build this case, we needed a larger number of reference samples from the Caribbean Scotland Yard and the Metropolitan Police sent a representative to the Caribbean to collect volunteer samples from the Caribbean police and forensic workers. Through the application of our forensic technology, we narrowed the suspect pool significantly from 50,000+ to around 500 to 1,000 individuals.

      You may also have noted our efforts with Penn State University, including the use of a 3-D imaging camera. We will be scanning the photos and searching for additional genetic markers. We hope that some day not too distant, DNAWITNESS will include a 3-D imaging capability that is reconstructed from a composite of DNAWITNESS photo database samples and DNA markers, creating a `fuzzy photograph` for detectives in 3-dDimaging.

      The benefits we derive from the forensics market has a direct application to our research and product development in the pharmacogenomics market If we are able to discern a person`s eye color, hair color or bone density from a DNA sample and we are able to link it to other descriptive or phenotypic markers, then we have a much better chance at predicting whether or not a patient will or will not respond to a particular drug or treatment. In effect, forensics is our training ground.


      Thank you for your support.,

      Company Contact:
      Richard Gabriel
      CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848
      Avatar
      schrieb am 24.08.05 21:28:09
      Beitrag Nr. 21 ()
      Hallo croko altes Haus (seit Neustem mit fettem Anstrich :cool: ),

      habe mich soeben an dein Beispiel gehalten und nochmal nachgelegt, zu 5 US-Cent.

      Aber jetzt ist erst mal Schluss mit verjuxen. Jetzt sollte mal was kommen.
      Avatar
      schrieb am 25.08.05 00:44:04
      Beitrag Nr. 22 ()
      Hi Michi,

      Du hast Mehl :)

      cu Croko
      Avatar
      schrieb am 26.08.05 11:07:40
      Beitrag Nr. 23 ()
      Begeistert bin ich nicht gerade:
      75.000 Dollar + 2.000.000 Aktien zu 0,05 macht zusammen 175.000 Dollar.
      Und wofür das Ganze? Damit mehr Investoren geworben werden können, um weitere (firmeneigene) Aktien an den Mann zu bringen! Also weitere Verwässerung!
      Nachhaltige eigene Einkünfte der Firma wären mir lieber.

      Hier die Meldung:
      Form 8-K for DNAPRINT GENOMICS INC

      25-Aug-2005

      Entry into Material Agreement


      Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
      Financial Consulting Agreement with Market Pulse, LLC

      On August 19, 2005 the Registrant and Market Pulse, LLC ("Market Pulse") entered into a Financial Consulting Agreement ("Agreement"). Under the Agreement, Market Pulse will develop a program to increase investor awareness of the Registrant, including profiling the Registrant for three months on Market Pulse`s website and in its online newsletter sent to subscribers once a week for the next three months. Additionally, Market Pulse has agreed to distribute the Registrant`s press releases to its subscribers, and may, in its sole discretion, issue investment opinions based on the press releases.

      In exchange for the financial consulting services provided to Registrant, Market Pulse shall receive $75,000 and two million restricted shares of the Registrant`s common stock.
      Avatar
      schrieb am 27.08.05 18:58:28
      Beitrag Nr. 24 ()
      Michi,

      nächste Woche nochmal 1000 Doller und dann warte ich mal ab - habe ein gutes Gefühl wie damals... ;)

      Von EK 2,5 cent auf bis 18 glaube ich... :) - bin leider nich ganz oben raus aber knapp 400% in die Tasche :D

      Die Frage ist wann hat die Verwässerung ein Ende....

      Aber mal was zur "soliden" Geldanlage - was hälst Du von Süss Microtec ???

      cu & happy WE - Croko
      Avatar
      schrieb am 27.08.05 21:03:21
      Beitrag Nr. 25 ()
      Croko,

      ich sehe schon, wir laufen im Moment investitionsmäßig parallel. Ich habe damals im Juni 03 beim Anstieg auf 17 oder 18 Cent auch einen wunderbaren Schnitt gemacht. Vielleicht ist das der Grund, dass ich immer noch dabei bin und auf ein zweites Wunder hoffe.
      Aber ich bin hier SEHR vorsichtig geworden, denn die Gefahr der Dilution ist vielfach größer als die Wahrscheinlichkeit dieses Wunders.

      Was Süss angeht: Da war ich Ende der 90er Jahre mal investiert, bin dann rechtzeitig mit einem kleinen Gewinn raus und habe mich seitdem nicht mehr drum gekümmert.

      Auch Dir ein schönes Rest-Wochenende

      Michi
      Avatar
      schrieb am 29.08.05 16:19:59
      Beitrag Nr. 26 ()
      eieieieieiei .......... :eek:
      Avatar
      schrieb am 29.08.05 17:20:59
      Beitrag Nr. 27 ()
      Die neuen Vierteljahres-Zahlen sind da:
      (genauso besch*** wie der momentane Kursverlauf)

      http://finance.yahoo.com/q?s=DNAG.OB

      PERIOD ENDING 30-Jun-05 31-Mar-05 31-Dec-04 30-Sep-04
      Total Revenue 349 241 137 166
      Cost of Revenue 260 150 54 127

      Gross Profit 89 91 83 38

      Operating Expenses
      Research Development 495 302 328 192
      Selling General and Administrative 483 603 368 674
      Non Recurring - - - -
      Others - - - -

      Total Operating Expenses - - - -


      Operating Income or Loss (890) (815) (614) (828)

      Income from Continuing Operations
      Total Other Income/Expenses Net (7) (69) (319) -
      Earnings Before Interest And Taxes (897) (884) (933) (828)
      Interest Expense 11 22 15 18
      Income Before Tax (908) (906) (948) (846)
      Income Tax Expense - - - -
      Minority Interest - - - -

      Net Income From Continuing Ops (908) (906) (948) (846)

      Non-recurring Events
      Discontinued Operations - - - -
      Extraordinary Items - - - -
      Effect Of Accounting Changes - - - -
      Other Items - - - -


      Net Income (908) (906) (948) (846)
      Preferred Stock And Other Adjustments - - - -

      Net Income Applicable To Common Shares ($908) ($906) ($948) ($846)



      Add to Portfolio Set Alert Email to a Friend

      Get Income Statement for Another Symbol: Symbol Lookup


      • Sector Analysis




      Sign Up for a Free Trial to EDGAR Online Premium!
      Get the critical business and financial information you need for more than 15,000 U.S. public companies.
      Sign Up Now - Learn More
      Avatar
      schrieb am 01.09.05 09:59:54
      Beitrag Nr. 28 ()
      Michi,

      habe heute trotzdem noch einmal 225.000,- zu 0,033 nachge-
      legt.Mal sehen was so kommt.

      hvs1:D
      Avatar
      schrieb am 01.09.05 10:37:14
      Beitrag Nr. 29 ()
      hvs1

      Ui! Das wären 4,5 Millionen nach "alter" Rechnung! :eek:

      Mutig bist Du ja!

      Übrigens: In USA hat einer prophezeit, dass DNAG Ende dieser Woche bei 0.1 stehen würden (allerdings hat der sich schon einige Male vertan).
      Wenn ich heute welche zu 0,03 kriege, fasse ich noch ein paar Stücke nach (aber nur noch sehr vorsichtig)

      Michi
      Avatar
      schrieb am 01.09.05 10:43:19
      Beitrag Nr. 30 ()
      hvs1

      Ui! Das wären 4,5 Millionen nach "alter" Rechnung! :eek:

      Mutig bist Du ja!

      Übrigens: In USA hat einer prophezeit, dass DNAG Ende dieser Woche bei 0.1 stehen würden (allderdings hat der sich schon einige Male vertan).
      Wenn ich heute welche zu 0,03 kriege, fasse ich noch ein paar Stücke nach (aber nur noch sehr vorsichtig)

      Michi
      Avatar
      schrieb am 01.09.05 11:00:27
      Beitrag Nr. 31 ()
      Sorry für das Doppelposting,
      aber nachdem mein Beitrag 5 Minuten lang nicht erschienen war, dachte ich, es war nix.
      Avatar
      schrieb am 02.09.05 21:25:31
      Beitrag Nr. 32 ()
      @Michikita :)

      "Take me down to da paradise city" :lick:

      Tony bekommt jetzt jede Woche Post - setz mal ne email auf - ich denke mal Dein englisch ist besser....

      Mich hat es in die Abfallverwertung verschlagen (Kölner Unkraut geht eben nich kaputt) - habe immer gedacht die verbrennen das alles :rolleyes:

      Irgendwann wenn wir alt sind sehen wir uns in der Stadt der Engelchen und treten Henry in den Arsch...

      (Darf ich das hier so schreiben...??? ):laugh::laugh::laugh:

      Cu Croko
      Avatar
      schrieb am 09.09.05 11:14:15
      Beitrag Nr. 33 ()
      Michi,

      haben wir den Grund erreicht?
      Vor dem RS wären das 0,0012.

      Gruß hvs1
      Avatar
      schrieb am 09.09.05 13:03:59
      Beitrag Nr. 34 ()
      hvs1

      der Downtrend hat eine so klare Linie, dass ich befürchte, es geht noch ein gutes Stück weiter so.
      Das kann nur eine Bomben-News ändern.

      Ich bin zum Glück nur sehr vorsichtig investiert und werde auch in nächster Zeit nicht nachkaufen. Momentan ist jeder Kauf zu früh.

      Gruß

      Michi
      Avatar
      schrieb am 09.09.05 17:29:37
      Beitrag Nr. 35 ()
      hvs1,

      und noch ein kurzes Wort: Das Management kümmert sich erwiesenermaßen einen Scheißß um ihre Alt-Aktionäre.
      Wer ihnen zu Beginn das Geld gegeben hat spielt überhaupt keine Rolle mehr. Es wird dilutet auf Teufel komm raus, völlig unerheblich was Tony F. so verbal von sich gibt.

      Gabriel und seine Miss Tamborini als Geschäftsführer gönnen sich ein fürstliches Gehalt, das höher ist als die Einkünfte der Company; finanziert wird alles über Neuausgabe von Aktien.
      Und wenn die fast alle sind, wird ein Resplit gemacht und die Story geht von vorne los. Denk mal dran, was Deine ürsprünglichen Aktien jetzt noch wert sind! ZUM HEULEN!!
      Ich befürchte, wir werden früher oder später noch einen weiteren Resplit sehen. Und dann wären unsere letzten Käufe auch absolute Fehlkäufe gewesen.

      Meine momentane Einschätzung: DNAG ist kein Longfrist-Invest. Ich stimme Croko zu: Auf der Lauer liegen und im richtigen Moment zuschlagen. Das hat momentan die größte Erfolgswahrscheinlichkeit.

      Klingt zwar übel, ist aber Ergebnis meiner langjährigen Erfahrung mit dieser Company.

      Gruß Michi
      Avatar
      schrieb am 12.09.05 18:54:01
      Beitrag Nr. 36 ()
      Leute, nur weiter so!!!
      Immer mehr an die Öffentlichkeit-Medien!!!!!
      Er sollte auch mal sagen, wann kommen die §§§§§§§§§§§§§§§§:lick::lick::lick::lick::lick:


      DNAPrint genomics to Present at New York Society of Security Analysts Medical Services Industry Conference
      SARASOTA, Fla., Sept. 12, 2005 (PRIMEZONE) -- DNAPrint(TM) genomics, Inc. (OTCBB:DNAG) announced today that president and chief executive officer Richard Gabriel will be presenting at the Medical Services Industry Conference sponsored by The New York Society of Security Analysts (NYSSA) on Wednesday, September 21, at The Harvard Club, 27 W. 44th St., in New York City, at 3:10 p.m. Eastern time.

      Mr. Gabriel will provide an overview of DNAPrint genomics and its recent activities in the area of pharmacogenomics. Specifically, Mr. Gabriel`s presentation will focus on how the company utilizes recent genomics and chemistry advances to develop next-generation drugs ("theranostics") maximizing efficacy and minimizing side effects by tailoring medications for specific individuals.

      Mr. Gabriel`s presentation will be available by means of a live Web cast that can be accessed on the company`s Web site at www.dnaprint.com or at http://www.shareholder.com/DNAPrint/medialist.cfm. The Web cast, which includes a PowerPoint presentation, will also be archived.

      Those wishing to attend Mr. Gabriel`s presentation can register on The New York Society of Security Analysts, Inc., Web site at http://www.nyssa.org/eseries/source/Meetings/ibomeetregister…

      Conference attendees, including mutual and pension fund managers and analysts for the medical services industry, will have an opportunity to hear senior executives discuss the latest developments within the medical services industry sector.

      The New York Society of Security Analysts (NYSSA), established in 1937, is a non-profit organization that provides investment professionals a forum for the exchange of ideas and information. Its goals are to inform and educate investors and to advance the professional competence of investment professionals including portfolio managers, security analysts, investment advisors, and others involved in the investment process.
      Avatar
      schrieb am 12.09.05 20:05:49
      Beitrag Nr. 37 ()
      Die Paragraphen? :confused:

      Oder meinst Du die Dollers :D
      Avatar
      schrieb am 14.09.05 17:32:58
      Beitrag Nr. 38 ()
      Hi Michi - eine ist ausgeführt und eine offen - da ich direkt unter $.05 gekauft habe waren es schon 50% Minus :rolleyes:

      Jetzt (oder gleich) Kaufkurs 3 cents und dann ist Feierabend ;)

      Vielleicht klappt es ja mal wieder ....

      Nur dieses Mal verkrümmel ich mich bei 15 cent :D

      cu Croko
      Avatar
      schrieb am 14.09.05 17:49:53
      Beitrag Nr. 39 ()
      croco,

      sorry, versteh ich nicht!
      In USA liegt das momentane ask bei 2,5 Cent. Was meinst Du mit 3?
      Avatar
      schrieb am 14.09.05 17:58:12
      Beitrag Nr. 40 ()
      mein Durchschnitt ;)

      Bei mir geht es im Moment eh drunter und drüber (wann eigentlich nicht :rolleyes: ) - vielleicht habe ich mich ja falsch ausgedrückst :)

      Muss nochmal weg ne Wohnung ankucken...

      cu Croko
      Avatar
      schrieb am 15.09.05 18:07:00
      Beitrag Nr. 41 ()
      15 Sep 2005, 11:49am ET

      Last price:0.03 (25.00%)
      DNAG detailed pricing and financial information. Metric Value
      Day`s Low & High: 0.025 - 0.0315
      Open: 0.026
      Previous Close: 0.024
      Volume: 4,240,228 :eek::eek:

      Das wären vor dem R/S über 80 Mio. Aktien gewesen!!!!

      Gutes Zeichen!

      g4
      Avatar
      schrieb am 15.09.05 18:17:14
      Beitrag Nr. 42 ()
      g4

      und inzwischen sind wir noch ein Stückchen höher.

      Ich habe mir aber inzwischen abgewöhnt in Zahlen von vor dem Resplit zu denken.
      Warum?
      Es gibt 1.500 Millionen a/s (wie vor dem r/s) und das momentane ask liegt bei ca. 3,5 Cent. Auch vergleichbar mit dem pps vor dem r/s.

      Die Dinge sind wie zuvor, nur mit zwei Unterschieden:

      1) Die Firma kann wesentlich mehr shares verkaufen als vorher

      2) Die Alt-Aktionäre haben ca. 95% ihres Einsatzes in wenigen Monaten verloren, sind also die Gearschten.

      Gruß Michi
      Avatar
      schrieb am 15.09.05 18:56:23
      Beitrag Nr. 43 ()
      Shit,meine Order in F fängt an zu schimmeln...:cry:

      cu Croko :look:
      Avatar
      schrieb am 16.09.05 08:14:22
      Beitrag Nr. 44 ()
      Moin Michi!

      Also, ich habe meinen finanziellen Einsatz tatsächlich abgeschrieben* und sehe das Ganze nun nur noch von der heiteren Seite. :laugh:


      Gruß ... g4

      * Oder glaubt tatsächlich jemand von Euch, dass dieses Teil noch um rd. 4000% steigen könnte? ;)
      Avatar
      schrieb am 16.09.05 09:36:18
      Beitrag Nr. 45 ()
      G4,

      die Hoffnung stirbt zuletzt.
      Ja,ich glaube,daß das Ding noch um 4000% steigen kann,
      nur wann das ist,stehr in den Sternen.

      hvs1
      Avatar
      schrieb am 16.09.05 10:20:27
      Beitrag Nr. 46 ()
      hvs1

      absolut entscheidend ist, dass die Company endlich eigene Einkünfte erzielt. Und zwar in einer Höhe, dass insgesamt ein positiver Cashflow stattfindet.

      Solange die laufenden Kosten aus dem Verkauf von Aktien bestritten werden, solange verwässert wird und die Absicht besteht, dies auch weiterhin zu tun, solange wird es mit dem Kurs weiter runter gehen.

      Genügend selbst erwirtschaftete Einkünfte und dann noch ein Durchbruch im Bereich der personalisierten Medizin, und Deine Vorstellung von 4000% wird wahr.

      Gruß Michi

      Croko, keine Bange, Du kriegst sie noch billig genug!
      Avatar
      schrieb am 16.09.05 17:41:05
      Beitrag Nr. 47 ()
      g4

      wie sinnlos das Rückrechnen auf Resplit-Zeiten ist, siehst Du am heutigen Tag:

      Bisheriger Umsatz 5 Mill. Stück (wären 100 Mill alt)

      Schon realistischer: bid 2 Cent (wären 0,001 Dollar alt; ein zehntel Cent!!! :mad: )
      Avatar
      schrieb am 20.09.05 01:31:34
      Beitrag Nr. 48 ()
      Hi Michi,

      musste alles umstellen aufgrund einer vorerst räumlichen Trennung von meiner Frau... :rolleyes:

      Alles ausser Patriot steht zum Verkauf an - bin auf Wohnungsssuche in Köln und melde mich wieder...

      cu Croko ;)
      Avatar
      schrieb am 20.09.05 10:14:07
      Beitrag Nr. 49 ()
      Hi Croko,

      hast ja schon ein "bewegtes Leben"! :eek:

      Mach et jut!

      Michi
      Avatar
      schrieb am 27.09.05 14:48:28
      Beitrag Nr. 50 ()
      Tuesday = Newsday

      http://www.primezone.com/newsroom/news.html?d=86765

      Source: DNAPrint genomics, Inc.
      DNAPrint genomics Completes Initial Research for Production of Company`s First Pharmaceutical Product
      New Super EPO Test/Drug Combination Enters Preclinical Development Stage

      SARASOTA, Fla., Sept. 27, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) today announced the completion of initial research for the production of PT-401, a more powerful version of the anemia drug Erythropoietin (EPO), which has advanced into the preclinical development stage for the Company`s first pharmaceutical product.

      "Our research surveyed several potential host cells for the production of PT-401," stated Hector Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We have selected one that the research indicates will provide superior glycosylation, which is critical for the processing of PT-401. We anticipate that this will lead to greater therapeutic efficacy and later on will be beneficial to expediting regulatory approval. In addition, we have optimized the structure of the gene encoding PT-401, thus providing excellent production efficiency and an optimal structure/activity profile of the active compound. Our production schedule remains on target."

      DNAPrint(tm) obtained an exclusive worldwide license from Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC) in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin (EPO), which has a worldwide market exceeding $10 billion and which is growing at an average annual rate of 21%. Production of a Super EPO dimer is central to DNAPrint`s overarching strategy to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "Theranostics," which maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors. In June 2005, DNAPrint selected Proteos, Inc., to handle pre-clinical analysis of PT-401 and to manufacture the first batch of the new drug.

      About DNAPrint genomics, Inc.

      DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm).

      Forward Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      CONTACT: DNAPrint genomics Inc.
      Richard Gabriel
      President and CEO
      (941) 366-3400

      The Wall Street Group, Inc.
      Ron Stabiner
      (212) 888-4848
      Avatar
      schrieb am 27.09.05 16:50:06
      Beitrag Nr. 51 ()
      Versteh ich nicht:confused::confused:

      Eigentlich gute News, aber der Kurs sackt gemein ab!!!!!!!!!!!!:cry::cry::cry::cry:
      Avatar
      schrieb am 27.09.05 18:24:33
      Beitrag Nr. 52 ()
      Eristoff,

      es gibt mehrere Erklärungsmöglichkeiten dafür.

      Die für mich wahrscheinlichste: Die Company schmeißt JETZT heftig shares raus. Im Umfeld einer guten Nachricht geht der Kurs ein wenig hoch. Wenn sie jetzt zwei Millionen rauswerfen, haut das den Kurs nicht übermäßig in Grund und Boden. Ist zwar deprimierend für die Longs, aber that`s life!

      Weitere Möglichkeit: Es sind die Naked-short-seller, die unbedingt einen hohen Kurs vermeiden müssen.
      Ist aber alles Spekulation!
      Avatar
      schrieb am 30.09.05 09:15:40
      Beitrag Nr. 53 ()
      Hohe Umsätze und ein moderater Kursanstieg in den letzten Tagen.
      Ob da was im Busch ist?

      Ich habe mal ein wenig nachgefasst. Aber so wie sich die Igel vermehren: Gaaaaanz vorsichtig.

      Michi
      Avatar
      schrieb am 03.10.05 14:11:40
      Beitrag Nr. 54 ()
      . . . und wieder mal haben wir geholfen, einen Fall aufzuklären:

      http://biz.yahoo.com/pz/051003/87106.html

      DNAPrint genomics Forensics Technology Assists Police in Identifying Suspect in California Double Murder
      Monday October 3, 7:00 am ET

      SARASOTA, Fla., Oct. 3, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTC BB:DNAG.OB - News) today confirmed that its DNAWITNESS forensics technology narrowed down a list of potential suspects during a police investigation that led to an arrest in the murder of two women in Napa, Calif.

      The brutal stabbings of Leslie Ann Mazzara and Adriane Michelle Insogna, both 26, in a home they shared in the Northern California community, had stumped police for nearly 11 months because the women had no known enemies and there was no apparent motive. Police had speculated that the killer knew one or both of the victims.

      Being held in custody was a man identified by authorities as Eric Matthew Copple, 26, of Napa. Police conducted more than 1,300 interviews during the investigation and collected DNA samples from 218 individuals, all men who had social or work contact with all three roommates who lived in the home. A third woman escaped unharmed during the Nov. 1, 2004, attack and called police.

      The California Department of Justice Crime Lab and DNAPrint genomics previously determined that an analysis of blood samples collected at the crime scene indicated that the suspect was a male. Forensic evidence also pointed to a killer who smoked Camel Turkish Gold cigarettes, a hybrid of the popular cigarette brand. NapaPolice issued a statement to the media on Sept. 22, 2005, saying that DNAPrint genomics` forensics laboratory had further determined that the ancestry of the person of interest was white with 96% Northern European ancestry and 4% Southeastern European.

      ``We received a DNA sample from the Napa Police on Nov. 23, 2004 and returned the results of our DNAWITNESS analysis two days later,`` stated DNAPrint genomics President and Chief Executive Officer Richard Gabriel. ``More recently, the case was revisited when DNAPrint was asked to analyze the sample with our EUROWitness technology to further refine the information. With information from DNAPrint, the Napa Police Department did a media release describing a white male adult who smokes or did smoke Camel Turkish Brand Cigarettes.``

      The San Francisco Chronicle newspaper reported that Napa Police Department Investigations Bureau Commander Jeff Troendy confirmed that DNA-related evidence and the media release led to the arrest of Copple. Troendy was quoted as saying, ``The media release last week helped us get to this point, sometimes things happen very quickly.``

      About DNAPrint genomics, Inc.

      DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWitness RETINOME (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA, and EURO-DNA. Recently announced and as a part of the Company`s Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated. The Company`s first theranostic product (drug/test combination) is PT-401, a ``Super EPO`` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response

      Forward Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



      Contact:
      DNAPrint genomics, Inc.
      Richard Gabriel, President and CEO
      (941) 366-3400

      The Wall Street Group, Inc.
      Ron Stabiner
      (212) 888-4848


      --------------------------------------------------------------------------------
      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 12.10.05 22:28:54
      Beitrag Nr. 55 ()
      News-chen:

      http://biz.yahoo.com/iw/051012/097631.html

      Press Release Source: DNAPrint genomics, Inc.

      DNAPrint genomics Forms Pharmaceutical Subsidiary
      Wednesday October 12, 7:00 am ET

      New Unit Confirms Company`s Commitment to Development of Personalized Medicines

      SARASOTA, FL--(MARKET WIRE)--Oct 12, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it has established DNAPrint Pharmaceuticals, Inc., a new wholly owned pharmaceutical subsidiary focused on personalized medicine.

      "Since its inception, DNAPrint genomics successfully has leveraged its broad-based expertise in genomics into three business segments -- ancestry for the consumer market, forensics technology for law enforcement and pharmacogenomics -- personalized medicine based on a patient`s DNA," stated Company President and Chief Executive Officer Richard Gabriel. "With our ANCESTRYbyDNA(TM) and DNAWITNESS(TM) technologies serving as a foundation for the Company`s business, DNAPrint Pharmaceuticals is being targeted as the engine for further expansion and growth. We now have the corporate flexibility to concentrate on the pharmaceutical products we are currently licensing or have under development. To further finance this effort we will also be seeking funding for DNAPrint Pharmaceuticals."

      "We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company`s main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint`s Chairman and Chief Medical Officer, who will head the new subsidiary`s day-to-day operations. "We believe that test/drug combinations called `theranostics` are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company`s commitment to the development of these products."

      Data Monitor and the Pharmaceutical Manufacturer`s Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year, driven primarily by a flood of new drug targets and the increase in the U.S. demand for drug treatments as the baby boomer population ages. Many of these targets were identified through genomics, opening the way for DNAPrint genomics to develop theranostic drugs to reduce side effects and provide greater efficacy through accompanying genomic response tests designed to ensure that patients receive the appropriate medication and dosage.

      DNAPrint took a significant step in pharmaceutical development in July 2005 by acquiring an 18% stake in the German pharmaceutical company Biofrontera, which also has a number of compounds under development. Biofrontera is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.

      DNAPrint`s first test/drug combination is PT-401, being developed in collaboration with Harvard Medical School`s Beth Israel Deaconess Medical Center (BIDMC). PT-401 is a more powerful version of erythropoietin used for the treatment of anemia in renal dialysis patients (end stage renal disease). This "Super EPO" dimer protein drug is currently in pre-clinical development and will be targeted to patients with a genetic disposition indicating their propensity to have the best clinical response.

      DNAPrint is also collaborating with the H. Lee Moffitt Cancer Center on the development of two other pharmacogenomic products: OVANOME(TM), a test for predicting an ovarian cancer patient`s response to TAXOL/Carboplatin treatment, and STATINOME(TM), a test for predicting adverse response to cholesterol lowering medicines known as Statins.

      About DNAPrint

      DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Contact:
      Company Contact:
      Richard Gabriel
      President and CEO
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848

      -------------------------------------------------------------------------------
      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 27.10.05 20:29:49
      Beitrag Nr. 56 ()
      Diese News habt Ihr sicher schon gesehen, der Vollständigkeit halber nochmal hier:

      http://biz.yahoo.com/pz/051027/88606.html

      Press Release Source: DNAPrint genomics, Inc.

      DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
      Thursday October 27, 7:00 am ET

      SARASOTA, Fla., Oct. 27, 2005 (PRIMEZONE) -- DNAPrint genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.

      ADVERTISEMENT
      [-69780]
      ``Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality,`` stated Tony N. Frudakis, Ph.D., DNAPrint`s founder and Chief Scientific Officer. ``The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community.``

      Geneticists use ``molecular addresses`` to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar ``sequence`` addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.

      This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint`s unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.

      About DNAPrint genomics, Inc.

      DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company`s first theranostic product (drug/test combination) is PT-401, a ``Super EPO`` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint`s family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.

      Forward Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      DNAPrint genomics, Inc.
      Richard Gabriel, President and CEO
      (941) 366-3400

      The Wall Street Group, Inc.
      Ron Stabiner
      (212) 888-4848

      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 27.10.05 20:32:41
      Beitrag Nr. 57 ()
      Meine Meinung dazu:

      Im Gegensatz zu sich überschlagender Begeisterung in diversen Threads diesbezüglich hier onboard bin ich der Meinung, dass auch diesmal daraufhin kein gewaltiger Kurssprung erfolgen wird.

      Lasst Euch nicht verrückt machen; der Abwärts-Trend bleibt uns noch eine ganze Weile erhalten.

      Bin nicht froh drüber, ist aber meine Erfahrung!

      Michi
      Avatar
      schrieb am 28.10.05 09:35:47
      Beitrag Nr. 58 ()
      Hi,

      hier gibts doch nur eine Richtung !!!

      Insolvent, das ist ja nur Kapitalvernichtung pur und die Unterstützung eines Gehirnamputierten mit Namen Frukadis.

      Wer hier von bahnbrechenden Erfolgen erzählt, meint wohl die Kapitalvernichtung der letzten Jahren, sonst hat ja Frukadis nichts zu wege gebracht.

      Das ist ein Gehirnamputierter der liquitiert gehört.

      Opti...
      Avatar
      schrieb am 01.11.05 11:38:39
      Beitrag Nr. 59 ()
      Da hat sich DNAPrint wieder mal billig eine Firma und passende Technologie unter den Nagel gerissen:
      Kenna Technologies, Inc.

      Mit diesen Werkzeugen und Leuten könnten die klinischen Tests beschleunigt werden.

      Hier das Filing:

      FORM 8-K

      October 25, 2005
      DNAPrint genomics, Inc.

      Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

      On October 25, 2005, the Registrant entered into a Stock Purchase Agreement (the "Agreement") with the shareholders of Kenna Technologies, Inc., a Delaware corporation ("Kenna"). Kenna develops software and related technologies for building computational models that mimic complex biological systems. The Registrant expects that Kenna`s computational models will become key components for its development of more effective therapies and diagnostic products. In acquiring Kenna, the Registrant also gains access to Kenna`s BoneFusion and CellCycleFusion models, which simulate bone remodeling processes and molecular pathways. These pathways are common targets of current cancer therapies.

      Under the Agreement, the Kenna shareholders exchanged all of the outstanding shares of Kenna for 1,500,000 shares of the Registrant`s common stock. In addition, the Registrant agreed to hire certain key employees of Kenna, including Drs. Barbara Handelin and Tandy Herrin, who will support the clinical development of DNAPrint`s PT-401 with simulations to help design optimal clinical trials.
      Avatar
      schrieb am 01.11.05 11:40:00
      Beitrag Nr. 60 ()
      . . . und hier der Link zu Kenna Technologies:

      http://www.kennatechnologies.com/
      Avatar
      schrieb am 03.11.05 15:37:55
      Beitrag Nr. 61 ()
      Ich hatte in den letzten Tagen ein gutes Gefühl bezüglich DNAG aufgrund der Menge an positiver News.

      Deshalb habe ich gestern noch einmal nachgekauft; zu 0,0148.
      Gerade noch rechtzeitig.

      Die positive Richtung scheint sich heute fortzusetzen.
      Schaut mal auf den Tagesbeginn in USA:

      Jetzt schon eine Million über die Theke gegangen (nach 6 Minuten!!) und das ask steht momentan auf 0,0167 :eek: :eek:

      Leute, Croco: Vielleicht ist das jetzt DER Zeitpunkt!

      Alles natürlich nur meine Meinung!

      Michi
      Avatar
      schrieb am 03.11.05 15:45:59
      Beitrag Nr. 62 ()
      S C H E I § § E ! !

      Sie explodieren und ich hab kein Cash mehr!

      :cry: :cry: :cry:
      Avatar
      schrieb am 03.11.05 15:57:32
      Beitrag Nr. 63 ()
      Der Kurs beruhigt sich wieder etwas.

      Intervention der MMs? :confused:
      Avatar
      schrieb am 03.11.05 16:13:38
      Beitrag Nr. 64 ()
      Eines ist gerade klar geworden:

      0,02 ist die neue Widerstandslinie nach oben.

      Heute gab es (bis jetzt) einen deutlichen Abpraller.

      Wenn aber diese Linie durchbrochen wird . . . .
      Avatar
      schrieb am 03.11.05 16:29:41
      Beitrag Nr. 65 ()
      Avatar
      schrieb am 03.11.05 19:46:53
      Beitrag Nr. 66 ()
      Über 20 Millionen shares Umsatz allein heute.

      Warum? :confused: :eek: :confused:
      Avatar
      schrieb am 03.11.05 20:34:19
      Beitrag Nr. 67 ()
      Wieso schreibt ihr denn immer hier und nicht im Thread, wo auch die Kursdaten von DNAG sind????

      Da rede ich nämlich schon lange von dem Anstieg, den wir seit ein paar Tagen haben und dass ich auch noch mal nachgelegt habe. War heute sogar schon kurz im PLUS!!!

      Ich verkauf die Dinger nicht mehr. Ich glaub immer noch daran, dass mich DNAG reich macht!!:kiss:
      Avatar
      schrieb am 03.11.05 20:49:06
      Beitrag Nr. 68 ()
      [posting]18.562.528 von FCHennes am 03.11.05 20:34:19[/posting]Hennes!

      Ich bin schon ziemlich lange in DNAP investiert!

      Schon lange vor dem Resplit. Ich habe jede Menge Höhen und Tiefen mitgemacht.

      Ich gehöre zu denen, die von DNAP schlichtweg verarscht worden sind, weil ich nämlich meine shares im Verhältnis 1 für 20 gekürzt bekommen habe.

      Und der pps ist jetzt wieder der gleiche wie vor dem RS.

      Ich werde auf keinen kurzfristigen Jubel-Thread antworten.
      Ich biete und erwarte eine langfristige und ernsthafte Analyse dieser Firma.

      Nix für ungut ;)

      Michi
      Avatar
      schrieb am 03.11.05 21:17:50
      Beitrag Nr. 69 ()
      @Michiko

      Dann ham wa ja was gemeinsam: Langfristig dabei zu sein.

      Wenn die wieder bei 0,10 US-cent sind, dann kommst du wieder ins andere Board o.k.?
      Avatar
      schrieb am 04.11.05 08:15:43
      Beitrag Nr. 70 ()
      Hallo FC Hennes,

      was ist dein Kursziel in ferner Zukunft für die DNAG?`

      Gruß

      Gesalbter.:)
      Avatar
      schrieb am 04.11.05 16:17:40
      Beitrag Nr. 71 ()
      Ei der Daus!

      Und heute geht`s kräftig weiter bergauf!

      Schon über 20% plus bei über 16 Millionen gehandelten shares bis jetzt! :eek:

      Muss doch mal schauen, wo das herkommt!

      Michi
      Avatar
      schrieb am 04.11.05 18:25:37
      Beitrag Nr. 72 ()
      Mein (vorläufiger) Eindruck des heutigen Börsentags:

      Die Fima "lebt" momentan noch, mangels genügend eigener Einkünfte, vom Verkauf eigener Aktien.
      Das bedeutet Dilution - Verwässerung der Anteile der bisherigen Aktionäre.

      Heute wurden - bis jetzt - mehr als 30 Millionen shares über die Theke gereicht. Ein guter Teil davon dürfte von DNAPrint selbst kommen, zwecks weiterer Finanzierung der Unternehmens-Aktivitäten.

      Dennoch ist der pps nicht nur nicht gesunken, sondern sogar um ca. 20% bisher gestiegen.

      Das ist ein sehr gutes Zeichen!

      Es ist ein großes Interesse und Kaufbedürfnis am Markt vorhanden.

      Sieht gut aus! :)

      Schaun mer mal weiter!

      Michi
      Avatar
      schrieb am 04.11.05 20:56:52
      Beitrag Nr. 73 ()
      g4,

      haste heute nachgekauft?

      Wenn schon, denn schon! ;)

      Gruß

      Michi
      Avatar
      schrieb am 14.11.05 15:13:04
      Beitrag Nr. 74 ()
      News bezüglich Ovanome (Krebsbehandlung der Eierstöcke):

      http://biz.yahoo.com/iw/051114/0101019.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics and SeraCare`s Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
      Monday November 14, 7:00 am ET

      SARASOTA, FL and OCEANSIDE, CA--(MARKET WIRE)--Nov 14, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.

      "The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative`s extensive network of physician-managed centers with DNAPrint`s proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."

      "We anticipate that the study`s findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."

      This marks the second collaborative project between DNAPrint and Genetics Collaborative.

      About SeraCare Life Sciences

      SeraCare Life Sciences, Inc. is a manufacturer and supplier of biological materials and services essential for the use and manufacture of diagnostic tests and the discovery, development and commercial production of pharmaceuticals. The Company`s offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and the Global Repository®, comprised of clinical samples (DNA, RNA, tissue, and serum) for use in the drug discovery and development processes. SeraCare is headquartered in Oceanside, CA, and maintains facilities in Cambridge and West Bridgewater, MA; Frederick and Gaithersburg, MD; and Hatboro, PA. For more information please visit http://www.seracare.com.

      About DNAPrint

      DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

      Forward Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:

      Richard Gabriel
      President and CEO
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 15.11.05 14:47:54
      Beitrag Nr. 75 ()
      Aus Gründen der Vollständigkeit hier die News zur Beteiligung an Ellipsis Biotherapeutics:

      http://biz.yahoo.com/iw/051115/0101183.html

      Press Release Source: DNAPrint genomics, Inc.

      DNAPrint genomics to Acquire Ellipsis Biotherapeutics
      Tuesday November 15, 7:00 am ET

      Compatible Technologies Target Development Drugs for Personalized Medicine

      SARASOTA, FL--(MARKET WIRE)--Nov 15, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it has entered into an agreement to acquire the clinical genomics and genotyping assets of Ellipsis Biotherapeutics Corporation ("Ellipsis"), a privately held drug and diagnostic discovery company based in Toronto, Canada.

      ADVERTISEMENT
      Under terms of the agreement, Ellipsis is selling these core assets for 6,500,000 shares of DNAPrint genomics common stock. Pending completion of DNAPrint due diligence and Ellipsis shareholder approval, the transaction is expected to be completed by Nov. 30, 2005. DNAPrint will retain Ellipsis` employees, management and business operations. In addition, DNAPrint will retain the Ellipsis Biotherapeutics name and operate Ellipsis Biotherapeutics as a subsidiary of DNAPrint genomics.

      "Ellipsis has developed novel drug technologies and has spun those operations out," stated Hector J. Gomez, M.D., Ph.D., DNAPrint Chairman and Chief Medical Officer and head of its wholly owned DNAPrint Pharmaceuticals, Inc. subsidiary. "The value for DNAPrint is that Ellipsis` platform technology is highly compatible with our mission to expand our capabilities and increase our revenues."

      Richard Gabriel, DNAPrint President and Chief Executive Officer, noted that DNAPrint is actively involved in development of pharmacogenomics through in-house research, licensing agreements and the acquisition of synergistic technologies, all targeting future growth for the Company. "Our recent acquisition of Kenna Technologies, which builds computer models that mimic complex biological systems, as well as Ellipsis` synergistic gene platform applications, will broaden our capabilities and add to the growing number of products in our pipeline."

      Ellipsis is located in downtown Toronto adjacent to the academic health science complex and major teaching hospitals. Using the Beckman Coulter GenomeLab SNPstream and the Illumina Beadstation, Ellipsis performs contract SNP genotyping for academic centers, hospitals, human health care corporations and biotech companies. Its diverse services include human, plant and animal analyses.

      "We are very excited to become part of the DNAPrint group of companies," stated Dr. Laurence Rubin, Chief Executive Officer of Ellipsis. "Our core competencies provide a unique fit for the future growth and development of our contract services as well as opportunity to participate in novel research programs and collaborations."

      About DNAPrint

      DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

      Forward Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:
      Richard Gabriel
      President and CEO
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 15.11.05 14:49:57
      Beitrag Nr. 76 ()
      Tuesday = Newsday! Hier der 10QSB-Report:

      http://biz.yahoo.com/e/051115/dnag.ob10qsb.html

      Form 10QSB for DNAPRINT GENOMICS INC

      15-Nov-2005

      Quarterly Report


      Item 2. MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

      The "forward-looking statements" safe harbor does not apply to our company because we issue "penny stock" and are excluded from the safe harbor pursuant to
      Section 27A(b)(1)(C) of the Securities Act of 1933, as amended, and Section 21E(b)(1)(C) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Nevertheless, this Quarterly Report on Form 10-QSB contains forward-looking statements. In addition, from time to time, the Company or its representatives have made or may make other forward-looking statements orally or in writing. Such statements may include, without being limited to, statements concerning anticipated financial performance, future revenues or earnings, business prospects, projected ventures, new products, anticipated market performance and similar matters. The words "plan," "budget, "intend," "anticipate," "project," "estimate," "expect," "may," "might," "believe," "potential," "could," "should," "would" and similar statements are intended to be among the statements that are forward-looking statements. We caution our readers that, because such statements reflect the reality of risk and uncertainty that is inherent in doing business, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, those set forth in the Company`s Form 10-KSB for 2004 in the Management`s Discussion and Analysis of Financial Condition and Results of Operations under the heading "Certain Factors Which May Affect the Company`s Future Performance" which are incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this report. Except as otherwise required to be disclosed in periodic reports required to be filed by companies registered under the Exchange Act by the rules of the SEC, the Company has no duty and undertakes no obligation to update such statements.

      The following discussion and analysis should be read in conjunction with the balance sheets as of December 31, 2004 and September 30, 2005 and the financial statements for the three and nine months ended September 30, 2005 and 2004 included with this Form 10-QSB.

      Critical Accounting Policies

      The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that have a significant impact on the results we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Actual results may differ from these estimates under different assumptions or conditions. Below, we discuss this further, as well as the estimates and judgments involved.

      Asset Impairment

      We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In performing the review for recoverability, we estimate the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) is less than the carrying amount of the asset, an impairment loss is recognized. Otherwise, an impairment loss is not recognized. Management estimates the fair value and the estimated future cash flows expected. Any changes in these estimates could impact whether there was impairment and the amount of the impairment. Since we are in the development stage, we do not have much history to determine our estimated cash flows. If we do not meet our targeted cash flows for our services and if the estimated disposition of the equipment is lower, this could result in a write-down of our equipment. Our equipment is very specialized equipment related to genomics research, and there probably will not be a large demand for our used equipment. The amount of our net fixed assets is the amount of the maximum risk if our assumptions were not correct. Each year the assets will have higher depreciation and the maximum risk will decrease correspondingly.

      Allocation of Research and Development Costs

      Prior to 2004, our research and development costs were derived by allocating certain costs based on total labor effort. The percentage of total labor effort expended on research and development was an estimate by management. During 2004, we refined our process of allocating costs by identifying and directly expensing certain costs related to research and development and allocating certain other costs based on total labor effort that is estimated by management and employees. With some of these costs, a percentage of a total purchase order price is allocated to research and development. Also during 2004, we implemented a time card process that gives us a more refined estimate of certain employees` time. During 2005, as raw materials became significant, we began recording inventory for our raw materials. As the raw materials are used, they are charged to research and development expense based upon actual usage for research and development. We continue to refine our process of identifying time associated with research and development. These refinements to estimates could increase or decrease our income statement expense categories of research and development, cost of sales and selling, general and administrative. Over time we believe this change in allocating costs will result in a lower allocation of administrative costs to research and development. Also, as we hire employees, the department in which the employee is hired will have a direct impact on the allocation of administrative costs to research and development. For example if a person is hired in research and development, the allocation to research and development for other administrative costs will increase because labor effort percentage for research and development will have increased. If a person is hired in administration, the allocation to research and development for other administrative costs will decrease because the labor effort percentage for research and development will have decreased. Changes to these estimates could have a significant impact on the accrual and related compensation expense and/or deferred compensation.

      Valuation of Goodwill

      Goodwill is reviewed annually for impairment or more frequently if impairment indicators arise. This annual impairment test is performed in the last quarter of each fiscal year. The goodwill impairment test requires a comparison of the fair value of the Company to the amount of goodwill recorded. If this comparison reflects impairment, then the loss would be measured as the excess of recorded goodwill over its implied fair value. Although the Company`s management believes that the estimates and assumptions used are reasonable, actual results could differ.

      Estimation of Fair Market Value

      We use the Black Scholes Option Model to determine fair market value in certain instances (i.e. to value warrants and the intrinsic value of the convertible debt and non-detachable warrants). The Black Scholes Option Model requires estimated assumptions in its computation. We estimate the assumptions used in each calculation based upon the transaction term and what we believe most appropriately reflects the transaction. If different estimates of the assumptions were used, it could result in different fair market value amounts being calculated. Additionally, various methods can be used to determine the fair market value of the warrant. If a different model were used besides the Black Scholes Option Model, it could result in different fair market value amounts being calculated.

      Summary

      Although we have been in existence for a number of years, management`s efforts to develop our business have not yet resulted in the generation of significant revenues. We have chosen to focus on increasing sales volume in the consumer and forensic markets while continuing to develop products for introduction to the pharmacogenomics market. During 2005, we added seven new distributors to sell our consumer products.

      We continue to devote substantially all of our efforts in initiating and developing our planned principal operations. We have reported that while sales of our ancestry product, ANCESTRYbyDNA(TM) and paternity services have increased compared to the prior year, sales of forensic product DNAWitness(TM) and genotyping services decreased. Our new consumer product EURO-DNA(TM) 1.0 was introduced in the marketplace in late 2004. We acquired Trace Genetics late during the second quarter which will contribute revenues during the last half of 2005. Trace Genetics brings two new complementary technologies to our autosomal testing for determining the percentage of a person`s ancestry: Y-chromosome testing for tracing ancestry by following the direct paternal line and mitochondrial (mtDNA (TM)) testing for the direct maternal line. Trace also maintains one of the largest Native American mtDNA(TM) databanks which, when combined with DNAPrint`s, will be one of the largest in North America. Other similarly large databases are controlled by groups such as the Sorensen foundation, various Native American foundations and tribes, and some Universities. Our pharmacogenomics products are still in development. Because our products are relatively new to the market, we believe that sales will continue to fluctuate from period to period until we can better determine through continued market research and experience how and where to best market and sell the products.

      Management continues to implement and refine operational procedures and controls to support future growth and development. We intend to support research and development as a vital component of our overall growth strategy. Until potential customers are familiar with our technology and products, which will come from continued research and development and proven market use, it is unlikely that we will generate significant revenue.

      Management plans to continue to focus on increasing sales in the market areas of forensics and genealogy and to move towards the introduction of new and expanded products in these markets. During July 2005, we expanded our DNAWitness(TM) product suite which now includes:

      DNAWitness(TM) 2.5 -- Tests crime scene DNA to assist detectives, forensic scientists and medical examiners in corroborating eyewitness reports and confirming suspect identities. DNAWitness(TM) 2.5 provides a BioGeographical Ancestry report that includes a photo database for reference samples of individuals. Reported ancestral origins are Sub-Saharan African, Native American, East Asian and Indo-European.

      EuroWitness(TM) 1.0 -- Tests crime scene DNA to determine more specific geographic origins if the test sample ancestry is 50% or more Indo-European. EUROWitness 1.0 provides a BioGeographical Ancestry report that includes relative percentages of Northwest European, Southeast European, Middle Eastern or South Asian.

      Retinome(TM) -- A predictive test for individual eye color from DNA. Retinome(TM) predicts eye color if the sample is 50% or greater European ancestry as to whether eye color is blue, mostly blue, brown or mostly brown. A representative eye photo database is also provided along with relevant photo database pictures of the individual references.

      STR-Witness(TM) -- A genetic "matching" used as a bar code to track and report the samples. STR-Witness(TM) is the same test used for determining an individual`s identity from an available DNA sample. Crime labs run this test to screen the Federal Bureau of Investigation`s Combined DNA Index System (CODIS) database for possible matches.

      DNAWitness-Y(TM) -- A new Y-chromosome test that determines the direct paternal ancestral lineage from the male sex chromosome. DNAWitness-Y(TM) can be used as an identification tool in cases where a mixture of male and female samples exists.

      DNAWitness-Mito(TM) -- A new mitochondrial DNA test that examines ancestral lineages along the maternal line. DNAWitness-Mito(TM) can be used as an identification tool when other DNA testing fails to yield results or the DNA sample is too deteriorated.

      We plan to continue market research within both the forensics and genealogy segments to further expand our knowledge and understanding of the most efficient way to market and sell our products.

      In our pharmacogenomics segment, we will continue work on OVANOME(TM), a Taxol screening diagnostic test, and STATINOME(TM), a test for the cardiac drug market, which are both currently under development. We will also continue our efforts on other research and development projects that are underway. Our OVANOME(TM) technology is under development with researchers at the Moffitt Cancer Center in Tampa, Florida, and we are in the midst of completing an initial 80 person trial under an approved IRB (Internal Review Board) which approves all clinical trial related work at the center. We are also enrolling an additional 200 subjects to further validate and support the data we obtained in our earlier trial. We will continue to explore joint venture opportunities, particularly within the pharmacogenomic segment, in order to potentially expand our position within the pharmaceutical market. A major goal of our joint venture program is to seek opportunities for a drug pipeline acquisition. Our recent licensing of a `Super` Erythropoietin (EPO) molecule from Beth Israel Deaconess Hospital (BIDMC) is a step forward in that direction. We plan to combine our ability to screen patients and track patient response to the standard form of EPO when compared to our newer, `Super EPO`. We believe this will improve our clinical efficacy and reduce the unwanted side-effects of standard EPO treatment for anemia. We plan to begin development of our new product and have GMP material ready for early stage pre-clinical development work by or during the first quarter of 2006 in accordance with our licensing agreement with BIDMC.

      Additionally, on June 7, 2005, we entered into a consulting agreement with Dr. Arthur Sytkowski, the Director of BIMDC to consult on the development of a new, more potent and longer acting form of EPO. Under the consulting agreement, Dr. Sytkowski has agreed to perform certain consulting services, including advising on medical, regulatory and patent issues, training personnel and providing assistance with EPO research and development. Also during late June, we entered into a collaborative research agreement with BIDMC to provide three researchers to us over a six-month period to conduct certain research work related to our EPO research.

      We anticipate beginning to work with clinicians at Massachusetts General Hospital for patient monitoring of standard EPO treatment of Kidney dialysis patients. Assuming we file an Investigational New Drug Application (IND) and it is approved, we hope to commence clinical studies at Massachusetts General and other centers that will be identified over time. We do not anticipate filing an IND application with the FDA during 2006. At present we are developing a manufacturing process for the PT-401 and also preparing for cGMP manufacturing of the product for pre-clinical development work. We have retained an experienced developer and manufacturer of EPO like products, and we will be advancing this development effort through the balance of this year and into 2006.

      On October 25, 2005, we entered into an exclusive Licensing Agreement (the "License") with Dr. Mark Froimowitz to develop a series of methylphenidate analogs or Ritalin-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder ("ADHD"), and depression. The licensed compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the bloodstream, thus reducing a patient`s required daily dosage and the potential for drug abuse. We have the exclusive right to develop, use, market and sell products derived from the licensed compounds.

      On October 25, 2005, we acquired all of the stock of Kenna Technologies, Inc. ("Kenna"). Kenna develops software and related technologies for building computational models that mimic complex biological systems. We expect that Kenna`s computational models will become key components for our development of more effective therapies and diagnostic products. In acquiring Kenna, we also gain access to Kenna`s BoneFusion and CellCycleFusion models, which simulate bone remodeling processes and molecular pathways. These pathways are common targets of current cancer therapies. We exchanged 1,500,000 shares of our common stock for all the outstanding shares of Kenna. In addition, we hired certain key employees of Kenna, including Drs. Barbara Handelin and Tandy Herrin, who will support the clinical development of our PT-401 with simulations to help design optimal clinical trials.

      Internally, management will continue to develop and implement organizational policies and procedures to increase operating efficiency and move us closer to our goal of attaining and maintaining our planned principal operations.

      Our plan of operations for the ensuing twelve months includes efforts to: 1) increase sales of our existing products and services; 2) introduce new and expanded products and services in the genealogy and forensic markets; 3) continue promoting our genotyping and paternity services while continuing to concentrate on research and development for both our existing products and our anticipated pharmacogenomic products and services. We expect to add personnel in the laboratory and in administration, as growth warrants. Capital expenditures needed for the next twelve months are discussed below under the section entitled "Liquidity and Capital Resources".

      The following discussion of our historical financial results should be read against this background.

      Results of Operations

      Three and nine months ended September 30, 2005 compared to the three and nine months ended September 30, 2004

      Revenues and Cost of Sales

      During the three and nine months ended September 30, 2005 and 2004, revenues were $316,983 and $906,470 for 2005, respectively and $165,647 and $648,925 for 2004, respectively. A $151,336 increase in revenues for the third quarter from the prior period is a 91% increase while a $257,545 increase in revenues for the nine month period ending September 30, 2005 compared to the prior period is a 40% increase. In addition to the revenues recognized in the accompanying statement of operations, we also have recorded deferred revenues of $113,792 as of September 30, 2005. Deferred revenue resulted from some ANCESTRYbyDNA(TM) and EURO-DNA(TM) client testing that was not complete as of September 30, 2005. These amounts will be recognized as revenue in the fourth quarter of 2005.

      The approximately $151,000 increase in revenues for the three months ended September 30, 2005 compared to the same period in the prior year is mainly the result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $126,000, our paternity services increasing by approximately $10,000 and EURO-DNA(TM) revenues increasing approximately $31,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $60,000 from our genotyping services and $8,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.

      The approximately $258,000 increase in revenues for the nine months ended September 30, 2005 compared to the same period in the prior year is a result of our ANCESTRYbyDNA(TM) revenues increasing by approximately $136,000, our paternity services increasing by approximately $89,000 and our EURO-DNA(TM) revenues increasing approximately $74,000 compared to the same period in the prior year. These increases are due to our increased promotion and marketing of these services. We recorded approximately $16,000 of revenues from our mtDNA(TM) product, $11,000 of revenues from our DNAWitness-Mito(TM) and $10,000 of revenues from our Y-chromosome products which were added to our product line when we acquired Trace Genetics. This was offset by a decrease of approximately $78,000 from our genotyping services and $15,000 from our DNAWitness(TM) sales. In addition, we had approximately $15,000 of other revenues.

      Paternity sales are generated primarily through our various distributors and from our website www.ancestrybydna.com. The majority of the increase in sales during 2005 compared to 2004 was from a distributor that was added during the second quarter of 2004. Paternity testing is an add-on service, and we expect revenues to continue to fluctuate in this market. While we have not yet implemented a formal marketing and sales plan for this service, we continue to perform market research and gather information in order to define and implement a formal marketing strategy. One distributor accounted for approximately $105,000 of our paternity sales during the first nine months of 2005. We do not expect these revenues to continue for the balance of the year and are working hard to replace the potential short-fall. During the third quarter and into the last quarter we will be accelerating our direct marketing and mail campaign for our ANCESTRYbyDNA(TM) and DNAWitness(TM) products and services as well as the Trace Genetics products and services.

      Genotyping sales were generated primarily through work with universities with one university being our major client of this service. The decrease of genotyping services of approximately $60,000 during the third quarter of 2005 compared to the same period in 2004 and approximately $78,000 during the nine months ended September 30, 2005 compared to the same period in 2004 was the result of decreased service provided to one university. To date, our genotyping service customers have come to us either through client referrals or our general website. In the future, we plan to concentrate our genotyping services on specific diseases, including cancer, neurological disorders, and heart disease. By concentrating on specific diseases, we hope to develop an expertise that will attract customers in those areas requiring external assistance and additional research capacity. One university accounted for approximately $150,000 of our genotyping sales during the first nine months of 2005.

      As part of our on-going genotyping contract services work for one of our new customers, we have offered to perform ANCESTRYbyDNA testing services on 284 children suffering from a disease known as ALL or Acute Lymphocyte Leukemia and anticipate under a joint publication agreement to submit a manuscript for publication during 2006. Following this early pre-screening, the ALL program will test nearly 3,000 children afflicted with this disease in hopes that we will be better able to help the research hospital determine the genetic markers that are inherited and that may play a role in disease formation, advancement or remission. Treatment protocols or treatment regimes include multiple drug therapies and include, Taxol and Taxol like derivatives as well as other chemotherapy treatments and protocols. It is too early to determine the potential benefits to us, but we believe that our donation of our technology and services is crucial to the development of better and improved treatments for ALL. Currently, nearly 10-20% of the children afflicted with this disorder do not survive beyond 18-24 months after diagnosis. We believe that our technology combined with the research hospital`s other work and including the contracted genotyping work performed by us for them, may help in reducing this dreadful statistic.

      We continue to market our DNAWitness(TM) product through marketing to various agencies, our attendance at trade shows and through our relationships with Lynn Peavey catalog, Orchid Biosciences, and ReliaGene Technologies. We continue to seek to develop other distributors of our services and products. During 2004, our products, DNAWitness(TM) 2.0, RETINOME, and EURO-Witness 1.0 were featured in the Lynn Peavey Company catalog and the Lynn Peavey Web site. We trained Lynn Peavey Company personnel to establish and conduct seminars and training programs for detectives, crime laboratory personnel and crime scene personnel on DNAWitness(TM). Similarly, we have trained nearly 2,000 forensic personnel that include detectives, prosecutors and forensic scientists about our technology and its use. We anticipate continuing to train personnel on the use of our technology and products throughout 2005. Because these are new products and there are no similar products being marketed, we believe that forensic revenues will continue to fluctuate as we continue to research the markets and refine our sales and marketing strategy for our products. We have identified and applied for several grants and submitted our technology for federal review for applications that include human identification and terrorist tracking. We have not experienced and do not anticipate any funding of our research and development or deployment of our technology into any of these applications in 2005. We believe that the restraint of our sales in the forensics market does not originate from a lack of desire to use the technology by the detective or the prosecutor but rather a lack of funding for the increased staff that will be required to review cold case files, open new investigations or identify missing persons from stored human remains. We believe that the bulk of our investigative support will come through local and regional police, fire and detective agencies that do not require any federal funding to use our services and technology. We will however, continue to pursue much larger applications for our technologies on a global basis and will participate in several forensic and biometric venues in the remainder of 2005 that offer us a broad platform exposure to the world market. We are also seeking distributors of our products and services on a global basis applying our technology wherever the need could arise.

      During the third quarter of 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased approximately $126,000. This is due to increased awareness and interest in genealogy and increased advertising during the third quarter by us in several markets. During the nine months ended 2005 compared to the same period in 2004, our sales of ANCESTRYbyDNA(TM) increased by $136,000. When we introduced our ANCESTRYbyDNA(TM) 2.5 during 2004, we increased the pricing which has resulted in a lower volume of product sold, but at a higher margin. Also, the product is relatively new to the market, and we believe sales will continue to fluctuate from period to period until we can better determine through continued market research and time how and where to best market and sell . . .
      Avatar
      schrieb am 17.11.05 19:20:52
      Beitrag Nr. 77 ()
      Interview mit Richard Gabriel (Geschäftsführer von DNAPrint) über die Haupt-Geschäftsbereiche der Company

      http://www.dnaprint.com/welcome/pdf/DNAPrint.pdf
      Avatar
      schrieb am 18.11.05 17:03:06
      Beitrag Nr. 78 ()
      NEWS:

      http://biz.yahoo.com/iw/051118/0101735.html

      Press Release Source: DNAPrint genomics, Inc.

      DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum
      Friday November 18, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Nov 18, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that Dr. Barbara Handelin, the Company`s General Manager of Computational Biology, will be presenting before The Wall Street Analyst Forum Institutional Investor Conference at The Roosevelt Hotel, Madison Avenue at 45th Street, in New York City at 11:00 a.m. Eastern time on Wednesday, November 30.

      During the 40-minute presentation, which can also be heard via a live webcast on the Company`s website at www.dnaprint.com or at http://www.investorcalendar.com/CEPage.asp?ID=97888, Dr. Handelin will provide an overview of the Company and discuss its goals and outlook for the future. The webcast will also be archived. To register for the conference, please visit www.analyst-conference.com or contact The Wall Street Group, Inc. at 212-888-4848.

      The Wall Street Analyst Forum brings together financial analysts and portfolio managers who are interested in learning about the companies participating in the investor conference and provides them the opportunity to personally meet company personnel and learn more about the company.
      Avatar
      schrieb am 27.11.05 11:29:49
      Beitrag Nr. 79 ()
      Hi Michiko,

      hast Du rechtzeitig nachgekauft?

      hvs1
      Avatar
      schrieb am 27.11.05 11:58:00
      Beitrag Nr. 80 ()
      Hallo hvs1,

      ich bin zwar nicht mehr mit soviel Cash drin wie früher einmal (gebranntes Kind und so), aber so ca. 250.000 shares halte ich momentan.
      Die Jungs drüben in Ami-Land sind ja ganz aus dem Häuschen vor Begeisterung und erwarten ab nächsten Montag so alles Mögliche.
      Ich lass mich gerne zur Abwechslung mal positiv überraschen!

      Wie sieht`s mit Deinem Invest aus?

      Michi
      Avatar
      schrieb am 27.11.05 12:12:01
      Beitrag Nr. 81 ()
      hvs1,

      hast Du den Khandaker-Research-Report gelesen?
      Sehr empfehlenswert!

      http://www.khandaker.com/index.cfm?page=viewcompany&CoID=879…
      Avatar
      schrieb am 27.11.05 12:28:38
      Beitrag Nr. 82 ()
      Michiko,

      gib mir eine Kurzinfo aus Deiner Sicht.
      Danke im voraus.

      hvs1

      Sitze am Sonntag im Büro und arbeite.
      Avatar
      schrieb am 27.11.05 12:44:07
      Beitrag Nr. 83 ()
      hvs1,

      ich sitze selbst gerade am Schreibtisch, korrigiere Tests bzw. setze neue auf für die nächste Woche.
      Außerdem wartet die Family auf mich :laugh:

      Die Kurzfassung würde unseren Eindruck über die Möglichkeiten bestätigen, wegen derer wir seit längerer Zeit investiert sind.

      Wegen der "Feinheiten" empfehle ich Dir ein eigenständiges Studium des Reports. Muss ja nicht gleich sein.

      Schönes Restwochenende ;)

      Michi
      Avatar
      schrieb am 27.11.05 13:03:43
      Beitrag Nr. 84 ()
      Michiko,

      ich habe mir den Report ausgedruckt und nehme ihn
      mit nach Hause.Zu Hause habe ich meinen PC entfernt,
      da meine Frau gestreikt hat.Aus dem Büro direkt an den
      PC war ihr zuviel.Der Report ist 11 Seiten lang.Bin zwar
      Dr. der Ing.- Wissenschaften,aber mein Englisch ist grottenschlecht.Wird ne Zeit dauern,bis ich das Zeug ge-
      lesen und verstanden habe.Beim Überlesen aus dem Drucker
      habe ich auch den Eindruck,daß wir richtig liegen.
      Muß heute abend ins Arosa zum Adventessen,wird sicher gut
      werden.Wünsche Dir noch einen schönen 1. Advent.

      hvs1
      Avatar
      schrieb am 27.11.05 13:30:44
      Beitrag Nr. 85 ()
      Michiko,

      bevor ich nach Hause gehe,habe ich noch einmal im
      Investors-Hub die Message 349867 von Stockquire gelesen.
      Report von Khandaker,aber noch ausführlicher-23 Seiten-
      Mit Tabellen und Price Tarket.

      hvs1
      Avatar
      schrieb am 27.11.05 13:38:01
      Beitrag Nr. 86 ()
      Michiko,

      entschuldige bitte,war im Ranging Bull.

      hvs1
      Avatar
      schrieb am 27.11.05 13:52:03
      Beitrag Nr. 87 ()
      hvs1,

      ich schaue praktisch nie ins RB. Ist mir zu marktschreierisch.

      Danke für den Tipp.

      Michi
      Avatar
      schrieb am 27.11.05 16:39:56
      Beitrag Nr. 88 ()
      News:

      DNAPrint genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.

      http://biz.yahoo.com/pz/051027/88606.html
      Avatar
      schrieb am 27.11.05 19:48:58
      Beitrag Nr. 89 ()
      Die News ist vom 27.Oktober 05, nicht vom 27.November!!
      Avatar
      schrieb am 27.11.05 20:22:56
      Beitrag Nr. 90 ()
      Sorry, hast Recht!

      Ich war in Eile und habe nur den 27sten gelesen.
      Avatar
      schrieb am 28.11.05 15:27:51
      Beitrag Nr. 91 ()
      bid und ask über 4 Cent und schon 370 000 Stück vor dem Gong verkauft! :eek:
      Avatar
      schrieb am 28.11.05 15:30:22
      Beitrag Nr. 92 ()
      UIIII!!!!

      Ich glaube, heute geht es heiß her! :D
      Avatar
      schrieb am 28.11.05 15:36:09
      Beitrag Nr. 93 ()
      Jetzt der Rückschlag: bid und ask wieder knapp unter 4.

      Wenn jetzt ne gute News käme . . . . . .
      Avatar
      schrieb am 28.11.05 15:47:01
      Beitrag Nr. 94 ()
      Alles klar! :D

      Schon 14 Millionen über die Theke, bid und ask wieder über 4 Cent.

      Gutes Zeichen! :)
      Avatar
      schrieb am 28.11.05 16:47:46
      Beitrag Nr. 95 ()
      . . . und wieder runter!

      Würde mich mal interessieren, wieviele shares die company heute wieder auf den Markt geschmissen hat!

      Zweistellige Millionen-Umsätze, und trotzdem geht`s kaum hoch!?! :mad:
      Avatar
      schrieb am 29.11.05 16:43:28
      Beitrag Nr. 96 ()
      Ich habe in den letzten Tagen an einem Amerikanischen Börsen-Board (I-Hub) zum wiederholten Mal eine Beobachtung gemacht:

      der Kurs geht hoch . . .

      die Pusher sind plötzlich wieder da . . .

      mehrere gleichzeitig . . .

      der Kurs steigt weiter . . .

      bei hohem Kurs werden 40 Millionen Aktien geschmissen . . .

      der Kurs geht wieder runter . . .

      die Pusher sind plötzlich wieder verschwunden . . . !

      Same procedure as last year?

      Same procedure as EVERY year!

      Alles natürlich nur meine Meinung . . .

      . . . und Ähnlichkeiten mit Vorgängen in diesem Board sind natürlich nur rein zufällig!!!!!
      Avatar
      schrieb am 29.11.05 19:52:53
      Beitrag Nr. 97 ()
      [posting]19.091.894 von Michiko am 29.11.05 16:43:28[/posting]ist doch immer dieselbe masche an der otc:D

      hier etwas aus einem anderen thread


      DIE TÖDLICHE KUNST DER AKTIENMANIPULATION
      von einem unbekannten Autor in Kanada

      In jedem Beruf gibt es ein duzend oder mehr wichtige Regeln. Sie zu wissen ist ,was den Amateur vom Professional trennt. Sie nicht zu kennen? Lasst es mich so sagen: wie sicher würdest Du Dich fühlen, wenn Du plötzlich alleine eine Boeing 747 fliegst während sie auf der Landebahn landet?
      Wenn Du nicht gerade ein Berufsflieger bist, wärst Du zu Tode erschrocken und würdest Dir in die Hose machen. Behalte das in Erinnerung während Du diesen Artikel liest.

      ....weil ich Dir erklären werde, wie Manipulation des Marktes wirkt!

      Um erfolgreich zu spekulieren, sollte man eins voraussetzen: Die Small Cap Märkte bestehen in erster
      Linie, um dich zu schröpfen
      Ich spreche hier von Märkten wie Vancouver, Alberta, den OTC(Pinksheets, OTC BB u.a.)Man kann das auch auf andere Märkte ausdehnen wie Toronto, New York, Nasdaq, London ....

      Der durchschnittliche Investor wird nicht viel Erfolg haben mit dem Smallcaps-Glücksspiel ....
      Damit diese Märkte sich fortsetzen, müssen neue Verlierer in den Markt kommen. Die Annahme stimmt nicht ,dass solche verrückte Aktivität nur kurzlebig sein kann. Ich schlage eine andere Lösung vor.
      Was die Professionals und die Bankenaufsicht wissen und verstehen, aber der Rest von uns nicht, ist dies:

      Regel Nr. 1
      alle heftigen Preisbewegungen - ob rauf oder runter -sind das Resultat von einem oder mehreren(gewöhnlich einer Gruppe) von Professionellen, die den Preis manipulieren

      Das soll erklären, warum eine Minengesellschaft etwas Gutes findet und nichts passiert. Gleichzeitig, ohne irgendeinen offensichtlichen Grund, rast eine Aktie plötzlich nach oben bei niedrigem Volumen. Irgend jemand manipuliert die Aktie ,oft mit einem nicht begründeten Gerücht.

      Damit diese Manipulationen wirken, nehmen die Professionals an, dass (a)die Leute dumm sind und (b)die Leute vor allem kaufen, wenn der Preis der Aktie hoch ist und (c) verkaufen, wenn der Preis niedrig ist . Daher kann der Marktmanipulator solange erfolgreich sein, wie er die Menge kontrolliert

      Lasst es uns klar sagen: Der Grund ,warum Du in diesen Märkten spekulierst, ist dass Du gierig und optimistisch bist. Du glaubst, dass es morgen besser ist und Du musst schnell Geld machen Es ist diese Einstellung ,die der Marktmanipulator ausnutzt Er packt Dich bei Deiner Gier und Furcht für eine bestimmte Aktie! Wenn er will, dass Du kaufst, sieht die Zukunft der Aktie aus wie die nächste Microsoft.
      Sobald der Manipulator will, dass Du das sinkende Schiff verlässt, wird er plötzlich sehr vorsichtig mit seinen Bemerkungen über die Company. Dies bringt uns zu der nächsten Regel:

      Regel Nr.2
      Sobald der Marktmanipulator seine Aktien verkaufen will, wird er eine Good News Promotion Kampagne starten

      Hast Du Dich jemals gewundert ,warum eine bestimmte Company dargestellt wird als sei sie das Größte seit der Erfindung der Brotschnitte? Dies Sentiment wird bewusst hergestellt. Newsletterschreiber werden angeheuert- ob heimlich oder nicht- ,um einen bestimmten Wert hochzujubeln. Public Relation Firmen werden angeheuert und auf ein nichts ahnendes Publikum losgelassen. Kontrakte, um in Radiotalkshows zu erscheinen ,werden unterschrieben und ausgeführt. Eine Reklame- Kampagne beginnt(Fernsehreklame, Zeitungsanzeigen, Wurfsendungen)Die Banken kriegen billige Aktien ab, damit sie die Firma in ihren Kundenbriefen empfehlen. Die Firma tritt bei Investmentkonferenzen auf ,um Dir zu erzählen, wie wirklich ganz anders ihre Firma ist. Merkwürdige kleine begeisterte Threads tauchen in den Bords auf ,immer von der gleichen Sorte Pusher, je mehr, um so besser. Die HYPE geht los. Je cleverer ein Stock Promoter ist, um so besser sind seine Kenntnisse der Werbebranche. Kleine Tricks werden benutzt, z .B. lass eine völlig unbekannte Firma interessant aussehen indem du sie mit einer kürzlichen Erfolgsstory vergleichst. Das ist die Positionspredigt s. Ries und Trout; Der einzige Grund warum Du zu diesem anscheinend unglaublichen Bankett eingeladen wirst, ist der ,dass Du das Hauptgericht bist! Nachdem der Marktmanipulator Dich in sein Investment gesaugt hat indem er seine Papiere gegen Dein Geld getauscht hat, schließen sich die Mauern um Dich. Warum ist das so?

      Regel Nr.3

      Sobald der Manipulator seine Aktien verkauft hat, wird er eine Kampagne mit schlechten oder gar keinen Nachrichten starten

      Deine Lieblingsaktie stagniert oder geht etwas runter von ihrer Höhe. Plötzlich ist da ein Vakuum von News, entweder gar keine Nachrichten oder schlimme Gerüchte.......Keine Nachrichten mehr" tut uns leid, er ist nicht im Büro" oder " er wird nicht vor Montag zurück sein"

      Die wirklich aalglatten Marktmanipulierer werden sogar die Bords und die Journalisten entsprechend mit negativen Geschichten über die Firma füttern. Oder eine Propagandakampagne mit negativen Gerüchten auf allen Komunikationsebenen starten ,sogar jemanden anstellen, um den Preis zu drücken. Sogar jemanden anstellen, der den Analysten angreift, der zuvor begeistert über den Wert geschrieben hatte(Dies ist kein Spiel für Leute mit schwachem Herzen!)

      Du siehst die Aktie endlos dahintreiben, Du kannst sogar ein Gefühl der Hilflosigkeit entwickeln, so als ob Du im All schwebst ohne Rettungsleine. Das genau ist es ,was der Manipulator will (s.Regel Nr. 5)Veilleicht tut er dies ,um die tiefe Enttäuschung über einen missglückten Deal zu vermeiden. Oftmals hörst Du den Refrain " oh, das sind die jungen Unternehmen ...sehr riskant..." oder " 9 von 10 Firmen machen jedes Jahr pleite und dies ist eine Venture Capital Börse für junge Unternehmen" .Denke nicht, dass das nicht geplant war.!.....

      Regel Nr.4

      jede Aktie, die bei hohem Volumen zu einem hohen Preis gehandelt wird, signalisiert die Verkaufsphase der Professionals

      Als das Volumen geringer war, war auch der Preis niedriger. Die Professionals sammelten ein. Sobald der Preis steigt, erhöht sich das Volumen. Die Professionals kauften niedrig und verkauften hoch. Die Amateure kauften hoch ( und werden bald genug niedriger verkaufen)......Der Marktmanipulator wird alles in seiner Macht stehende tun, um Dich aus der Aktie draußen zu halten, manchmal indem Du hinausgeschüttelt wirst, solange bis der Preis zwei bis dreimal höher ist und er selbst genug Aktien eingesammelt hat.....Wann immer Du ein sehr hohes Volumen siehst, nachdem die Aktie um 75 grad gestiegen ist, hat die Verkaufsphase begonnen und Du wirst wahrscheinlich zum Höchstpreis ...kaufen.
      .......Erfolgreiche Kurzfristtrader gehen gewöhnlich aus einer Aktie raus, sobald das Volumen hoch ist, Amateure werden gierig und kaufen hier.

      Regel Nr.5

      Der Marktmanipulierer wird immer versuchen Dich zum Kaufen zu kriegen, wenn der Preis so hoch wie möglich ist ,und zum Verkauf beim niedrigst möglichen Preis

      So wie der Manipulator jeden nur möglichen Trick benutzt, um Dich zur Party einzuladen, wird er dich grausam und brutal von seiner Aktie vertreiben, sobald er Dich geschröpft hat .Die erste falsche Annahme ist die, dass der Stockpromoter dich reich machen will indem Du in seine Firma investierst. So beginnt eine Reihe von Lügen, die laufen solange wie es Dein Magen verträgt.
      Du kriegst den ersten Hinweis, dass er Dich getäuscht hat, wenn die Aktie bei dem höheren Level durchsackt. Irgendwie hat sie den Dampf verloren und Du weißt nicht warum. Tja ,sie hat den Dampf verloren, weil der Stockmanipulator aufgehört hat, sie zu pushen. Sie ist zu stark aufgebläht und er kann niemanden mehr überzeugen, sie zu kaufen. Das Volumen trocknet aus während der Preis durchzusacken scheint.

      Wenn dies ein wirklicher Deal ist, dann bist Du wahrscheinlich die letzte Person, die benachrichtigt wird und Du wirst zu einem niedrigeren Preis rausgetrieben

      ........Wenn der Manipulator dich aus der Aktie vertreiben will. wird es ein Orchester von Gerüchten geben, die zirkulieren, auf dich wird geschossen werden aus verschiedenen Richtungen...Du wirst den Beweis in einem sehr scharfen Absturz des Kurses sehen bei riesigem Volumen. Das bist Du und deine Kumpel, die nach dem Ausgang rennen. Wenn der Deal wirklich ist, will der Manipulator all deine Aktien oder so viel wie möglich kriegen zum niedrigst möglichen Preis. Der Marktmanipulator wird dich hinausschütteln ,indem er den Preis so niedrig wie möglich treibt, so kann er soviele Aktien wie möglich wieder einsammeln.(der Autor verweist hier auf verschiedene Mining Companies in Kanada)
      Die Phase des Einsammelns war tödlich still. Erst sobald die Insider all ihre Aktien eingesammelt hatten, haben sie dir ihr Geheimnis verraten!

      Regel Nr .7

      Du wirst der letzte sein, der informiert wird, wenn das Geschäft Zeichen von Schwäche zeigt

      Ein Rückblick wird Dir oft zeigen, dass da ein kleiner Rückgang im Kurs war ,gerade als die Bohrproben aufgeschoben wurden oder das Geschäft platzte. Die Manipulatoren begannen ihre Aktien zu verkaufen, um den Kurssturz einzuleiten. Und um dies zu beschleunigen. Der schnelle Absturz macht es dir unmöglich ,mehr dafür zu kriegen als Du bezahlt hast....und gibt Dir einen besseren Grund ,noch etwas zu warten falls der Kurs zurückkommt. Dann beginnt die Drifting Phase und Furcht überkommt dich. Wenn Du nicht gerade Nerven wie Stahlseile hast und es Dir leisten kannst ,den Stockmanipulator auszusitzen, wirst Du sehr wahrscheinlich die Aktien zu einem billigen Preis verkaufen. Denn der Insider ,Makler oder die emittierende Bank sind verpflichtet ,die Aktien zurückzukaufen, um die Firma am Leben zu erhalten und Kontrolle über sie zu behalten. Je weniger er dafür zahlen muss, um so niedriger werden die Kosten für eine neue Stockpromotion zu einem zukünftigen Zeitpunkt.. Auch wenn die Firma gar keine Zukunft mehr hat, wird doch der Mantel noch einen gewissen Wert haben....

      Regel Nr.8

      Der Marktmanipulator wird dich so in seine Aktie zwingen, dass du den Preis hochtreibst

      Er wird sein eigenes Papier kaufen, so dass Du nach einem höheren Preis langst. Er wird dich zu einem höheren Preis zwingen, indem er die Aktien zum laufenden Preis aufkauft. Man kann die Marktmanipulation vermeiden indem nicht kauft, zu den Zeiten des anormal hohen Volumens ,bekannt als: " die Aktie hochjagen zu einem höheren Preis"

      Regel Nr.9

      Der Marktmanipulator ist sich deiner Gefühle ,die du während des Anstiegs und des Absturzes erfährst ,wohl bewusst und wird damit spielen wie mit einem Klavier

      Während des Anstiegs wirst du einen Anfall von Gier haben, die dich zwingt in die Aktie zu investieren.
      Während des Absturzes wirst Du Angst haben, dass Du alles verlierst...daher wirst Du zum Ausgang rennen. Kannst Du sehen wie einfach es ist und wie klar eine Glocke läutet? Denke nicht ,dass dies Schema nicht in den Verstand eines jeden Marktmanipulators eintätowiert ist. Der Marktmanipulator wird dich den ganzen Weg rauf und runter manipulieren. Wenn er es sehr gut macht ,kann er es so aussehen lassen als sei jemand anderes daran schuld, dass Du dein Geld verloren hast. Du wirst wieder diese Aktie kaufen, er wird dich wieder so erschrecken, dass Du denkst ,du wirst jeden Penny verlieren. Du wirst vor Entsetzen davonrennen. Und schwören, dass Du nie wieder in solche Aktien investierst, Aber viele von Euch tun es doch. Der Manipulator weiß, wie er Dich zurückbringt zu einem neuen Spiel.

      Letzte Regel
      Ein neuer Schub von Zockern wird mit jedem neuen Spiel geboren

      Die Finanzmärkte sind ein grausames ,unfreundliches und gefährliches Spielfeld, ein Platz, wo die neuesten Amateure gewöhnlich am meisten geschröpft werden, von denen die die Regeln kennen. Es wird immer einen vertrauenden Dummen geben, den die tollwütigen Hunde in Stücke reißen So wie ich die Pflicht habe sicher zustellen, dass jeder von euch versteht ,wie dieses Spiel gespielt wird, so habt Ihr dieselbe Pflicht, dass Eure Mitspieler an der Börse diese Regeln verstehen .Wenn diese Bemühung von vielen eifrig unterstützt würde, könnten die Finanzmärkte vielleicht die unehrlichen Manipulatoren abschütteln und die Promoter könnten uns rechtmässige Spiele anbieten. Die Finanzmärkte sind ein Finanzierungswerkzeug. Die Firmen borgen das Geld von Dir, wenn Du in ihre Firma investierst oder spekulierst. Sie wollen, dass der Kurs steigt, so dass sie ihr Geschäft mit weniger Verdünnung ihrer Aktien finanzieren können.....wenn sie gute Leute sind. Aber wie würdest du fühlen über einen Freund oder ein Familienmitglied ,das Geld von dir pumpt und niemals zurückzahlt? Das wäre ganz einfach Diebstahl Also ist ein Marktmanipulierer jemand der dein Geld stiehlt.. Lass nicht zu, dass er das weiterhin tut.........Mach deine sorgfältige Recherche bevor du investierst. Such dir gute Companies mit denen du spekulierst und steig unten ein. Alles andere ist kriminell oder dumm!....
      Avatar
      schrieb am 29.11.05 19:58:46
      Beitrag Nr. 98 ()
      regel nr 4 kannste gut am chart erkennen.

      Avatar
      schrieb am 29.11.05 20:01:56
      Beitrag Nr. 99 ()
      [posting]19.095.168 von Corgar am 29.11.05 19:52:53[/posting]Corgar,

      ich sehe, inzwischen verstehen wir uns! :laugh:

      Ich habe diesen Artikel schon des öfteren gelesen. Man kann das nicht oft genug tun, wenn man im Revolver-Markt investiert ist.

      Hoffentlich bist Du nicht zu hoch bei DNAG eingestiegen!

      Langfristig bin ich jedenfalls nach wie vor positiv gestimmt; nur die Kurzfrist-Pusher mit ihrem Marktgeschrei gehen mir auf die Nerven.

      Alles Gute den wahren Longs.

      Michi
      Avatar
      schrieb am 29.11.05 20:03:04
      Beitrag Nr. 100 ()
      Ähem, die #100 hätte ich doch gerne für Mich ;)
      Avatar
      schrieb am 29.11.05 20:23:28
      Beitrag Nr. 101 ()
      [posting]19.095.296 von Michiko am 29.11.05 20:03:04[/posting]nein...bin öfters mal in otc werten und kann oft nicht glauben wie dreist die firmen sind. wenn dann steige ich so niedrig wie möglich ein und meistens auch nur mit spielgeld. ist für den nervenkitzel!
      Avatar
      schrieb am 29.11.05 20:36:59
      Beitrag Nr. 102 ()
      [posting]19.095.548 von Corgar am 29.11.05 20:23:28[/posting]Corgar,

      wie Du sagst: Es ist erstaunlich, wie dreist die Firmen sind.

      Und genauso erstaunlich: Es funktioniert!!

      Es muss wirklich entweder an der Dummheit oder an der Gier der Anleger liegen, dass immer wieder Cash in aussichtlose Companys gepumpt wird.

      In dieser Beziehung halte ich die Pusher für noch schädlicher als die Basher.
      Avatar
      schrieb am 29.11.05 20:43:55
      Beitrag Nr. 103 ()
      da kann jede klitsche der otc genommen werden...überall ist ein haken dabei. können oftmals die aussichten glänzend sein...es geht runter und runter. dann kapitalmassnahmen wie man als normaler mensch sie sich nicht ausdenken kann...manchmal hasse ich die otc dafür. andererseits sind auch kurskapriolen drin, wie sie rational auch nicht erklärbar sind...der rausch der börse. das liebe ich an der otc....kleine odysee an deinen thread!

      denke mal, jeder der an der otc spielt, sollte einen totalverlust einkalkuliert haben...dann kann nicht so viel schief gehen.:rolleyes:
      Avatar
      schrieb am 30.11.05 18:31:00
      Beitrag Nr. 104 ()
      Barbara Handelin von DNAPrint hat heute im Wall Street Analyst Forum vorgetragen.
      Es geht um die Entwicklungen und die Zukunfts-Aussicht der Company.

      Falls euch die aufgelegten Folien (slide-show) interessieren, oder besser noch, falls ihr direkt hören wollt, was sie gesagt hat, klickt mal hier rein: (Wenn ihr runter scrollt, könnt ihr die Folien abrufen)

      http://www.vcall.com/console/ConsoleFrameset.asp?ID=97888&br…
      Avatar
      schrieb am 30.11.05 20:46:35
      Beitrag Nr. 105 ()
      Sieht doch alles ganz gut aus, was die da machen. Wenn man das alles glauben darf..
      Avatar
      schrieb am 30.11.05 21:57:08
      Beitrag Nr. 106 ()
      Trooper2,

      genau DAS ist das Problem!

      Hört sich alles wunderprächtig an. Aber: Wann kommt Kohle rein in die Firma?

      Wann müssen sie nicht mehr von Dilution leben?

      Wann kann der pps nachhaltig steigen?

      Es gibt ne Menge Shareholder, die schon seit Jahren warten und heftig geblutet haben.
      Avatar
      schrieb am 30.11.05 22:08:18
      Beitrag Nr. 107 ()
      Beobachte DnaP. schon seit 2001, letzte Woche habe ich zum ersten mal gekauft und Mo. habe ich leider noch mal zugekauft, hätte mal noch warten sollen.
      So wie ich das sehe, wirt der Kurs mit kleinen Paketen gedrückt, also heute auf jeden Fall
      Avatar
      schrieb am 30.12.05 11:32:09
      Beitrag Nr. 108 ()
      Was wird DNAPrint mit dieser guten Million Dollar machen?

      8k-Filing:

      Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT


      On December 22, 2005, the Registrant issued to Dutchess Private Equities Fund II, L.P. (“Dutchess”) a promissory note (the “Note”) in the amount of $1,380,000 for a purchase price of $1,150,000.


      As previously reported, on September 28, 2004, the Registrant entered into an Investment Agreement (the “Investment Agreement”) with Dutchess, pursuant to which Dutchess has committed to purchase common stock of the Registrant up to an aggregate purchase price of $35 million over a two year period. The Dutchess Agreement provides that the Registrant from time to time may deliver a put notice to Dutchess, and Dutchess is obliged to purchase the dollar amount of common stock set forth in the notice.


      The Note is due and payable in full on December 15, 2006. Other than the discount inherent in its purchase price, the Note is noninterest-bearing. The Note will be repaid using 100% of the proceeds of each put notice delivered by the Registrant to Dutchess under the Investment Agreement. The Note is also secured by a security interest in substantially all of the Registrant’s assets pursuant to a Security Agreement with Dutchess.


      In connection with the Note, the Registrant also paid Dutchess a facility fee of $65,000 and issued to Dutchess a non-interest bearing convertible debenture in the amount of $330,000 payable on December 15, 2010. The shares of common stock underlying the debenture carry piggyback registration rights. The debenture may be converted at Dutchess’s option at a conversion price equal to the lesser of 75% of the lowest closing bid price during the 15 trading days prior to the conversion date or $0.022.


      http://www.sec.gov/Archives/edgar/data/1127354/0001231742050…
      Avatar
      schrieb am 31.12.05 13:44:32
      Beitrag Nr. 109 ()
      Was wohl wird sie mit der Kohle machen?

      Die unendlichen Löcher stopfen und Vorstandsgehälter zahlen ...
      Avatar
      schrieb am 14.01.06 16:54:35
      Beitrag Nr. 110 ()
      Davon könnte DNAPrint profitieren:
      (Eine Milliarde Dollar und DNAPrint Genomics wird eigens erwähnt!)

      PRESIDENT BUSH ALLOCATES 1 BILLION DOLLARS TO IMPROVE THE USE OF FORENSIC DNA TECHNOLOGY
      By Ben Butkus, Inside Bioassays editor

      NEW YORK, Nov. 3 (GenomeWeb News) - A new law signed by President Bush over the weekend sets aside more than $1 billion in federal funding over the next five years to increase and improve the use of forensic DNA technology at US law enforcement agencies.

      According to the Library of Congress Thomas database, a portion of the legislation, called the "Justice for All Act of 2004," is designed to "eliminate the substantial backlog of DNA samples collected from crime scenes and convicted offenders, improve and expand the DNA testing capacity of federal, state, and local crime laboratories, and increase research and development of new DNA testing technologies."

      The new funding could be good news for companies such as Applied Biosystems, Orchid BioSciences, DNAPrint Genomics, ReliaGene Technologies, MicroFluidic Systems, and Tecan.

      "We are well-positioned to accommodate the increasing testing volumes expected to result from this landmark legislation," Paul Kelly, CEO of Orchid, said in a statement yesterday.

      The act is divided into four titles, two of which include sections that authorize funding or increase support for specific initiatives related to DNA testing. These sections include:

      --Section 202, which increases authorized funding for the DNA Analysis Backlog Elimination program to $151 million annually for the next five years, expanding upon the DNA Analysis Backlog Act of 2000;

      --Section 203, which calls for expansion of CODIS, the national database of DNA identification information;

      --Section 206, which states that grants may be made, via vouchers and contracts, to private, for-profit laboratories to assist in collecting DNA samples from offenders and processing crime scene DNA;

      --Section 305, which authorizes $15 million in grants per year for the next five years to support research and development to improve forensic DNA technology;


      --Section 307, which authorizes $42 million in funding per year for the next five years to the FBI to apply towards nuclear DNA analysis, mitochondrial DNA analysis, regional mitochondrial DNA laboratories, CODIS, the Federal Convicted Offender DNA program, and DNA research and development;

      --Section 308, which authorizes $2 million in grants per year for the next five years to promote the use of forensic DNA technology to identify missing persons and unidentified human remains.

      http://www.synergeneprofiling.fr/news2.asp
      Avatar
      schrieb am 26.01.06 18:09:45
      Beitrag Nr. 111 ()
      Hier sind die News (ich gebe zu: etwas verspätet):

      http://www.marketwire.com/mw/release_html_b1?release_id=1074…

      DNAPrint Genomics, Inc. Has Licensed a Diabetes Diagnostic Test Developed by Dr. Jose Halperin at Harvard Medical School

      SARASOTA, FL -- (MARKET WIRE) -- 01/26/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company and Harvard University have entered into a sponsored research and a field-exclusive licensing agreement. Under the agreement, DNAPrint Genomics, Inc. will sponsor further development in the Laboratory for Translational Research (LTR) at Harvard Medical School of a diagnostic test devised in the Laboratory to target early identification of the population at risk of developing vascular diabetic complications. The Company also will conduct work directed toward its eventual commercialization of the test.

      Diabetes is the number one cause of renal transplants, blindness and leg amputations. These are all vascular (blood vessel) complications of diabetes and are the most serious and burdensome effects of the disease for diabetic patients. Treatment of these complications of diabetes consumes 10-15% of the overall US health budget. Therefore, early detection of the diabetic population at risk is a major public health priority as set out by the National Heart Lung and Kidney Institute of the National Institutes of Health in the 1990s. Dr. Jose Halperin, head of the LTR, and members of his research group discovered that a molecule -- called CD59 -- which is a regulator of the complement system, appears to be a key player in how small blood vessels are damaged during the spikes in blood glucose levels that are common in diabetic individuals. Continuous damage to these microvessels is the underlying cause of the kidney, nerve and heart disease that more than 60% of diabetic patients suffer over a lifetime. This discovery of a molecule that is a hallmark of such vessel damage will enable DNAPrint Genomics, Inc. to develop a test to identify even very early stages of microvascular complications.

      Highlighted Links
      DNAPrint Genomics, Inc.
      MacReport.Net

      "Unfortunately, by the time patients are diagnosed with a major complication of diabetes, it may be too late for effective therapy by most available medications and changes in life style," said Dr. Hector Gomez, Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary of DNAPrint Genomics, Inc. This collaboration will further the development of new diagnostic tests that will help physicians and healthcare providers re-direct predisposed patients to healthier lifestyle changes and perhaps even some day, medications to help slow down or prevent the onset of vascular diabetic complications.

      "This well advanced technology licensed by DNAPrint Genomics Inc. was developed with support from the National Institutes of Health, which funded much of the early discovery work. We are pleased to have the opportunity to sponsor research that will further develop and eventually commercialize this important diagnostic test that could significantly improve the management of diabetes," said Richard Gabriel, CEO and President of DNAPrint Genomics, Inc.

      About DNAPrint Genomics, Inc.
      Avatar
      schrieb am 26.01.06 18:12:28
      Beitrag Nr. 112 ()
      . . . und was ist die Reaktion darauf?

      Ein Tagesplus von etwa 20%.

      Schätze mal, dass sich da einige Harvard-Leute eingedeckt haben.

      Das kann nur Gutes bedeuten. Ich habe zum Glück gestern schon nachgekauft.
      Avatar
      schrieb am 28.01.06 00:18:18
      Beitrag Nr. 113 ()
      Hier das neue 8k-Filing:

      http://biz.yahoo.com/e/060127/dnag.ob8-k.html

      Form 8-K for DNAPRINT GENOMICS INC

      27-Jan-2006

      Entry into Material Agreement, Financial Obligation Matter


      Item 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

      License Agreement with Harvard Medical School

      On January 24, 2006, the Registrant entered into an exclusive license agreement (the License) with Harvard College through the Laboratory for Translational Research at Harvard Medical School. The License provides for sponsored research and the clinical development and commercialization of a diagnostic test targeting early identification of the population at risk of developing vascular diabetic complications. The research will be conducted under the supervision of Dr. Jose Halperin. The sponsored research payments total approximately $2.5 million and will be paid in quarterly installments of approximately $208,333 over approximately three years.

      Under the License, the Registrant has the exclusive right to develop, market and sell products and services derived from the research. The Registrant must pay the Licensor a six percent (6%) royalty on the net sales of products and services covered by the License and thirty percent (30%) of all non-royalty sublicense income. The Registrant is also required to pay escalating minimum annual license maintenance fees totaling $850,000 through January 1, 2012. The Registrant is obligated to make annual License maintenance fees of $250,000 through the License term, but, beginning January 1, 2013, the annual license fee of $250,000 is credited against royalty payments. Additionally, the Registrant is obligated to pay the Licensor previously incurred patent costs of approximately $100,000 upon the execution of the License, and is responsible for paying the costs associated with patent application, maintenance and prosecution during the License term.
      Avatar
      schrieb am 31.01.06 16:26:55
      Beitrag Nr. 114 ()
      . . . und neue News:

      http://biz.yahoo.com/iw/060131/0107948.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Expands High-Throughput Genotyping Capacity
      Tuesday January 31, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Jan 31, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the expansion of the Company`s high-throughput genotyping capacity from 1.3 million to more than 3.9 million genotypes per day.

      "Multiplexing and advanced automation protocols provide the flexibility to process large or small genotyping studies without compromising cost per genotype," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "Increasing high-volume throughput advances our ability to determine genotypes at economical costs to our customers and business partners. Coupled with our population ancestry technology, we can achieve better research results at a business-smart price."

      The increase in processing capacity particularly targets the pharmaceuticals and healthcare market. It enables the Company to process clinical trials samples to ensure that patient population groups are accurately categorized, and perform large scale genotyping work for the various industries interested.

      DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis, Ph.D., noted that the Company has key advantages over other laboratories offering genotyping services. "We are unique in our expertise in population structure analysis using our Ancestry Informative Markers (AIM)," said Dr. Frudakis. "We can demonstrate to our customers that failure to understand the ancestral or biological structure of their study population can significantly confound and even compromise genetic studies. We offer a unique approach to maximizing the probability of success in pharmacogenetic, predisposition, risk profiling and susceptibility studies that many companies are pursuing alongside drug and diagnostics development."

      DNAPrint has genotyping facilities at its Sarasota headquarters and at laboratories in Richmond, Calif., and Toronto, Canada, which utilize sophisticated equipment manufactured by Beckman Coulter and Illumina, Inc. The U.S. laboratories are genotyping with the ultra sensitive and robust GenomeLab SNPstream from Beckman Coulter while the Toronto lab is equipped with the Illumina bead machine and is also offering HAP MAP SNP genotyping services.

      "Results from the GenomeLab SNPstream from Beckman Coulter are 99+% reproducible, providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data," Dr. Frudakis noted.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). Recently announced and as a part of the Company`s Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as an identification tool when other DNA testing either fails to yield results or the sample might be too deteriorated.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:
      Richard Gabriel
      CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 31.01.06 16:30:15
      Beitrag Nr. 115 ()
      . . . und achtet vor allem auf diesen Absatz etwa in der Mitte des Postings:

      "Results from the GenomeLab SNPstream from Beckman Coulter are 99+% reproducible, providing the kind of validation that we believe the U.S. Food and Drug Administration (FDA) is seeking for its clinical trials data," Dr. Frudakis noted.
      Avatar
      schrieb am 03.02.06 11:29:17
      Beitrag Nr. 116 ()
      Hier ein guter Link, um sich umfassend über DNAG zu informieren:

      http://www.dnapinvestor.com/welcome.shtml
      Avatar
      schrieb am 07.02.06 16:42:03
      Beitrag Nr. 117 ()
      Ein wenig Butter aufs trockene Brot:

      Press Release Source: DNAPrint genomics, Inc.

      DNAPrint Genomics Provides Ancestry Test Results for Event Organizers at Human Rights Awareness Conference
      Tuesday February 7, 8:18 am ET

      SARASOTA, Fla., Feb. 7, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that it has provided DNA test results to 18 persons of varying ethnic backgrounds who are leaders or organizers of the annual Human Rights Awareness Day, 2006 for the education of approximately 300 high school students in Nassau County, New York.

      A workshop at Hofstra University on Thursday, Feb. 9, 2006, entitled ``Who Are We Really?`` will explore typical stereotypes and perceptions that people may have about each other. The workshop also will help high school juniors understand that genetically they are 99.9% the same as the person sitting next to them, although they may have very different appearances. DNAPrint`s various tests define the anthropological lineages of individuals that can aid students in understanding how they are similar and different from a scientific or genealogical perspective. To demonstrate that ancestry tests often provide surprising results about genetic lineages, 18 conference planners and educators took DNAPrint`s ANCESTRYby DNA(tm) 2.5, and some who qualified took the broadened EURO-DNA 1.0 tests. They plan to share their own test results with attendees of the workshop.

      ANCESTRYbyDNA(tm) 2.5 is a pan-chromosomal test for genetic ancestry that reviews 176 Ancestry Informative Markers (AIMs) to provide the percentages of the major bio-geographical population groups, Sub-Saharan African, Indo-European, East Asian or Native American. The AIMs were carefully selected from large-scale screens of the human genome; and are characterized by sequences of DNA that are more prevalent in people from one area of the world than another. EURO-DNA 1.0 breaks Indo-European ancestry into four groups, reporting individuals` percentages for each: Northwestern Europe (Britain, Ireland, Scandinavia, etc.), Southeastern Europe (Italy, Greece, Turkey, etc.), Middle East and South Asia (India and Pakistan).

      ``The results are sometimes very surprising, but those that have taken the tests are really pleased,`` said Sgt. Gary Shapiro, Nassau County Police Department and moderator of the panel. ``That`s a common response among people who are tested. Some persons who think of themselves as Caucasian thought they would be 100 percent European, and then learn that they have some African, Asian or Native American ancestry. People who describe themselves as Black or African American sometimes discover that the African ancestry is a minority portion of their DNA.``

      ``Avoiding racial stereotypes and learning how closely everyone is related genetically is an important topic for young adults to discuss and understand,`` stated Richard Gabriel, President and CEO of DNAPrint. ``We are pleased to contribute to this valuable event, and we applaud the conference sponsors for undertaking a serious and significant topic that is essential for future generations to understand in order to treat each other with respect. Genealogical and anthropological lessons can also be very interesting and worthwhile from an educational perspective. DNAPrint is proud to participate in valuable public service projects and youth training like the Human Rights Awareness Day. We offer our compliments to Renaire Frieson, the conference chairperson, for putting together this important seminar series for young people.``

      The Human Rights Awareness Day conference is co-sponsored by the Nassau County Commission on Human Rights and the following organizations; BOCES of Nassau County, Nassau County Police Department, New York Civil Liberties Union, Office of the Nassau County District Attorney, What Color is Love, Inc. and local educators.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The company`s first theranostic product is PT-401, a ``Super EPO`` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to http://www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:
      Richard Gabriel, CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848
      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 07.02.06 17:28:17
      Beitrag Nr. 118 ()
      Na wer sagt`s denn, dass Hähne keine Eier legen!

      Und schon tut sich was!! :D
      Avatar
      schrieb am 08.02.06 17:50:46
      Beitrag Nr. 119 ()
      Avatar
      schrieb am 09.02.06 18:13:44
      Beitrag Nr. 120 ()
      Es sieht so aus, als wäre der Boden erreicht . . .


      . . . und mir kribbelt`s mal wieder in den Fingern.


      Habe gerade nachgekauft. Knapp über 0,02.


      Aber v o r s i c h t i g !

      Michi
      Avatar
      schrieb am 13.02.06 20:29:47
      Beitrag Nr. 121 ()
      Hoho!

      Mir scheint, mein Bauchgefühl war mal richtig! :D
      Avatar
      schrieb am 13.02.06 20:32:16
      Beitrag Nr. 122 ()
      . . . aber wo sind die News?

      So ein Anstieg bei diesem Volumen geschieht doch nicht ohne Hintergrund?

      Tuesday = Newsday? :confused:
      Avatar
      schrieb am 14.02.06 14:24:56
      Beitrag Nr. 123 ()
      Hier sind sie:

      NEWS February 14, 2006 - 7:00 AM EST

      DNAG

      Dnaprint Pharmaceuticals Retains DOCRO for Development of Immunoassay to Better Detect Diabetic Vascular Complications
      DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that DOCRO, INC (DOCRO) has been retained to provide consulting and product development services to DNAPRINT PHARMACEUTICALS, Inc., its subsidiary drug and diagnostics development company. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint`s recently in-licensed intellectual property relating to glycated CD59. http://www.dnaprint.com/welcome/press/press_recent/2006/0126…

      Glycated CD59 has shown promise as a potentially highly sensitive marker of the common complications of diabetes. These complications frequently result from obstruction of the small blood vessels that provide nutrients and oxygen to organs and tissues. At least 60% of diabetic patients will develop these and other life limiting complications, including renal failure due to microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries. Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar -- glucose -- levels experienced by even well controlled diabetic patients. Current clinical diagnosis of these complications, based on symptoms or laboratory tests, often occurs only after the patient suffers irreversible consequences to their health. If the CD59 test proves to be a sensitive measure of early cellular and molecular events in the vessel damage process associated with diabetes, patients receiving the test may be treated earlier and the disease progression may be slowed or blunted.

      Founded in 1996 and located in Seymour, Connecticut, DOCRO is a full service contract research organization (CRO) specializing in the design and conduct of clinical trials of in vitro diagnostic products attempting to gain marketing clearance or approval from the U.S. Food and Drug Administration. DOCRO offers complete clinical trial management, guidance on FDA regulatory procedures, and technology development.

      "DOCRO is a leading CRO specializing in the commercialization of diagnostic technologies," commented Dr. Hector J. Gomez, MD, PhD, DNAPrint`s Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals. "DOCRO`s proven formula for success has resulted in an unparalleled track record at the FDA with over seventy consecutive successful FDA submissions."

      "We are particularly impressed with DOCRO`s success in managing clinical trials and their ability to provide the appropriate documents required by the FDA. DOCRO`s commitment to quality and integrity has facilitated multiple successful FDA submissions and eventual market introductions of diagnostic tests. DOCRO`s team will be an advantage as we navigate our CD59 test through the multiple steps of the FDA process," noted Chief Executive Officer Richard Gabriel.

      "After seventy successful FDA submissions, DOCRO has had diverse and extensive experience with a wide variety of immunoassays and other diagnostic tests in many medical specialties and settings. We believe we can be a knowledgeable partner with DNAPrint Pharmaceuticals in helping develop this technology to help diabetic patients further understand and manage their health and well being," commented Thomas Soriano, President and CEO of DOCRO.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
      Avatar
      schrieb am 14.02.06 14:29:05
      Beitrag Nr. 124 ()
      . . . und hier ist der Link:

      http://biz.yahoo.com/iw/060214/0109692.html
      Avatar
      schrieb am 14.02.06 14:35:48
      Beitrag Nr. 125 ()
      Wir haben ein Pharmazie-Unternehmen, das bei 2 Cent steht.

      L Ä C H E R L I C H !!!
      Avatar
      schrieb am 14.02.06 14:44:58
      Beitrag Nr. 126 ()
      Brief in Frankfurt 0,037. Es wird knapp!
      Avatar
      schrieb am 15.02.06 18:31:59
      Beitrag Nr. 127 ()
      Meine Einschätzung der momentanen Lage möchte ich nicht nur im Pusher-Thread darstellen, sondern auch hier:

      Zum Problem wird inzwischen, dass ein immer wiederkehrendes Muster zu erkennen ist:
      Der Kurs geht ein Stück hoch, ein paar Puscher fangen an zu schreien und " machen auf die günstige Gelegenheit aufmerksam" (ich will ja keine Namen nennen). Danach geht es noch ein Stückchen hoch . . .

      . . . und dann wieder rapide abwärts! Immer wieder!

      Also: Die Aktionäre werden inzwischen auf dieses Muster geimpft. Mit anderen Worten: Wenn es beim nächsten Mal ein Stück hoch geht, wird ein dauerhafter Anstieg gar nicht mehr abgewartet, sondern sofort in großem Umfang verkauft.

      Wenn da nichts Grundlegendes passiert, sitzen wir noch nach Jahren auf dieser Zickzack-Linie; mit deutlichem Trend nach unten.
      Avatar
      schrieb am 16.02.06 13:35:20
      Beitrag Nr. 128 ()
      Wenn das noch einmal so einen Run gäbe wie im Juni 2003 . . . :lick:


      News:
      http://biz.yahoo.com/iw/060216/0110067.html

      Press Release Source: DNAPrint Genomics, Inc.

      South Louisiana Serial Killer Workshop to Be Presented at the American Academy of Forensics Science (AAFS) Annual Meeting on February 20, 2006 in Seattle, Washington
      Thursday February 16, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Feb 16, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Dr. Matthew Thomas, Senior Scientist, is a scheduled speaker at the South Louisiana Serial Killer Workshop at the AAFS Annual Meeting on February 20, 2006 in Seattle, Washington. Dr. Thomas will explain DNAPrint Genomics` role in focusing investigation efforts towards the correct suspect, Derrick Todd Lee, in the South Louisiana Serial Killer case. Dr. Thomas`s presentation will explain the science behind the DNAWitness(TM) product and demonstrate the process that resulted in test results reflecting Derrick Todd Lee`s 85% Sub-Saharan African ancestry. This information was instrumental in focusing investigation efforts on appropriate suspects. The refocused investigation resulted in an arrest less than two months after DNAPrint Genomics provided the information and the suspect was ultimately convicted.


      The American Academy of Forensic Sciences is one of the world`s largest and most renowned organizations of forensic scientists, with nearly 6,000 members in 57 countries. The annual meeting involves presentation of scientific papers and workshops designed to keep forensic scientists on the cutting edge of solving crime. One such workshop at this year`s meeting involves a very complex, multifaceted investigation, which culminated in the apprehension and conviction of a serial killer. The experts involved in the case, including an investigator, several scientists, the profiler and legal experts, will come together to share their expertise and learning experiences, in the hopes of educating attendees so they can solve similar crimes more efficiently in their home jurisdictions.

      In 2002 and 2003, murders of six victims were linked to a single assailant in Southern Louisiana. Multiple agencies were involved in the investigation and eventual prosecution of the cases, culminating in the death penalty sentence of Derrick Todd Lee in 2004. The hunt for the serial killer generated considerable media coverage, and resulted in wide sweeping effects to policy, legislation and funding. A variety of approaches were taken in the forensic investigation and prosecution of the crimes, including a blending of new technologies and trusted older techniques. The investigative use of databases generated unique leads when applied to the field of physical matching and comparison. A variety of DNA analytical methods, techniques, and applications were employed to link crimes together, eliminate suspects, implicate Lee, and bring novel investigative information to the serial killer task force, including ancestry determination which demonstrated that he was 85% African.

      "The successful outcome of the Louisiana Serial Killer case in 2003 was a milestone for our DNAWitness forensic technology and brought nationwide attention to DNAPrint`s capabilities in helping to solve complex crimes," stated President and Chief Executive Officer Richard Gabriel. "Since that time, DNAWitness or Retinome(TM) technologies are currently being utilized in more than 100 cases worldwide. Retinome(TM) provides an accurate inference of iris (eye) color from the measurement of proprietary single nucleotide polymorphisms (SNPs) distributed throughout the human genome and is a further advancement of DNAWitness technology. We are proud of our role in this investigation and we believe that there are many cases that would benefit from the application of our forensic technologies."

      The forensic community will benefit by learning the keys to success, and avoiding the pitfalls, in large, multidiscipline, multiple-murder investigations. Techniques learned will be immediately employable by forensic scientists, investigators and administrators in their own jurisdictions and casework. The forensic community and society as a whole will benefit through protection of individuals` rights by rapid exoneration of innocent suspects, the increased public safety resulting from early apprehension of serial predators, and the reduced-cost benefit of an effective investigation using the latest technology.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:
      Richard Gabriel
      CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 21.02.06 16:57:40
      Beitrag Nr. 129 ()
      Kleine Schritte, aber immerhin: News

      Press Release Source: DNAPrint genomics, Inc.

      Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services
      Tuesday February 21, 9:22 am ET

      SARASOTA, Fla., Feb. 21, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Ellipsis Biotherapeutics, Inc. will complete a record quarter of revenue generation from high volume SNP genotyping. A significant portion of the revenue came from four contracts, including a major American university, two United Kingdom academic research groups, and one Toronto based academic hospital program. Ellipsis, acquired by the Company in November 2005, conducts SNP genotyping using state-of-the-art technologies. These include single-base primer extension platforms from Beckman Coulter, Inc. and the GoldenGate(tm) platform from Illumina, Inc. With a choice of platforms and scales for performing work, Ellipsis supports companies through the entire scope of their genotyping efforts. Projects include both high throughput screening of multiple samples as well as finer mapping to clarify associations of genetic predisposition in a variety of human diseases.

      ``Our goal is to deliver the highest quality SNP genotyping services to the marketplace, including project development, ongoing scientific advice and data analysis and interpretation,` commented Dr. Laurence Rubin, founder of Ellipsis. ``Ellipsis has completed these projects on schedule and within budget. Our services have been instrumental in helping scientists publish their work in respected scientific journals. In addition to completing large volume contract services for a variety of projects, we are participating in novel research programs, which has always been part of the company`s focus,` he added.

      ``We are extremely pleased that Ellipsis Biotherapeutics has met its first major milestone and has done it with better than budgeted goals and objectives. We expect that Ellipsis will continue to contribute to our revenue growth and assist our core pursuit of pharmaceuticals and diagnostics,` said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc.

      For further information on genotyping and other DNA services, please contact Ellipsis Biotherapeutics at (416) 586-0947.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a ``Super EPO` (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to http://www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company for additional forensics work. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. The Company also performs contract genotyping and other DNA services through its Ellipsis Biotherapeutics group in Toronto, Canada.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:
      DNAPrint Genomics, Inc.
      Richard Gabriel, CEO and President
      (941)366-3400

      The Wall Street Group, Inc.
      Ron Stabiner
      (212) 888-4848
      Source: DNAPrint genomics, Inc.
      Avatar
      schrieb am 22.02.06 16:26:28
      Beitrag Nr. 130 ()
      Hoho!

      DNAG - ab geht die Post!
      Avatar
      schrieb am 22.02.06 16:37:49
      Beitrag Nr. 131 ()
      Avatar
      schrieb am 23.02.06 22:41:48
      Beitrag Nr. 132 ()
      [posting]20.328.155 von Michiko am 22.02.06 16:37:49[/posting]Dieser Link müsste der richtige sein:

      http://www.cbsnews.com/stories/2006/02/22/earlyshow/main1336…

      "Syler Searches For Her Roots"
      Avatar
      schrieb am 24.02.06 14:56:49
      Beitrag Nr. 133 ()
      Eigentlich meinte ich weder den einen link noch den anderen, sondern noch was anderes.
      Die Info hinter meinem Link hat sich offensichtlich verändert; da stand vorher was anderes. Hatte aber auch was mit Syler zu tun.
      Avatar
      schrieb am 03.03.06 14:37:53
      Beitrag Nr. 134 ()
      NEWS:

      http://biz.yahoo.com/iw/060303/0111858.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Enters Into Sponsored Research Agreement With Massachusetts College of Pharmacy and Health Sciences
      Friday March 3, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Mar 3, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. According to the National Institute of Mental Health, between 3 and 5 percent of children have ADHD, or approximately 2 million children in the United States.

      The research will be conducted under the supervision of Dr. Mark Froimowitz, a researcher at the Boston-based College, who recently licensed the compounds to DNAPrint Genomics. The compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient`s required daily dosage.

      DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company`s newly formed subsidiary, DNAPrint Pharmaceuticals, Inc., said his staff and Dr. Froimowitz will be working together closely to develop "theranostic" test/drug combinations based on the compounds designed to ensure that patients receive the appropriate medicine and proper dosage based on a patient`s genetic constitution. Theranostic test/drug combinations are designed to reduce efficacy and side effects problems associated with conventional drug treatments.

      "These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine," Dr. Gomez stated. "DNAPrint`s capabilities in genomics and the College`s expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research."

      According to Dr. Froimowitz, Research Professor of Chemistry at the Massachusetts College of Pharmacy and Health Sciences, "These compounds have a number of desirable properties and possible therapeutic indications. The possibility of linking their clinical use to patient genomics represents the future of drug development."

      "Many researchers believe that a strong link exists among drug addiction, ADHD and depression. There is a tremendous variation, however, across patient populations, with respect to drug response for the therapies used to treat these disorders," said Richard Gabriel, Chief Executive Officer and President of DNAPrint Genomics, Inc. "In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz`s compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      About MCPHS

      Founded in 1823, Massachusetts College of Pharmacy and Health Sciences (www.mcphs.edu) is a private coeducational college offering graduate, professional and undergraduate degrees in pharmacy and health sciences. With campuses in Boston and Worcester, Massachusetts and Manchester, New Hampshire, MCPHS is the oldest institution of higher education in the City of Boston and its pharmacy program is the second oldest in the U.S. Professional or undergraduate degrees are offered in pharmacy, nursing, physician assistant studies, dental hygiene, radiologic sciences, environmental science, health psychology, chemistry, and premedical and health studies. Graduate programs are offered in drug regulatory affairs/health policy, drug discovery and development, pharmacy systems administration, pharmaceutical sciences, medicinal chemistry, and pharmacology. The College enrolls approximately 2,800 students, who are drawn from 32 states and 30 foreign countries, and employs more than 300 faculty and staff.

      MCPHS is accredited by the New England Association of Schools and Colleges and has received degree-granting authority from the Great and General Court of Massachusetts and the New Hampshire Postsecondary Education Commission.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:

      Richard Gabriel
      CEO and President
      941 366-3400

      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 07.03.06 12:47:15
      Beitrag Nr. 135 ()
      Avatar
      schrieb am 09.03.06 14:16:43
      Beitrag Nr. 136 ()
      . . . und weiter geht`s mit der News-Sammlung:

      http://biz.yahoo.com/iw/060309/0112547.html

      Press Release Source: DNAPrint Genomics, Inc.

      Harvard University Receives Notice of Allowance on Diagnostic Patent Claims Licensed to DNAPrint Genomics, Inc.
      Thursday March 9, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Mar 9, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Harvard University has received formal Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for 20 claims that cover diagnostic uses of a novel marker for diabetes licensed by the Company. DNAPrint entered into an agreement with Harvard in January 2006 to sponsor continued research based on the marker, CD59, in the Harvard Medical School laboratory of Dr. Jose Halperin, a named inventor of the allowed claims. These claims, once issued, will provide Harvard additional intellectual property protection to support the development and commercialization by DNAPrint of new diagnostic tests to better define and manage diabetes more effectively.


      The studies conducted by Dr. Halperin and his Harvard Medical School colleagues indicate that CD59 becomes inactivated in the presence of high blood glucose levels observed in patients with diabetes, and thus does not function normally to protect blood vessel walls from inflammatory damage. This leads to the obstruction of the many small vessels that provide critical nutrients and oxygen to organs and tissues. The common vascular disease complications suffered by individuals with diabetes -- nephropathy, retinopathy, neuropathy and atherosclerotic heart disease -- are all believed to be caused by this vascular obstruction and destruction. A test to detect CD59 in its glycated, inactive form would be a specific warning that the patient has had poor glucose control and that vascular complications are developing even before clinical symptoms show irreversible tissue and organ damage.

      "Microvascular damage in the kidney, blindness due to damage of blood vessels in the retina, and tissue death in the extremities due to damage of the nerves and obstruction of the arteries are major reasons why medical costs are so high for patients with diabetes as well as causing unfortunate suffering for this group of patients of all ages," commented DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., who also heads the clinical development for the Company`s newly formed subsidiary, DNAPrint Pharmaceuticals, Inc. "Today, there is no test that directly measures or monitors the progressive damage caused by the intermittent high sugar or glucose levels experienced by even well-controlled diabetes patients. Now we are able to move forward confidently with the development of our test, knowing that we have appropriate patent protection."

      "Approval of the latest patent claims represents a milestone for Dr. Jose Halperin of Harvard Medical School and his team," commented DNA Print President and Chief Executive Officer Richard Gabriel. "According to the Center for Disease Control and Prevention, the total direct and indirect cost for both type 1 and type 2 diabetes in the United States in 2002 (four years ago) was $132 billion. Our goal is to try to help patients with diabetes understand their disease earlier, and with this knowledge, attempt to minimize their physical complications as well as reduce the associated expense to the U.S. healthcare system. We also know from physician reports that diabetes is expressed more in some patient population groups than others, so coupling our new CD59 diagnostic with our genetic ancestry information will be a valuable tool in developing and understanding the CD59 diagnostic," he concluded.

      Details about the field-exclusive licensing agreement between DNAPrint Genomics, Inc. and Harvard University announced on January 26, 2006 can be found at:

      http://www.dnaprint.com/welcome/press/press_recent/2006/0126… DNAG-HARVARD.pdf

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:
      Richard Gabriel
      CEO and President
      (941) 366-3400

      Ron Stabiner
      The Wall Street Group, Inc.
      (212) 888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 09.03.06 16:32:49
      Beitrag Nr. 137 ()
      . . . und gleich noch eine drauf:

      http://biz.yahoo.com/iw/060307/0112224.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Scientist to Co-Chair Discussion on "Genetic Testing" at the American Association of Physical Anthropologists Annual Meeting
      Tuesday March 7, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Mar 7, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that Dr. Ripan Malhi will co-chair a symposium of 14 scientists and business persons for a discussion of ethical and sociopolitical issues surrounding consumer genetic testing as part of the 75th annual meeting of the American Association of Physical Anthropologists in Anchorage, Alaska. Dr. Malhi is the Senior Research Director of Trace Genetics, Inc., the Company`s wholly owned subsidiary. The four-day meeting, which begins Wednesday, March 8, features several symposiums and poster discussions. This symposium focuses on the interpretation of genetic test results and the public`s understanding of race, ethnicity, human genetic variation and evolutionary history of the human species.


      "The purpose of this symposium is to have a rigorous discussion of lineage-based and whole genome tests exploring the anthropological, biomedical, and societal applications of genetic ancestry testing," explains Dr. Malhi. "It should be a lively discussion. We have purposefully brought together competent spokespersons with diverse perspectives. This will be an opportunity for opinions to be expressed and challenged and, ideally, allow the group as a whole to resolve issues in a direct and productive manner."

      The symposium brings together scientists and experts from academia and private enterprise in an effort to build a consensus about how the public might best use genetic testing to understand their own ancestry within a valid scientific framework. Recent television specials and news publications have spurred public interest in genetic testing, resulting in the recent purchase by consumers of more than 150,000 genetic ancestry tests. The popularity of these genetic tests reflects a widespread interest by the public in using DNA technology to learn about family ancestry. Many anthropologists are concerned that the interpretation of the results of these tests may not give a complete and accurate picture of an individual`s personal genetic history.

      "Until recently the only way genealogists could determine their ancestors` origins was through records and oral history that traced ancestors as far back as the documentation existed. Now, genetic tests can reveal remote anthropological ancestry and suggest proportions of various ethnic and geographical origins such as Native American ancestry, in a given person`s heritage. Genealogists should use the information for the test`s intended purpose as one piece of a large and complex puzzle and avoid prejudice based on what they hoped they would find," commented Dr. Tony Frudakis, Chief Scientific Officer for DNAPrint Genomics.

      The symposium is a featured event of the annual meeting, and is scheduled to be the cover article of the Saturday, March 11, edition of New Scientist magazine.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company`s proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company`s first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company`s drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:

      Company Contact:
      Richard Gabriel
      CEO and President
      941 366-3400
      or
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: DNAPrint Genomics, Inc.
      Avatar
      schrieb am 09.03.06 17:56:02
      Beitrag Nr. 138 ()
      Langsamer aber gleichmäßiger Anstieg bei leicht überdurchschnittlichem Volumen.

      Gefällt mir! :)
      Avatar
      schrieb am 09.03.06 18:13:13
      Beitrag Nr. 139 ()
      Der Chart sieht gut aus, die News stimmen.

      Kapiert denn keiner von Euch, was hier läuft? :eek:

      Michi
      Avatar
      schrieb am 09.03.06 18:43:28
      Beitrag Nr. 140 ()
      Hi Michi :)

      Immer wenn ich auf den Zug will fährt er ab - bleibt nur noch SPAZ :(

      Gruß aus Köln :p
      Avatar
      schrieb am 09.03.06 18:52:37
      Beitrag Nr. 141 ()
      :eek::eek::eek:
      Avatar
      schrieb am 09.03.06 18:54:01
      Beitrag Nr. 142 ()
      [posting]20.602.573 von HenryR.Mandell am 09.03.06 18:43:28[/posting]Hi Ex-Dachlatte!

      Ich hoffe, es geht Dir gut!

      Schön, dass sich der Anteil der Fremdposter in meinem Thread von 0,001 auf 0,002% erhöht hat! ;)

      Mach et jut und lass wieder was von Dir hören, wenn es besser läuft.

      PS: Bei mir ist es mittlerweile bzgl. CMKX ziemlich spannend geworden. Da laufen die tollsten Gerüchte um.

      Gruß

      Michi
      Avatar
      schrieb am 09.03.06 19:22:15
      Beitrag Nr. 143 ()
      Ja, geht mir gut - wohne jetzt seit 6 Monaten wieder in Köln - bin heftig die Euronen am sammeln für nächste Woche - mir ist Patriot echt weggelaufen - hab mich schwarz geärgert (Quatsch, war die Sonnenbank):D - da häng ich 3 Jahre dran und dann das...

      Bin dann auch mal wieder weg - cu Croko
      Avatar
      schrieb am 09.03.06 19:57:55
      Beitrag Nr. 144 ()
      * S Ä U F F Z Z *

      Es ist wie immer: Kaum sind sie oben, schon gehen sie wieder runter!!

      Wie ne alte Jungfer, die ihr Wasser nicht halten kann!

      Wir brauchen substanzielle Revenues! Da führt kein Weg dran vorbei! :mad:
      Avatar
      schrieb am 09.03.06 20:37:40
      Beitrag Nr. 145 ()
      Rückschlag vorbei.

      Und wieder aufwärts!

      Es mag momentan eine finanziell schwachbrüstige Firma sein;

      die Zukunftschancen sind aber enorm.

      Aus diesem kühlen Grunde bin ich noch drin, und zwar heftig!

      Michi
      Avatar
      schrieb am 14.03.06 19:42:20
      Beitrag Nr. 146 ()
      Die momentane Pipiline von DNAG:
      (Quelle: ihub)


      DNAPrint Product Pipeline - Revised Mar 14, 2006

      DNAPrint Genomics - PRODUCTS PIPELINE – March 2006

      MILESTONES FOR FORENSICS AND CONSUMER MARKETS

      ANCESTRYbyDNA 2.0….R/D 2000-01…4Q 2002 market…Mar2004*replaced w/ V2.5
      ANCESTRYbyDNA 2.5….R/D 2003….Feb2004 market…Feb2005 Laptop Biochip System
      ANCESTRYbyDNA 3.0….R/D 2005.…Test kit.- 2006 market?
      EURO-DNA 1.0…..R/D 2003.....4Q 2004 market
      DNAWitness 2.0….R/D 2002……2003 market… 2004*replaced w/ V2.5
      DNAWitness 2.5 …R/D 2003...July 2004 market…Test kit - late 2005 ...global sales 2006
      DNAWitness 3.0………R/D 2005 (3.0 to include eye color)…market 2006?
      DNAWitness-Y…added to DNA Witness product…Aug 2005 market
      DNAWitness-Mito…added to DNA Witness product…Aug 2005 market
      EURO Witness 1.0……………..R/D 2004…….Feb2005 market
      RETINOME 1.0 Eyecolor …R/D 2003....4Q 2004 market…Test kit - late 2005…global sales 2006
      RETINOME HA Haircolor…….R/D 2004….2005-06 validate…..2007 beta test……..2008 market?
      SKIN SHADE………………… R/D 2005-07……2008 market?
      AMERIND 1.0…………………R/D 2005-06……2007 market?
      Genetic Family Tree DB……… R/D 2004…….online 2005
      Searchable Ancestry Genealogy DB…… R/D 2003….online 2004…expand 2005/06
      Searchable PhotoAncestryDB (Forensics)… R/D 2003….. online 2004…expand 2005/06
      DNA Database for Native Americans…develop 2003/2004….expand 2005/06
      DNA Database for African-Americans…. develop 2005…expand 2006
      3D Biometrics Imaging System for DNA fuzzy photo - Forensics –…Jun 2005

      MILESTONES FOR PHARMACOGENOMICS - DIAGNOSTICS AND THERANOSTICS

      Diagnostic Products - Predictive Drug Classifier Tests

      1) Ovanome - Taxol/Carboplatin efficacy for Ovarian Cancer
      * R/D 1998…Announced Mar 2000…Validation Studies 2002-2004…
      * Diagnostic Phase II - 2005…FDA-PMA 2Q06…Launch 2006
      * Market Potential - $50 Million Dollars

      2) PONV - Ondansetron – Chemo-nausea (DNAPrint/Moffitt)
      * R/D 2003…Diagnostic Phase II - 2005/06…..FDA-PMA 4Q06…Launch 2007
      * Market Potential - $500 Million Dollars

      3) Statinome - Lipitor, Zocor, efficacy, liver, muscle adverse myalgia response
      * R/D 1998/2004…Diagnostic Phase II - 2005/06…FDA-PMA 2Q07...Launch 2008
      * Market Potential - $1 Billion Dollars

      4) Melphalan/Topotecan – Multiple Myeloma (DNAPrint/Moffitt)
      * R/D 2003…Diagnostic Phase I - 2005/08….FDA-PMA 1Q08…Launch 2009
      * Market Potential - $50 Million Dollars

      5) Acenome – Ace Inhibitors - Enalapril, Lisinopril efficacy, muscle, adverse cough
      * R/D 1998/2004…Diagnostic Phase I - 2005/08 …FDA-PMA 2Q08...Launch 2009
      * Market. Potential - $750 Million Dollars

      6) BC-LOH – Breast Cancer (DNAPrint/Moffitt)
      * R/D 2003… Diagnostic Phase I - 2004/08…FDA-PMA 3Q08…Launch 2009
      * Market Potential - $400 Million Dollars

      7) Xeliri/Xelox – Colon Cancer (DNAPrint/Moffitt)
      * R/D 2003… Diagnostic Phase I - 2005/08…FDA-PMA 4Q08…Launch 2009
      * Market Potential - $200 Million Dollars

      8) Diabetes – Pre-Diabetes and Diabetic Complications
      * R/D 2005... Diagnostic Phase I – 1Q06… FDA-PMA 1Q09…Launch 2010
      * DNAPrint licensed diabetes diagnostics test from Harvard Medical School – Jan 26, 2006
      * Market Potential - $5 Billion Dollars
      * New - Feb 14, 2006 - DNAPrint Pharmaceuticals Retains DOCRO for Development of Immunoassay to Better Detect Diabetic Vascular Complications. DOCRO will perform technical and clinical assistance and provide guidance on the regulatory requirements associated with the design of clinical trials necessary to commercialize DNAPrint`s recently in-licensed intellectual property relating to glycated CD59. "DOCRO is a leading CRO specializing in the commercialization of diagnostic technologies," commented Dr. Hector J. Gomez, MD, PhD…"DOCRO`s proven formula for success has resulted in an unparalleled track record at the FDA with over seventy consecutive successful FDA submissions."

      Theranostics Products – Drug and Drug Test Combinations

      9) PT-201 – Opthalmic Allergies
      * Phase II – 2Q06…FDA-NDA 4Q07…Launch 2008
      * Market Potential - $50 Million Dollars

      10) PT-202 – Nasal Allergies
      * Phase I – 2Q06…FDA-NDA 4Q07…Launch 2008
      * Market Potential - $50 Million Dollars

      11) PT-301 – Atopic Dermatitis
      * Phase I – 2Q06…FDA- NDA 2Q08…Launch 2009
      * Market Potential - $600 Million Dollars

      12) PT-401 - Super EPO Anemia Drug – Renal Failure
      * License Apr 2005…Pre-clinical 4thQ 2005/2006…FDA-NDA 2009…Launch 2010
      * Market Potential - $2.5 Billion Dollars – Revised 3/14/06 - $11 Billion Dollars
      * DNAPrint exclusive worldwide license to develop a Super EPO anemia drug for renal failure
      * Consulting contract with Super EPO inventor/patent-holder to help DNAPrint develop Super EPO drug
      * Contract for CRO to manufacture Super EPO drug for pre-clinical testing, ready Fall 2005 (completed)
      * Sept 2005 – Super EPO drug begins pre-clinical testing. Production schedule remains on track
      * TWST – “We expect to file a New Drug Application (NDA) by 2009 and a product launch somewhere around 2010.”
      * New – Mar 14, 2006 – DNAPrint™ Genomics Pharmaceuticals Division Announces That Research on Development of Super EPO Drug for Anemia Market Shows Promising Early Results “

      13) PT-501 – ADHD - Methylphenidate – Ritalin-like Compounds
      * License Oct 2005….Pre-clinical 2005…FDA-NDA 2009…Launch 2010
      * Market Potential - $4.6 Billion Dollars
      * Oct 25, 2005 -- DNAPrint genomics, Inc. today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company`s wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine….Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, (Decision Resources, Inc)….
      *Dr. Froimowitz and DNAPrint genomics are working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.
      * TWST - Drug addiction compound has actually been selected by the National Institute of Drug Abuse (NIDA) for further study.
      * New – Mar 3, 2006 - DNAPrint announced that it has entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for the potential development of Ritalin(TM)-like compounds as possible medications for drug abuse, attention deficit hyperactivity disorder (ADHD) and depression. “In fact, the National Institute of Drug Abuse has selected one of Dr. Froimowitz`s compounds for their pre-clinical drug addiction development program. We will be supplying purified compounds to NIDA for further development."

      14) PT-502 – Drug Addiction - Methylphenidate – Ritalin-like Compounds
      * License Oct 2005…. Pre-clinical 2005…FDA-NDA 2010…Launch 2011
      * Market Potential - $500 Million Dollars

      15) PT-503 – Depression - Methylphenidate – Ritalin-like Compounds
      * License Oct 2005….Pre-clinical 2005…FDA-NDA 2011…Launch 2012
      * Market Potential - $7 Billion Dollars

      16) Cancer Compounds – **TI inhibitors in-licensed, closing imminent…4Q05 (Khandaker Report)

      Biofrontera’s Drug Pipeline:

      17) BF 200 ALA - 5-aminolevulinic acid - for actinic keratosis – in Clinical Phase III 2006…Market 2008

      18) BF-Derm1 - for antihistamine-refractory urticaria – in Clinical Phase II 2006…Market 2009

      19) BF 37 - Atopic Dermatitis - for eczema skin rash - Clinical Phase II….Sept 2005…Market 2010

      20) BF 200 ALA – Kondyloma – for epidermotropic human papillomavirus (HPV)…in Clinical Phase II…Market 2009

      21) BF 200 ALA – VIN III – for vulvar intraepithelial neoplasia …in Clinical Phase II…Market 2009

      22) 5-HT2B receptor antagonist - for migraine prophylaxis - in Preclinical 2005…Market ?

      Other DNAPrint Studies

      23) Immune System Deficiencies and Suppressants - Sirolimus, Tacrolimus, Mycophenolate
      * R/D 2001…NYU?…. Fall 2005 - Elipsis Biotherapeutics – Crohn’s Disease and other immune system disorders

      24) Acute Lymphocyte Leukemia (ALL)
      * R/D 2005…Joint Publication late 2005….DNA Screening Test 2006?…..

      25) Cervical Cancer and Environmental Tobacco Smoke
      * FAMRI Grant Feb 2003….2 year grant….Publication 2006?....

      PARTNERS

      * Forensics and Consumer Genealogy - Lynn Peavey, Orchid Biosciences, and ReliaGene Technologies
      * Forensics – DNAPrint working with defense industry consultant, Defense Life Sciences, towards defense and homeland security applications…Aug 2005

      MERGERS, ACQUISITIONS, and SUBSIDIARIES

      * DNAPrint Pharmaceuticals Subsidiary – DNAPrint Genomics forms wholly owned pharmaceutical subsidiary focused on personalized medicine, DNAPrint Pharmaceuticals…Oct 12, 2005
      * "We are at the forefront in the development of personalized medicines and genomics-based pharmaceuticals, the Company`s main focus," stated Hector J. Gomez, M.D., Ph.D., DNAPrint`s Chairman and Chief Medical Officer, who will head the new subsidiary`s day-to-day operations. "We believe that test/drug combinations called `theranostics` are the wave of the future and that our new DNAPrint Pharmaceuticals subsidiary affirms the Company`s commitment to the development of these products." Data Monitor and the Pharmaceutical Manufacturer`s Association expect the worldwide pharmaceutical market to more than triple over the next 10-15 years to an estimated trillion dollars a year.

      * DNAPrint ACQUISITION – Trace Genetics…Acquired Jun 2005
      * Trace Genetics – diagnostics specialists in genetic identity DNA analysis, with expertise in genetic genealogy, forensics, molecular diagnostics and population genetics
      * Trace Genetics will do product testing, production, and sales for forensics and consumer genealogy while DNAPrint continues core drug discovery research and clinical trials for DNAPrint’s growing drug pipeline.

      * DNAPrint ACQUISTION…Biofrontera AG…July 13, 2005
      * DNAPrint Genomics Acquires 18% Interest In Biofrontera AG, a Small German Pharmaceutical Company
      * Biofrontera has proprietary programs for gene expression analysis and has 3 drugs already in their pipeline
      * Biofrontera just acquired a new drug (Sept 2005) and now has 4 drugs in their pipeline
      * Biofrontera milestone: Biofrontera stated intentions to do an IPO stock offering in Europe.
      * Sept 2005 – Biofrontera completes bond funding for $20 million euro. Biofrontera’s new IPO stock offering is on track within 9 months
      * Sept 2005 – Biofrontera acquires new drug for Atopic Dermatitis for it’s drug pipeline

      * DNAPrint ACQUISITION – Kenna Technologies, Inc…Acquired Oct 25, 2005
      Kenna Technologies, Inc., expertise in computational biology. Kenna is an in-silico drug discovery company developing proprietary biological simulations that will improve and accelerate drug discovery and development. Kenna’s platform provides a new rationale for selecting drug targets, evaluating the activity of candidate compounds, and planning clinical trials for promising drug compounds.

      * DNAPrint ACQUISITION – Elipsis Biotherapeutic Corporation…Acquired Dec 22, 2005
      SARASOTA, Fla., Dec. 22, 2005 -- DNAPrint Genomics, Inc. today announced the completion of its previously announced acquisition of Ellipsis Biotherapeutics Corporation, which will operate as a drug and diagnostic subsidiary. Ellipsis will retain its existing personnel and continue to be managed by Dr. Laurence Rubin, who is also the Director of the Division of Rheumatology at St. Michael`s Hospital in Toronto. His research has focused on the genetic determinants of osteoporosis, rheumatoid arthritis and other inflammatory diseases. In addition, Ellipsis has acquired a diverse portfolio of genetic data and intellectual property from unique patient populations, specifically with Inflammatory Bowel Disease (Crohn`s disease) including last year`s publications of the discovery of a gene for Crohn`s disease. Diagnostic applications are currently under development in this and related areas of autoimmune inflammatory disorders.
      * New – Feb 21, 2006 - Ellipsis Biotherapeutics Completes Four Contracts for High Through-Put Genotyping Services For Record Quarter Of Revenues

      * New - DNAPrint - Research Sponsorship Agreement with Mass.College of Pharmacy and Health Sciences - 8-K Jan 31, 2006
      On January 31, 2006, the Registrant entered into a Research Sponsorship Agreement with the Massachusetts College of Pharmacy and Health Sciences for sponsored research in connection with the synthesis and testing of certain (Ritalin) compounds as possible human medications for drug abuse, attention deficit hyperactivity disorder, and depression. The research will be conducted under the supervision of Dr. Mark Froimowitz. The Registrant had previously licensed exclusive rights to the compounds from Dr. Froimowitz on October 19, 2005 under an Exclusive Licensing Agreement. The sponsored research payments total $300,000 and will be paid in monthly installments of $25,000 over one (1) year.
      ---------

      All drugs, projects, acquisitions, and other data listed in this DNAPrint pipeline may or may not be inclusive of all possible drugs, projects or acquisitions that DNAPrint may presently be involved in. Milestone dates are subject to change by DNAPrint Genomics.

      ** Note: All above information on DNAPrint`s research, acquisitions, and drug products pipeline are all documented from DNAPrint’s newsletters, PR`s, Analyst Reports, and SEC filings.

      Of course, Do Your Own DD….and make your own best informed investment decisions.
      Avatar
      schrieb am 16.03.06 22:20:09
      Beitrag Nr. 147 ()
      :eek::eek::eek:


      Avatar
      schrieb am 17.03.06 14:14:34
      Beitrag Nr. 148 ()
      *LOL*

      Wenn hier plötzlich so viele DNAG-Threads aufpoppen, muss ich meine 2 Cents auch noch dazugeben:

      TODOMOOOOOOOOOOOOOOOOoooooooooooooooooooon! :laugh:

      Michi
      Avatar
      schrieb am 21.03.06 13:08:06
      Beitrag Nr. 149 ()
      Hier die News in Englisch: (Weiter unten die Google-Übersetzung)

      marketgainer.com: Releases Coverage for DNAPrint Genomics Incorporated

      Monday , March 20, 2006 12:50 ET

      Mar 20, 2006 (M2 PRESSWIRE via COMTEX) -- Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today`s activity on the OTC exchange has brought DNAPrint Genomics Incorporated (OTCBB:DNAG) to the attention of our research team. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. DNAPrint Genomics Incorporated develops genomics-based products and services that focus on the drug development, pharmacogenomic diagnostic tests, and forensics technology and consumer genetic tests. Share traded up 4% to $.03 this morning while trading 7.9 million shares.

      DNAPrint Genomics Incorporated announced today that President and Chief Executive Officer Richard Gabriel is the subject of an interview and webcast with the Wall Street Reporter magazine. During the interview, which can be accessed on the Company`s web site, Mr. Gabriel discussed the role of the Company in the development of "theranostics" -- drug/genetic test combinations to help ensure patients receive the appropriate medicine and proper dosage based on their genetic constitution, increasing efficacy and reducing side effects.

      "We have been focusing on licensing and technologies," Mr. Gabriel stated. "One lead compound is being evaluated by NIDA, which is the National Institute on Drug Abuse, and we have two other compounds which we`ve identified for attention deficit as well as depression, which is a new mechanism."

      Mr. Gabriel also noted that one of the projects the Company is currently working on is the development of new diagnostic tests to better define and manage the complications of diabetes more effectively, particularly microvascular damage.

      DNAPrint Genomics is also working under a licensing agreement with a well-known and prestigious East Coast medical center to clinically develop and commercially implement a "Super EPO," a more potent, longer-lasting form of the anemia treatment drug erythropoietin.

      To view some of the highlights that attribute to the recent corporate developments, and to see other companies in this sector please visit www.marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. This article is available for viewing in the featured articles section on our website. No Credit Card information needed.

      New to the Market Gainer`s website is our very own in-site blog, offering our subscribers the opportunity to communicate with fellow investors without all the spam found in other investment blogs. Click on talking stocks after you subscribe to join, and enhance your investment knowledge and community.

      The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.

      All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

      This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

      M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.


      Und hier die Übersetzung:

      marketgainer.com: Freigabedeckung für DNAPrint Genomics enthaltener Montag, März 20, 2006 12:50 UND Mrz 20, 2006 (M2 PRESSWIRE über COMTEX) -- Marktgewinner taucht schnell wie das ein Endgeschäft für die internationalen Kleinkappeninvestoren auf, die schauen, um einen Vorsprung vor den Märkten halten. Heutige Tätigkeit auf dem OTC-Austausch hat DNAPrint enthaltenes Genomics (OTCBB:DNAG) zur Aufmerksamkeit unserer Forschungsmannschaft geholt. Unser Ziel ist, eine Gemeinschaft der internationalen Investoren zu verursachen, denen durchweg und effektiv auf den enormen Gewinnen die kanadische Kleinkappe gross schreiben Sie und amerikanische Austäusche anbieten. DNAPrint enthaltenes Genomics entwickelt genomics-gegründete Produkte und Dienstleistungen, die auf die Drogeentwicklung, die pharmacogenomic Diagnosetests und genetischen die Tests der forensicstechnologie und des Verbrauchers konzentrieren. Anteil handelte herauf 4% bis $,03 heute morgen beim Handeln von 7,9 Million Anteilen. DNAPrint Genomics verband heute verkündet, daß Präsident und Generaldirektor Richard Gabriel das Thema eines Interviews und des webcast mit der Wall Street Reporterzeitschrift ist. Während des Interviews das auf der Web site der Firma erreicht werden kann, besprach Herr Gabriel die Rolle der Firma in der Entwicklung von "theranostics" -- die drug-/genetictestkombinationen zum Helfen, Patienten sicherzustellen empfangen die passende Medizin und die korrekte Dosierung, die auf ihrer genetischen Beschaffenheit, zunehmenden Wirksamkeit und Verringern von Nebenwirkungen basieren. "wir haben auf das Genehmigen und die Technologien konzentriert," Herr angegebenes Gabriel. "ein Leitungmittel wird von NIDA ausgewertet, der das nationale Institut auf Drogemißbrauch ist, und wir haben zwei andere Mittel, die wir für Aufmerksamkeitsdefizit sowie Tiefstand gekennzeichnet haben, der ist eine neue Einheit.", Herr Gabriel merkte auch, daß eins der Projekte, welche die Firma z.Z. an arbeitet, die Entwicklung der neuen Diagnosetests zum besser Definieren und effektiv Handhaben der Komplikationen von Diabetes, besonders microvascular Beschädigung ist. DNAPrint Genomics arbeitet auch unter einer Lizenzvereinbarung mit einer medizinischen Mitte der weithin bekannten und prestigious Ostküste, ein "Super-EPO klinisch zu entwickeln und kommerziell einzuführen," eine stärkere, länger anhaltendere Form des Anämiebehandlung-Drogeerythropoietin. Einige der Höhepunkte ansehen, die den neuen korporativen Entwicklungen zuschreiben, und andere Firmen in diesem Sektor www.marketgainer.com, für eine höfliche Subskription bitte sehen zum neuesten und aufregendsten finanziellen on-line-Rundschreiben auf dem Markt zu besuchen. Dieser Artikel ist für das Betrachten im gekennzeichneten Artikelabschnitt auf unserem website vorhanden. Keine Kreditkarteninformationen benötigten. Neu zum website des Marktgewinners unser besitzen sehr Inaufstellungsortblog, unseren Teilnehmern die Gelegenheit ist anzubieten, mit Mitinvestoren ohne das ganzes Spam zu verständigen, das in anderen Investitionblogs gefunden wird. Klicken Sie an sprechen Aktien, nachdem Sie unterzeichnen, um zu verbinden, an und erhöhen Sie Ihr Investitionwissen und -gemeinschaft. Die finanziellen Informationen und der finanzielle Inhalt, der von Marketgainer.com zur Verfügung gestellt wird, ist nur zu den informierenden Zwecken und sollte nicht verwendet werden oder analysiert werden wie ein Angebot zu verkaufen, ein Marketing eines zu kaufenden Angebots oder Aufschrift, Empfehlungen oder Förderung irgendeiner Firma oder Sicherheit von Marketgainer.com. Sie bestätigen und stimmen darin überein, daß jeder möglicher Antrag zu Information und wird weder festsetzt noch analysiert als Investitionrat von Marketgainer.com zu Ihnen freiwillig ist. Es wird stark empfohlen, daß Sie äußeren Rat von die qualifizierten Aktien suchen, die vor dem Bilden jeder möglicher Wertpapieranlage professionell sind. Marketgainer.com liefert oder garantiert kein zugelassenes, Steuer oder Buchhaltungrat oder Rat betreffend ist die Eignung, die Rentabilität oder den möglichen Wert irgendeiner bestimmten Investition, Sicherheit oder informierenden Quelle. Alles Material hierin wurde vorbei gründete nach den Informationen vorbereitet, die geglaubt wurden, um zuverlässig zu sein. Die Informationen, die hierin enthalten werden, werden nicht von Market Gainer garantiert, um genau zu sein, und sollten nicht betrachtet werden, um Sammel zu sein. Die Firmen, die in dieser Meinung besprochen werden, haben nicht die Aussagen genehmigt, die in dieser Meinung abgegeben werden. Diese Meinung enthält das Vorwärts-Schauen der Aussagen, die Gefahren und Ungewißheiten miteinbeziehen. Dieses Material ist nur zu den informierenden Zwecken und sollte nicht analysiert werden wie ein Angebot oder ein Marketing eines Angebots, um Sicherheiten zu kaufen oder zu verkaufen. Marktgewinner ist nicht ein genehmigter Vermittler, ein Vermittlerhändler, ein marktbestimmender Effektenhändler, ein Investmentbanker, ein Anlageberater, ein Analytiker oder ein Versicherer. Beraten Sie bitte einen Vermittler, bevor Sie irgendwelche Aktien kaufen oder verkaufen, die an angesehen werden oder hierin erwähnt sind. Diese Freigabe enthält "das Vorwärts-Schauen von Aussagen" innerhalb der Bedeutung des Abschnitts 27A der Sicherheitstat von 1933, wie geändert und Abschnitt 21E das Börsengesetz von 1934, wie geänderte und solche Vorwärts-schauende Aussagen gemäß den sicheren Hafenbestimmungen der privaten Sicherheitsrechtsstreit-Verbesserungtat von 1995 abgegeben werden. "Vorwärts-schauend beschreiben Aussagen" zukünftige Erwartungen, Pläne, Resultate oder Strategien und werden im Allgemeinen von den Wörtern wie "können", "Zukunft" vorangegangen, "Plan" oder "geplant", "werden", oder ""," erwartet, "" nimmt", "Entwurf" vorweg, "schließlich" oder "projiziert". Sie werden gewarnt, daß solche Aussagen abhängig von einer Menge Gefahren und Ungewißheiten sind, die die zukünftige Umstände, Fälle, oder Resultate veranlassen konnten, sich von denen materiell zu unterscheiden projiziert in die Vorwärts-schauenden Aussagen, einschließlich der Gefahren, daß die tatsächlichen Resultate von denen materiell sich unterscheiden können projiziert in die Vorwärts-schauenden Aussagen resultierend aus verschiedenen Faktoren, und anderer Gefahren, die in einem der Gesellschaften jährlichen Bericht auf Form 10-K oder 10-ksb und andere Archivierungen gebildet wurden von solcher Firma mit den Aktien und von der Austauschkommission gekennzeichnet wurden. M2-Kommunikationen Ltd. dementiert alle Verbindlichkeit zu der Information, die innerhalb M2 PressWIRE bereitgestellt wird. Daten geliefert durch genanntes party/parties. Weitere Informationen über M2 PressWIRE können an http://www.presswire.net auf dem World Wide Web eingeholt werden. Anfragen zu info@m2.com
      Avatar
      schrieb am 27.03.06 22:27:47
      Beitrag Nr. 150 ()
      Lostocos,

      seit einiger Zeit habe ich Deine Chart-Analysen kennen- und schätzen gelernt. Das klang irgendwie überzeugend, obwohl ich nicht viel davon verstehe.

      Wie sieht denn Deine Einschätzung nach dem ersten Tag dieser Woche aus?
      Die 2,5 Cent sind doch wohl deutlich unterboten worden!

      Danke für Deine Einschätzung,

      Michi
      Avatar
      schrieb am 30.03.06 08:40:42
      Beitrag Nr. 151 ()
      .. . und da hätten wir dann die neuesten Zahlen (Form 10KSB):

      http://biz.yahoo.com/e/060329/dnag.ob10ksb.html

      Mal reinschauen :cool:

      Michi
      Avatar
      schrieb am 30.03.06 10:58:57
      Beitrag Nr. 152 ()
      Guten Morgen Michi,

      ich bin nicht mehr so auf dem Laufenden - was ist davon zu halten ?

      Chris
      Avatar
      schrieb am 30.03.06 13:26:56
      Beitrag Nr. 153 ()
      Hi Chris,

      die Revenues sind zwar erfreulicherweise um ca. 60% gestiegen.

      Aber ansonsten ist das kein großer Bringer. Wenn jetzt überraschend ne heftige News käme, z.B. ein zugeteiltes Patent oder ne Kooperation mit einem der Big Boys, dann würden wir ziemlich schnell fliegen lernen.

      Sonst aber werden wir weiter unten rumdümpeln.

      Gruß

      Michi
      Avatar
      schrieb am 30.03.06 13:36:33
      Beitrag Nr. 154 ()
      Wie üblich... :rolleyes:

      Schaue mir das noch ein wenig von der Seitenlinie her an und daddel ein bisschen mit GWGO & IFLB :D

      cu
      Avatar
      schrieb am 30.03.06 14:14:13
      Beitrag Nr. 155 ()
      wo gehts mit dnag hin??
      weiter nach oben???;)

      svenja
      Avatar
      schrieb am 30.03.06 16:23:24
      Beitrag Nr. 156 ()
      Antwort auf Beitrag Nr.: 21.009.378 von brokersvenja007 am 30.03.06 14:14:13svenja,

      ich hoffe, dass es mehr wird als nur ein kleiner Spike!

      Michi
      Avatar
      schrieb am 11.04.06 12:21:58
      Beitrag Nr. 157 ()
      Ist Euch eigentlich das folgende Filing schon aufgefallen? Lest einfach mal schnell die 127 Seiten durch:

      http://www.secinfo.com/d15yrh.v7q.htm

      600 Millionen shares an Dutchess, die auf den Markt geschmissen werden können!

      Bin mal gespannt, was heute Nachmittag der Ami-Kurs dazu meint! :(

      Michi
      Avatar
      schrieb am 11.04.06 17:05:08
      Beitrag Nr. 158 ()
      Also, wie befürchtet, deutlich unter 2 Cent abgefallen.

      Im Moment stellen sich mir zwei Fragen:

      a) Wie lange dauert es bis zum nächsten Resplit?

      b) Wie hoch wird dieser diesmal ausfallen?

      Ich versuch`s mal mit zwei Antworten:

      a) Bis die erste Milliarde shares verpulvert ist!

      b) Deutlich heftiger als beim letzten Mal; vielleicht 1 für 100!

      Zwar bin ich von der Technologie dieser Firma überzeugt (sonst würde ich mich hier nicht engagieren), aber was momentan so finanziell läuft . . . :cry:
      Avatar
      schrieb am 11.04.06 17:15:03
      Beitrag Nr. 159 ()
      Warum Resplit? Es sind "nur" ca. 150mio. Shares im Markt, laut Otcbb.com
      Avatar
      schrieb am 11.04.06 17:25:28
      Beitrag Nr. 160 ()
      Antwort auf Beitrag Nr.: 21.162.845 von Trooper2 am 11.04.06 17:15:03Trooper,

      diese Zahlen sind absolut veraltet!

      Im Moment gehe ich von mindestens 300 Millionen os aus.

      Und mit den 600 Millionen für Dutchess - siehe meinen Link etwas weiter unten - sind wir von der Milliarde nicht mehr sehr weit entfernt!
      Avatar
      schrieb am 11.04.06 19:17:05
      Beitrag Nr. 161 ()
      Könntest Recht haben, laut Consors ist der Laden z.Z. $5,12mio wert.
      5,12/0,02= 256mio Shares.

      Ich würde mal sagen, so lange Dutchess die Shares hält wird es kein Resplit geben
      Avatar
      schrieb am 11.04.06 20:29:34
      Beitrag Nr. 162 ()
      Antwort auf Beitrag Nr.: 21.165.053 von Trooper2 am 11.04.06 19:17:05Ja, genau!

      Aber Dutchess ist kein Sozialverein; die wollen Cash machen.

      Und im Falle eines Falles werden die das auch tun! Völlig ohne irgendwelche Skrupel was die Altaktionäre angeht.
      Die waren, wie Du leicht nachvollziehen kannst, bisher immer die Gearschten. Und zwar kräftig!!

      Es ist zwar noch Hoffnung da (auch meinerseits), aber die in anderen Threads großenteils an den Tag gelegte (bewußt gezüchtete?) Naivität müssen wir hier völlig außen vor lassen.
      Die Wahrscheinlichkeit eines Totalverlustes ist ziemlich heftig.

      Michi
      Avatar
      schrieb am 12.04.06 15:23:41
      Beitrag Nr. 163 ()
      YESS!! Wir sind raus aus der NSS-Liste (Naked Short Selling)!

      http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3…

      Das könnte ein gutes Zeichen sein, denn wer shortet schon eine Aktie, die kurz vor dem Aufschwung steht!?!
      Avatar
      schrieb am 12.04.06 15:33:07
      Beitrag Nr. 164 ()
      Wir sind in den NewYorkTimes!
      Klasse Werbung!!

      http://www.nytimes.com/2006/04/12/us/12genes.html?_r=1&hp&ex…

      Bin mal gespannt, wie heute der Kurs darauf reagiert.

      Mich
      Avatar
      schrieb am 12.04.06 15:36:08
      Beitrag Nr. 165 ()
      Avatar
      schrieb am 20.04.06 13:49:01
      Beitrag Nr. 166 ()
      Leute, lest das mal: "Unsere SNP-Maps sind bei weitem die besten auf dieser Welt!" Brief an die Investoren:

      Impressve 1st Newsletter To Investors from DNAP:

      "We invested heavily in the infrastructure and expertise needed to perform research of the highest caliber. Having built our foundation, we are now actively engaged in the development of our pipeline of genomics-based patient classification products. Most of our future expenses will be directly related to operating this pipeline.

      We have constructed a library of SNP maps, showing where, in genes, individual human beings differ from one another. Our maps are by far the best in the world. Due mainly to our proprietary (and patent pending) protocols, our SNP maps are deeper and more detailed than those held publicly (NCBI) or privately (such as at Celera, Affymetrix, Incyte, Human Genome Sciences and even Gennaissance). Furthermore, our maps cover the entire length of the gene in the genome. The maps being constructed by others are focused at the ends. This is a crucial point because the depth and breadth of the maps are important! You can think of them as “treasure maps” - the more detailed and accurate the map, the better your chance of finding the treasure. As an investor in DNAPrint genomics, you should feel proud that you own a piece of the most comprehensive and valuable pharmaco-relevant SNP library on the planet.

      We continue to write code for the high-throughput and automated mining of complex genetic pattern from our data. When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.

      We have assembled a world-class laboratory with state-of-the-art equipment. We are sequencing well over 1 Million bases per week and scoring about 2,000 genotypes per day.

      We have assembled what may well be the most extensive, detailed and valuable pharmacogenomics specimen databank in the world. We have had the foresight to collect multi-drug consent from our donors, and to log everything in their patient files into our database. No other company does this. Since most of our patients are on multiple medications and since we genotype every person at every pharmaco-relevant marker (unlike our competition), we have the ability to perform multiple and simultaneous pharmacogenomics projects. Please appreciate what this means. Using this type of “master” databank, DNAPrint will be able to outrun its competition in getting pharmacogenomics products discovered and developed to market. For example, when a company decides to do a study on Drug X, they start by collecting specimens, picking markers out of a public database, genotyping and analyzing the results in slow time. Specimen collection, on its’ own, usually takes months. Going on to Drug Y, they start all over again. At DNAPrint, we will use our “master” databank to work 100 times faster. When we decide to look for a solution for problem Y related to use of Drug X, it is simply an informatics problem. The genotypes, patient data, consent – all of it – is in place and ready to be mined the minute we decide we want to spend time on the project. Unlike the competition, we don’t have to start from the beginning collecting specimens, making DNA, building SNP maps, selecting markers, genotyping and analyzing. This imparts a HUGE advantage to DNAPrint.

      As you can see, the level at which we are performing here at DNAPrint is about as high as it can be. We are the envy of our larger Nasdaq peers, and this bodes well for the prospects of increased shareholder value in the months and years to come. In fact, our research is already beginning to pay off. It is my personal goal to be able to announce to you, by year’s end, the company’s first product and product license.

      You should know that there are only about 40 companies in the entire world with the hardware technology we have and significantly fewer with the analytical/software technology we are developing. You should also know that of all of these genomics-capable companies, we are the only micro-cap. In fact, most pharmaceutical companies would have to spend well over $10 million to set up a division with our capabilities.

      This brings up the most important point I will leave you with.

      On a budget of about $1 million, a head count of 14 full time employees (10 on and 4 off-site), and a very small market cap of $20 million, we are literally beginning to outrun larger companies in terms of actual results and enabling infrastructure. We are working smarter, building deeper maps, making “master” databanks and building more sophisticated analytical algorithms than companies with budgets 10 times as large as ours. These things lead to products, which will lead to revenues and profits. They can also enhance shareholder value through other mechanisms. We will continue to build and devote ourselves to making DNAPrint a stunning success.

      We are the first micro-cap company that I know of, anywhere, to begin to make an impact in the challenging and expensive field of genomics. You should feel proud of the company you have helped build.
      Avatar
      schrieb am 20.04.06 14:14:00
      Beitrag Nr. 167 ()
      Und ein neues Patent für DNAG:

      http://www.marketwire.com/mw/release_html_b1?release_id=1239…

      DNAPrint Genomics Receives Notice of Allowance for Patent for Identifying Links Between Gene Sequences and Medical Traits
      Sophisticated Technology Utilized by Company's DNAPrint Pharmaceuticals Subsidiary

      SARASOTA, FL -- (MARKET WIRE) -- 04/20/2006 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company has received a Notice of Allowance from the U.S. Patent and Tradmark Office for a patent application, Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits).

      "Gene sequences are highly polymorphic in the population, which means that they come in various forms or 'flavors,'" stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Polymorphism is usually measured at the level of the single nucleotide polymorphism (SNP) but our technology measures at the level of the haplotype (strings of SNPs), which provides researchers considerably more information. The methods covered in the patent allow for an efficient and powerful means for identifying haplotype."

      The recent patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype analyses. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well. Because of limitations with traditional genome screening methods and the complex genetic characteristics of modern populations, AIMS are integral to the development of DNA tests for the inference of genetic ancestry based on phenotypes, including identifying certain physical characteristics, or an individual's predisposition to respond to certain drugs.

      "The Company is committed to developing a new class of drugs, called 'theranostics,' which are test+drug combinations designed to help ensure that patients receive the appropriate medicine and proper dosage based on their genetic constitution. The application of theranostics is also designed to increase efficacy and reduce side-effects," said DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "Our sophisticated genetics technology is playing a key role in the research and development of potential new drugs."

      Highlighted Links
      MacReport.Net
      DNAPrint™ genomics, Inc.

      "This patent cuts across a wide audience of developers from drug companies to people working on technology in the forensics and consumer areas," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We plan to vigorously utilize and practice our patents and we will be reviewing the fields of genetic testing, drug development, forensic sciences and consumer products with our patent counsel to determine potential areas of development. We want to ensure that we extract the greatest economic value out of this patent for our shareholders and investors."

      DNAPrint Genomics currently holds two patents and has several others pending or in the hands of patent counsel.
      Avatar
      schrieb am 20.04.06 15:30:57
      Beitrag Nr. 168 ()
      Ich wette, da wussten gestern schon welche mehr!

      Sonst wäre der Kurs nicht am Abend plötzlich wieder angestiegen.

      Michi
      Avatar
      schrieb am 20.04.06 17:32:04
      Beitrag Nr. 169 ()
      * F A U C H ! ! *

      Es sieht aus wie immer!

      Kaum geht der Sharepreis ein wenig hoch, schon schmeißt die Firma wieder einige Millionen Aktien und down again.
      Wieder nur ein Spike!
      Avatar
      schrieb am 20.04.06 17:36:07
      Beitrag Nr. 170 ()
      Wird gegen abend wieder steigen.
      Ruhig bleiben.:cool:
      Avatar
      schrieb am 12.05.06 23:08:11
      Beitrag Nr. 171 ()
      Das 8k-Filing:

      http://www.secinfo.com/d15yrh.vaw.htm

      Schaun mer mal!
      Avatar
      schrieb am 16.05.06 16:20:55
      Beitrag Nr. 172 ()
      Also, wenn sich keiner der anderen Hurra-Schreier(innen) zu Wort meldet, dann sage ich halt mal was:

      Das 10QSB-Filing ist draußen!

      http://biz.yahoo.com/e/060515/dnag.ob10qsb.html

      Wäre vielleicht mal ganz interessant, da rein zu schauen.

      Michi
      Avatar
      schrieb am 16.05.06 16:25:39
      Beitrag Nr. 173 ()
      Avatar
      schrieb am 16.05.06 16:48:21
      Beitrag Nr. 174 ()
      Antwort auf Beitrag Nr.: 21.607.373 von Michiko am 16.05.06 16:25:39. . . und falls einer wissen will, warum es heute einige Punkte hoch geht, hier noch News:

      Press Release
      Market-Pulse.com Announces Trade Alert for DNAPrint Genomics, Inc.
      Tuesday May 16, 9:05 am ET
      http://biz.yahoo.com/pz/060516/99182.html
      ATLANTA, May 16, 2006 (PRIMEZONE) -- Market-Pulse.com announces its trade alert for DNAPrint Genomics, Inc. (OTC BB: DNAG.OB - News). According to Bernard R. Schmitt of Market Pulse, ``The company just had excellent news out today regarding its Computational Biology Division completed a pre-clinical, first generation computational model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia.'' PT-401 is a potential competitor in the EPO market that exceeds $11 billion and is rapidly growing.
      Avatar
      schrieb am 17.05.06 14:51:19
      Beitrag Nr. 175 ()
      Hier ein interessanter Zahlenvergleich aus dem letzten Filing.
      Schaut Euch mal die Steigerung der Umsätze und Ergenisse an:

      Revenues
      1Q06...$678,399
      4Q05...$369,033
      3Q05...$316,983
      2Q05...$348,888
      1Q05...$240,599

      Gross Profit
      1Q06...$145,222
      4Q05...$73,683
      3Q05...$72,064
      2Q05...$88,625
      1Q05...$90,659

      (Allerdings haben die Kosten auch kräftig zugelegt; insgesamt ein Beleg dafür, dass die Firma ziemlich aktiv ist)

      Nur meine Meinung!

      Michi
      Avatar
      schrieb am 17.05.06 16:18:20
      Beitrag Nr. 176 ()
      Antwort auf Beitrag Nr.: 21.621.980 von Michiko am 17.05.06 14:51:19Na also!

      Uptrend mit Ansage! Heute schon +13%. Bis jetzt!

      Manchmal sind die Trends wirklich klar vorhersehbar.
      Avatar
      schrieb am 18.05.06 13:27:18
      Beitrag Nr. 177 ()
      Antwort auf Beitrag Nr.: 21.623.767 von Michiko am 17.05.06 16:18:20Personelle Verstärkung im Hause DNAG:

      http://biz.yahoo.com/iw/060518/0129996.html
      Avatar
      schrieb am 19.05.06 15:12:48
      Beitrag Nr. 178 ()
      Naja, dadurch, dass ich ja jetzt von diesem Thread weiss, werde ich Dich mal von Deinen Selbstgespraechen befreien. Ich war letzte Woche schon kurz davor meine Position frustriert bei 1.8c aufzugeben, aber aus irgendeinem Grund habe ich es nicht getan. Und dan kam der Anstieg ploetzlich und wie aus heiterem Himmel. So erschien es mir zumindest zunaechst, allerdings habe ich dann gesehen das kurz vor dem Anstieg das 10-Q veroeffentlich wurde. Als ich es dann gelesen hatte, wusste ich warum!

      Werde jetzt haeufiger hier reinschauen!

      Greets Onkelbaer
      Avatar
      schrieb am 01.06.06 17:31:10
      Beitrag Nr. 179 ()
      Wer sich dafür interessiert oder wer einfach nur seine amerikanischen Sprachkenntnisse erweitern will:
      Hier ein Link zu einem Interview mit Richard Gabriel (CEO von DNAG) über Chancen und Risiken der Ahnenforschung durch DNA-Analyse

      http://www.npr.org/templates/story/story.php?storyId=5438960
      Avatar
      schrieb am 03.06.06 13:13:04
      Beitrag Nr. 180 ()
      Avatar
      schrieb am 09.06.06 13:38:41
      Beitrag Nr. 181 ()
      Biofrontera geht in D an die Börse.
      In dem Zusammenhang wird aber in keinster Weise von DNAG gesprochen, gehört also auch nicht zu den maßgeblichen Gesellschaftern.
      Tja, viel heiße Luft, die DNAG produziert und die vorhandene Liquidität reicht vermutlich nicht mal mehr bis zum Jahresende, wenn nicht von irgendwo ein Lichtlein herkommt und sich der Börsenkurs berappelt ...
      Die Anlegergelder wurden hier kräftig verbrannt ...
      Avatar
      schrieb am 10.06.06 14:07:14
      Beitrag Nr. 182 ()
      Antwort auf Beitrag Nr.: 22.026.409 von Pushi2 am 09.06.06 13:38:41Pushi2,

      auf die Gefahr einer kräftigen Verwässerung (dilution) habe ich schon deutlich in meinem Eingangsposting hingewiesen. Ich glaube, alle Longs sind sich hierüber im Klaren.

      Im Zusammenhang mit dem Börsengang von Biofrontera wird in keinster Weise von DNAG gesprochen?
      Mag sein! Aber im Zusammenhang mit diesem IPO wird bisher eigentlich fast über garnichts gesprochen, logischerweise daher auch nicht über DNAG.
      Vielleicht zur Erinnerung ein Zitat: ``We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs,'' he concluded
      He: Das ist Prof. Hermann Lubbert, Chef der Biofrontera AG.
      Avatar
      schrieb am 11.06.06 10:57:13
      Beitrag Nr. 183 ()
      Mitglieder einer "Kampagne gegen das Verbrechen" in Neu-Seeland fordern die Polizei auf, die umstrittene neue Gen-Technologie einzuführen, mit deren Hilfe der wahrscheinliche ethnische Hintergrund eines gesuchten Verbrechers aufgedeckt werden kann!
      Achtet auf den Bezug zu DNAG (Louisiana-case in 2003).


      Lobby group appeals for ethnic profile tool in NZ
      11 June 2006
      By RUTH LAUGESEN

      Anti-crime campaigners are calling on the police to introduce controversial new genetic technology that can pick the likely ethnic background of the criminal they are hunting.


      British, American and Canadian police have begun limited use of "ethnic inference" tools, which scan DNA from a crime scene for genetic markers associated with particular ethnic groups.

      Sensible Sentencing Trust spokesman Garth McVicar said it should be introduced here. "Anything that is a crime-fighting tool has got to be supported in New Zealand," he said.

      But Greens MP Metiria Turei said that unless the tool was absolutely accurate, there was the danger it would reinforce prejudices.

      Scientists said the test could be successfully applied to New Zealand's main ethnic groups because the DNA of those with European, Maori and Pacific Island ancestry are markedly different. The test gives a probability that a suspect will be from a particular ethnic group.

      Ethnic inference was used in Louisiana in 2003 to track down a serial killer who had terrorised local women. Police had been looking for a white man in a white pick-up truck, based on eyewitness reports. But they changed their focus after a crime scene DNA analysis showed the offender was likely to have 85% African ancestry and 15% Native American ancestry. An African American man, Derrick Todd Lee, is now on death row after being arrested and convicted of two killings.

      New Zealand Police national forensic services adviser Inspector John Walker said the state of genetic science meant there were still too many limitations to the tool.

      AdvertisementAdvertisement"We are keeping a watching brief to see if it gets better. Police here don't see much value in it at the moment. There's no great exactness around it. It only provides a probability," Walker said.

      Victoria University molecular biologist Dr Geoffrey Chambers said more was being learned about genetic markers for ethnicity all the time. Future tools would give increasingly accurate information about appearance.

      "Potentially it's a useful tool if it delivers its promise, which is to reduce police time and release suspects from the burden of interview. But it's something that needs to be approached very carefully. It's easy to make the wrong inference and focus examination inappropriately."

      Turei said the relationship between Maori and the police was marked by a great deal of suspicion, and tools like this would not help. "Any kind of pseudo-science that suggests or encourages prejudice is not welcome here," she said.

      But McVicar said any tool used carefully would provide more information to the police.

      "We've got to get away from this political sensitivity that it's going to be offensive to one ethnic group or another. I don't give a damn about that. A lot of the victims of crime that are coming to us are Maori, and they just want to see offenders caught
      Avatar
      schrieb am 16.06.06 16:04:16
      Beitrag Nr. 184 ()
      Ist doch ein schönes Vatertags-Geschenk! :laugh:


      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Ancestry Test, Given as Father's Day Present by Detroit Free Press Columnist, Solves Old Family Mystery
      Friday June 16, 9:22 am ET

      SARASOTA, June 16, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that a newspaper columnist's quest to unravel an old family mystery was solved with a Father's Day gift -- the Company's ANCESTRYbyDNA(tm) test.

      ``The Coopers hail from Sussex County, Va.,' Detroit Free Press writer Desiree Cooper wrote in a column published in the newspaper on Wednesday, June 15. ``Annie Cooper was my dad's mother... rumored to be a full-blooded Cherokee originally from North Carolina.'

      Columnist Cooper set out to find out if the rumor was fact or fiction. ``Anticipating Father's Day, I sent my father a kit from DNAPrint Genomics, Inc. He swabbed the inside of his cheek and sent the sample back. The results are in: His ancestors were 57% Sub-Saharan African, 40% European and only 3% Native Indian.'

      But there still was one more mystery to be solved. Cooper sent her own DNA to another firm to see if she could trace her maternal roots back to Africa. It turned out that her DNA matched those of the Tikar people now living in Cameroon.

      Cooper went on to write that the tests were worth it. ``My genes may not be my destiny, but they are my history. And they hold the secrets to who I really am,' she concluded.

      Cooper's column can be accessed online at http://www.freep.com/apps/pbcs.dll/article?AID=2006606150317…
      Avatar
      schrieb am 23.06.06 10:09:00
      Beitrag Nr. 185 ()
      Tach zusammen!

      Lebt Ihr noch? :look:

      Also, nur falls es jemanden interessiert: Mir jucken ziemlich die Fingerchen, nochmal nachzukaufen! :eek:

      Es würde mir allerdings besser gehen wenn ich wüßte, dass ich nicht der Einzige bin, den es juckt! ;)

      Also, outet Euch, wenn Ihr noch da seid!

      Gruß ... g4
      Avatar
      schrieb am 24.06.06 14:57:18
      Beitrag Nr. 186 ()
      Moin g4

      gibt es einen konkreten Grund warum es Dich in den Fingern juckt? Oder ist das einfach nur so aus dem Bauch raus?

      Das Shareholder-Meeting war ja nun wirklich nicht das Gelbe vom Ei. Irgendwelche großartige News sind auch nicht in Sicht; alles ist im Ungefähren wie eh und jeh!
      Was das Super-EPO angeht, so wird das nach Aussage von Tony F. noch so "ca. 5 bis 10 Jahre" dauern, bis da mal was draus wird.
      Ganz schön gut, was?
      Er hat zwar auch versprochen, dass dann auch die Longs (also die Investoren vor dem Resplit) einen schönen Erfolg sehen würden, aber diese Aussage kannst Du erstmal den Hasen geben.

      Vielleicht . . . in 5 bis 10 Jahren . . . vielleicht auch nicht . . .
      Ist das eine gute Basis für ein Invest?

      Und was ist, wenn es dazwischen einen weiteren Resplit gibt (oder 2 oder 3 oder . . . )? Weil nämlich die eigenen Einkünfte nicht ausreichen um den Geschäftsbetrieb der (gut bezahlten) Manager weiterzuführen!?!

      Richard Gabriel hat zwar versprochen, dass es keinen weiteren r/s mehr geben wird, aber was ist von so einem Versprechen zu halten?

      Weitere Frage: Ist der momentane pps eine gute Einstiegsgelegenheit?
      Ob die 0,017 ein Boden ist oder nur eine weitere Zwischenstufe auf dem Weg zum 0,001 kann niemand sagen.

      Meine Strategie: Ich halte meinen Kram zusammen, werde aber momentan kein gutes Geld mehr dem schlechten hinterher werfen.

      Vielleicht werde ich bei guter Gelegenheit ein wenig traden.
      Aber alle shares werde ich dabei niemals aus der Hand geben; ich würde mir sonstwohin beißen, wenn dann -gegen alle Erwartung- der Kurs doch plötzlich steil nach oben gehen würde.

      Lass uns wissen, wie Du Dich entschieden hast.

      Gruß Michi
      Avatar
      schrieb am 06.07.06 08:51:02
      Beitrag Nr. 187 ()
      Powerpoint-Präsentation des Meeting vom 22. Juni 2006:

      http://www.dnaprint.com/welcome/pps/share_holder_metting_200…
      Avatar
      schrieb am 06.07.06 15:53:45
      Beitrag Nr. 188 ()
      Tja das war ja nun wohl nix mit dem Aktiengang von Biofrontera.
      Und damit auch nichts mit einer damit einhergehenden Aufwertung von DNAG wegen ihrer 18% Anteile.

      Jetzt wissen wir auch, warum der Kurs gestern Abend plötzlich abgekackt ist! :cry:
      Avatar
      schrieb am 17.07.06 13:38:25
      Beitrag Nr. 189 ()
      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Selects PT-502 Lead Research Compound for Development of Drug for Treating Depression
      Monday July 17, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Jul 17, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced it has confirmed positive results in an animal model for anti-depressant activity for its PT-502 lead compound being developed with the Massachusetts College of Pharmacy and Health Sciences.

      "The results of the assay are encouraging and have enabled us to select PT-502 as the lead candidate for a new anti-depressant therapy," stated Dr. Mark Froimowitz, Research Professor of Chemistry at the Boston College. "The test results clearly show that PT-502 is active in a widely used animal assay for anti-depressant activity. This approach uses the dopamine system as a means of treating depression and is different from traditional serotonin and norepinephrine reuptake inhibitors such as Prozac(TM)."

      In October 2005, DNAPrint Genomics announced that it has licensed a series of Ritalin(TM)-like compounds developed by Dr. Froimowitz. Ritalin(TM) is a well-known drug used for the treatment of attention deficit hyperactivity disorder (ADHD). These compounds have the potential to be enhanced pharmaceuticals for the clinical treatment of depression, drug addiction and ADHD.

      Dr. Froimowitz noted that anywhere from 30% or more of the patients treated with available anti-depressants either do not respond to treatment or have adverse side effects. "PT-502 is our new compound designed to selectively block the reuptake of dopamine with a slow onset, and a longer duration of action. This pharmacokinetic profile indicates that PT-502 should have little or no abuse potential. This offers a new model for the treatment of depression that affects nearly 20 million people a year in the U.S. alone. Finding a treatment that may augment or enhance the use of serotonin and norepinephrine reuptake inhibitors could help millions of people suffering with depression."

      "We are very encouraged by these preliminary results from Dr. Froimowitz's laboratory and we will be advancing the PT-502 compound as quickly as possible," said Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint and the Company's DNAPrint Pharmaceuticals division. "Neurological compounds such as those in our PT-500 series are exciting additions to our growing product and diagnostic development pipeline."

      Richard Gabriel, President and Chief Executive Officer of DNAPrint Genomics, noted that the compound series that the Company licensed from Dr. Froimowitz are focused on drug addiction, depression and attention deficit disorder. "We believe, as do many researchers and clinicians in the psychiatric field, that strong links may exist for certain individuals between drug addiction, attention deficit and depression in clinical evaluations of those individuals and it is important to understand the neurological inter-relationships between the three neurological disorders," he stated. "We will not only be using our Systems Biology to understand the relationships between these three distinct disorders but we will utilize our DNA Ancestry Informative Marker technology to help us sort out the patient population groups that are the most responsive to treatment using this new model of treatment for depression. We believe this will give us a significant advantage over existing drug therapies, especially for the refractive patient groups that may not respond to the 'one pill fits all' design of currently approved drugs."
      Avatar
      schrieb am 20.07.06 13:29:01
      Beitrag Nr. 190 ()
      . . . und eine weitere Pipi-PR (wann kommt endlich ne Bombe? Ne Partnerschaft mit Pfizer oder so?):

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Pharmaceutical Completes Sterility Testing on Anemia Drug Cell Lines for Clinical Development
      Thursday July 20, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Jul 20, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that sterility tests of specific cell lines for producing PT-401, the lead drug in the Company's product pipeline, have been completed satisfactorily, a significant step in developing material for preclinical and clinical trials.

      Studies performed by BioReliance®-Invitrogen Bioservices consisted of tests for the presence of bacterial and fungal contaminants, tests for bacteriostatic and fungistatic activity, tests for the presence of Mycoplasma and tests for the detection of MMV (murine minute virus). All of the tests were successful and no contamination was reported.

      As a result of the tests, preclinical development of PT-401, a more powerful form of the anemia drug erythropoietin (EPO), is continuing as planned. The sterile cell lines, called CHOs, will be used to create the frozen bank, or future source of PT-401, and for producing Good Manufacturing Practices (GMP) material for clinical trials.

      "The sterility testing is a major key in order for us to make GMP material, advance the pre-clinical testing and prepare a successful Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA)," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics and the Company's DNAPrint Pharmaceuticals subsidiary. "KBI Pharma has accepted the sterile cell lines and is now proceeding with the GMP manufacturing of PT-401. We are very pleased with the progress of this project."

      "Establishing our bank of sterile CHO cells is a crucial step in the development of PT-401," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "This cell line will become the 'factory' work-horse for producing PT-401 in commercial quantities not just for the pre-clinical and clinical testing but for production of the final drug."

      DNAPrint Pharmaceuticals is working with Dr. Arthur Sytkowski of Harvard Medical School's Beth Israel Deaconess Medical Center (BIDMC) on the development of "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. Dr. Gomez noted that Dr. Sytkowski's laboratory was crucial in achieving the successful test results for the cell lines. PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used for the treatment of anemia. PT-401 is a potential competitor in the EPO market that currently exceeds $10 billion and is rapidly growing.

      DNAPrint Genomics is utilizing its EPOFusion(TM) model to simulate the cellular and molecular dynamics influenced by the administration of the Erythropoietin class of protein drugs in anemia treatments. EPOFusion(TM) models the interaction of PT-401 -- a novel 2-copy (dimer) form of Erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion(TM) can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion(TM) model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.

      About Beth Israel Deaconess Medical Center

      Beth Israel Deaconess Medical Center is a patient care, research and teaching affiliate of Harvard Medical School and ranks fourth in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
      Avatar
      schrieb am 24.07.06 19:52:08
      Beitrag Nr. 191 ()
      Antwort auf Beitrag Nr.: 22.806.014 von Michiko am 20.07.06 13:29:01Moin Ihr unverbesserlichen Träumer... ;)

      Werde mir "...in and during next week..." :laugh: auch mal wieder was einpacken lassen...

      Ne grosse Tüte voll zu 1 cent :D

      Und dann bleibt es endlich liegen,

      Gruß aus Köln - Croko
      Avatar
      schrieb am 10.08.06 13:36:42
      Beitrag Nr. 192 ()
      Antwort auf Beitrag Nr.: 23.013.879 von HenryR.Mandell am 24.07.06 19:52:08Moin Herny,

      diesmal ist auch die Augenfarbe mit drin: Retinome 2.0

      http://biz.yahoo.com/iw/060810/0152528.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Announces First Scheduled Sales of Upgraded DNAWITNESS Product Featuring Retinome 2.0
      Thursday August 10, 7:00 am ET

      Australian Laboratory Scheduled to Purchase New Kits; Improved Iris Color Detection, In-Laboratory Processing Are Latest Improvements

      SARASOTA, FL--(MARKET WIRE)--Aug 10, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the first scheduled sales of its improved DNAWITNESS product incorporating several improvements made to the Retinome testing process, now called Retinome 2.0, which offers improved iris color detection and allows crime scene investigators to develop samples in their own laboratories.

      A laboratory at the Victoria University School of Molecular Sciences in Melbourne, Australia, which performs work in collaboration with the Victoria Police Forensic Science Service (VPFSS), is scheduled to purchase the first Retinome 2.0 kits under an International Science Linkages grant from the Australian Government's Department of Education, Science and Technology.

      "The upgrades to DNAWITNESS feature several improvements, including proprietary processes that offer greater precision and enhanced value," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are pleased that the forensics laboratory at Victoria University has chosen to purchase these kits, and we look forward to providing more of them in the future to Australian authorities and to law enforcement officials worldwide."

      Retinome 2.0 is an improved version of Retinome 1.0, a test developed from the Company's continued research on the genetics of human iris color. The new version includes additional patent-pending markers covering newly identified and informative regions of the human pigmentation gene OCA2. Retinome 1.0 will be discontinued in favor of the newly improved version of the test.

      In addition, the Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

      Since early 2005, the Company has been offering Retinome 1.0 as part of its DNAWITNESS package in order to test for iris color. DNAWITNESS employs patent pending database-driven methods to infer elements of physical appearance from crime scene DNA (www.dnawitness.net) and allow forensic investigators to "paint" molecular portraits from crime scene DNA.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


      Contact:
      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848

      Gruß vom Rhein,
      Michi
      Avatar
      schrieb am 15.08.06 00:10:49
      Beitrag Nr. 193 ()
      Hier ein Auszug aus dem neuesten 10QSB: (Vierteljahresbericht)

      Form 10QSB for DNAPRINT GENOMICS INC
      http://biz.yahoo.com/e/060814/dnag.ob10qsb.html
      14-Aug-2006

      Quarterly Report


      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
      RESULTS OF OPERATIONS
      Statements in this Form 10-QSB Quarterly Report may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on our current expectations, estimates and projections about our business based, in part, on assumptions made by our management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in this Form 10-QSB Quarterly Report, under "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in other documents which we file with the Securities and Exchange Commission.

      In addition, such statements could be affected by risks and uncertainties related to our financial condition, factors that affect our industry, market and customer acceptance, changes in technology, fluctuations in our quarterly results, our ability to continue and manage our growth, liquidity and other capital resources issues, competition, fulfillment of contractual obligations by other parties and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Form 10-QSB Quarterly Report, except as required by law.

      The following discussion and analysis should be read in conjunction with the balance sheets as of December 31, 2005 and June 30, 2006 and the financial statements for the three and six months ended June 30, 2006 and 2005 included with this Form 10-QSB.

      The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that have a significant impact on the results we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Actual results may differ from these estimates under different assumptions or conditions. Below, we discuss this further, as well as the estimates and judgments involved.

      Asset Impairment


      We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In performing the review for recoverability, we estimate the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) is less than the carrying amount of the asset, an impairment loss is recognized. Otherwise, an impairment loss is not recognized. Management estimates the fair value and the estimated future cash flows expected. Any changes in these estimates could impact whether there was impairment and the amount of the impairment. Since we are in the development stage, we do not have much history to determine our estimated cash flows. If we do not meet our targeted cash flows for our services and if the estimated disposition of the equipment is lower, this could result in a write-down of our equipment. Our equipment is very specialized equipment related to genomics research, and there probably will not be a large demand for our used equipment. The amount of our net fixed assets is the amount of the maximum risk if our assumptions were not correct. Each year the assets will have higher depreciation and the maximum risk will decrease correspondingly.

      Allocation of Research and Development Costs



      -19-
      We allocate costs by identifying and directly expensing certain costs related to research and development and allocating certain other costs based on total labor effort that is estimated by management and employees. With some of these costs, a percentage of a total purchase order price is allocated to research and development. We base the labor time on time cards submitted each pay period by the employees. We record inventory for our raw materials. As raw materials are used, they are charged to research and development expense based upon actual usage for research and development. We continue to refine our process of identifying time associated with research and development. These refinements to estimates could increase or decrease our income statement expense categories of research and development, cost of sales and selling, general and administrative. As we hire employees, the department in which the employee is hired will have a direct impact on the allocation of administrative costs to research and development. For example if a person is hired in research and development, the allocation to research and development for other administrative costs will increase because labor effort percentage for research and development will have increased. If a person is hired in administration, the allocation to research and development for other administrative costs will decrease because the labor effort percentage for research and development will have decreased. Changes to these estimates could have a significant impact on the accrual and related compensation expense and/or deferred compensation.

      Estimation of Fair Market Value


      We use the Black Scholes Option Model to determine fair market value in certain instances (i.e. to value warrants and the intrinsic value of the convertible debt and non-detachable warrants). The Black Scholes Option Model requires estimated assumptions in its computation. We estimate the assumptions used in each calculation based upon the transaction term and what we believe most appropriately reflects the transaction. If different estimates of the assumptions were used, it could result in different fair market value amounts being calculated. Additionally, various methods can be used to determine the fair market value of the warrant. If a different model were used besides the Black Scholes Option Model, it could result in different fair market value amounts being calculated.

      Derivatives


      We have reviewed our contracts and financial instruments to determine what derivatives and embedded derivatives we may have. We have then reviewed these derivatives and embedded derivatives to determine if they should be recorded as equity or a derivative liability valued at fair value. Judgment is used to apply the criteria of Statement of Financial Accounting Standards No. 133 and No. 155 and Emerging Issues Task Force 00-19 to the derivatives. Also judgment and estimates are required to determine the fair value of the derivative liabilities and the fair market value of the financial instrument as a whole. Although the Company's management believes that the estimates and assumptions used are reasonable, actual results may differ from these estimates under different assumptions or conditions.

      Summary

      Although we have been in existence for a number of years, we continue to be a development company while we develop products for introduction to the pharmacogenomics market. We continue to devote substantially all of our efforts to initiating and developing our planned principal operations in our pharmacogenomics products. We generate revenues in our consumer, forensic and services products, but these products have not yet resulted in the generation of significant revenues. Our revenue for the six months of 2006 has increased over the first six months of 2005 mainly due to an increase in sales of our ancestry product, AncestryByDNA(TM) and genotyping services. The increase in genotyping is the result of our acquisition of Ellipsis assets late in 2005. Our consumer revenues increased as a result of the revenue contribution from Trace Genetics which we acquired during mid-2005 and sales generated from increased advertising including


      -20-
      news stories and television shows. Our pharmacogenomics products are still in development. Because our products are relatively new to the market, we believe that sales will continue to fluctuate from period to period until we can better determine through continued market research and experience how and where to best market and sell the products.

      In our pharmacogenomics area, we have established a strategic alliance with Beth Israel Deaconess Medical Center ("Beth Israel") to develop a new, more potent and longer acting form of the anemia drug Erythropoietin ("EPO"). EPO is a glycoprotein naturally made by the body to stimulate red blood cell production; the currently marketed forms are manufactured using recombinant DNA technology and are used to treat anemia or low blood cell count. Under the agreement, Beth Israel has granted us an exclusive license to United States and foreign patents related to certain forms of EPO. We have the right to develop, use, market and sell products derived from the licensed patents. We have also entered into a consulting agreement with Dr. Arthur Sytkowski, the Director of Beth Israel, to consult on the EPO project. Dr. Sytkowski has agreed to perform certain consulting services, including advising on medical, regulatory and patent issues, training personnel and providing assistance with EPO research and development. During July 2006, we entered into a collaborative research agreement with Beth Israel to provide four researchers to us to conduct certain research work related to our EPO research.

      During late March 2006, we entered into a services agreement with KBI BioPharma for the production development of EPO.

      We entered into an exclusive licensing agreement with Dr. Mark Froimowitz to develop a series of compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder ("ADHD"), and depression. The licensed compounds are analogs of Ritalin, a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the bloodstream, thus reducing a patient's required daily dosage and the potential for drug abuse. We have the exclusive right to develop, use, market and sell products derived from the licensed compounds.

      We entered into an exclusive license agreement (the "Harvard License") with Harvard College through the Laboratory for Translational Research at Harvard Medical School. The Harvard License provides for sponsored research and the clinical development and commercialization of a diagnostic test targeting early identification of the population at risk of developing vascular diabetic complications. The research will be conducted under the supervision of Dr. Jose Halperin. Under the Harvard License, we have the exclusive right to develop market and sell products and services derived from the research.

      We entered into a research sponsorship agreement with the Massachusetts College of Pharmacy and Health Sciences ("MCPHS"), under which Dr. Mark Froimowitz will lead at MCPHS a research project that relates to the compounds that we license from him. The area of research is the synthesis and testing of monoamine transporter inhibitors as possible human medications for drug abuse, for ADHD, and for depression. The specific research covered by this agreement is the synthesis of quantities of compounds sufficient for animal testing, including developing methods for the resolution or chiral synthesis of compounds.

      We continue work on OVANOME(TM), a Taxol screening diagnostic test, and STATINOME(TM), a test for the cardiac drug market, which are both currently under development. We will also continue our efforts on other research and development projects that are underway. Our OVANOME(TM) technology is under development with researchers at the Moffitt Cancer Center in Tampa, Florida.

      We have an agreement with our Scientific Advisory Board member, to continue collaboration with us to develop commercial tests for genetic ancestry and particular physical phenotypes. We continue to work with him on upgrading our current ancestry products.


      -21-
      Our plan of operations for the ensuing twelve months includes efforts to: 1) increase sales of our existing products and services; 2) introduce new and expanded products and services in the consumer and forensic markets; 3) promote our genotyping and paternity services while continuing to concentrate on research and development for both our existing products and our anticipated pharmacogenomic products and services. We expect to add personnel in the laboratory and in administration, as growth warrants. Capital expenditures needed for the next twelve months are discussed below under the section entitled "Liquidity and Capital Resources".

      The following discussion of our historical financial results should be read against this background.

      RESULTS OF OPERATIONS

      Three and six months ended June 30, 2006 compared to the three and six months
      ended June 30, 2005


      Revenues and Cost of Sales


      During the three and six months ended June 30, 2006 and 2005, revenues were $577,202 and $1,255,601 for 2006, respectively and $348,888 and $589,487 for 2005, respectively. A $228,314 increase in revenues for the second quarter of 2006 compared to the same quarter from the prior period is a 65% increase while a $666,114 increase in revenues for the six month period ending June 30, 2006 compared to the same period in the prior year is a 113% increase. In addition to the revenues recognized in the accompanying statement of operations, we also have recorded deferred revenues of $270,111 as of June 30, 2006. Deferred revenue is recorded when the prepaid or billed order has been received, but all the services have not been completed as of June 30, 2006. These amounts will be recognized as revenue in the third quarter of 2006.

      The approximate increase of $228,000 in revenues for the three months ended June 30, 2006 compared to the same period in the prior year is mainly the result of our AncestryByDNA(TM) revenues increasing by approximately $174,000, our MtDNA(TM) revenues increasing approximately $64,000, Y SNP revenues increasing approximately $28,000, EURO-DNATM revenues increasing approximately $20,000 and forensics services revenues increasing approximately $11,000 compared to the same period in the prior year. These increases were offset by a decrease of approximately $53,000 from our paternity services and approximately $22,000 decrease from our genotyping services compared to the same period in the prior year. In addition, we had approximately $6,000 of other revenues.

      The approximate increase of $666,000 in revenues for the six months ended June 30, 2006 compared to the same period in the prior year is mainly the result of our genotyping revenue increasing by approximately $205,000, our AncestryByDNA(TM) revenues increasing by approximately $349,000, our MtDNA(TM) revenues increasing approximately $92,000, Y SNP revenues increasing approximately $50,000, EURO-DNATM revenues increasing approximately $32,000 and forensics services revenues increasing approximately $14,000 compared to the same period in the prior year. These increases were offset by a decrease of approximately $92,000 from our paternity services. In addition, we had approximately $16,000 of other revenues.

      Genotyping sales were generated primarily through work with universities with two consumers being our major clients of these services during 2006. The increase of genotyping services of approximately $205,000 during the first six months of 2006 compared to the same period in 2005 was the result of the revenue from our acquisition of Ellipsis during late 2005. The decrease of approximately $22,000 in genotyping revenues during the three months ended June 30, 2006 compared to the same period in the prior year is the result of lower revenues from a university which has decreased its genotyping outsourcing. Two of our customers accounted for approximately $290,000 of our genotyping sales during the first six months of 2006.

      During the three and six months ended June 30, 2006 compared to the same period in 2005, sales of our consumer services increased by approximately $286,000 and $523,000, respectively. This is due to


      -22-
      increased awareness and interest in genealogy. We have been featured in several articles and television spots which has resulted in an increase in sales of our consumer products during this quarter. We currently contract with distributors who also sell our consumer products as well as advertise on the Internet and in paper-based publications (i.e. through Google and Family Tree magazine) to grow sales of our consumer products. Our consistent sales come through our distributors. We will also continue to pursue adding distributors to increase our sales volume of our consumer products. One of our distributors accounted for approximately $240,000 of sales during the first six months of 2006.

      During the three and six months ended June 30, 2006 compared to the same period in 2005, sales of our forensic services increased by approximately $11,000 and $14,000, respectively. We continue to market our forensic services that we have to offer, but have focused our marketing efforts on our consumer products as the forensic sales are typically sold by referrals.

      During the three and six months ended June 30, 2006 compared to the same period in 2005, sales of our paternity services decreased by approximately $53,000 and $92,000, respectively. During 2005, we had one customer that accounted for the majority of our paternity revenue, and toward the end of 2005, this customer found an alternative source for this service. We do not expect our paternity services to be a large revenue generator for us in 2006 as we are focusing our marketing efforts on our consumer products.

      While we continue to improve and refine our accounting systems, we currently do not segregate product costs by product or service. We have been and continue to be a development stage company as described in Financial Accounting Standards Board Statement No. 7. We continue to devote substantially all of our efforts to initiating and developing our planned principal operations. We expect that our pharmacogenomic products and services, once introduced, will be our major revenue generator.

      During the three and six months ended June 30, 2006 compared to the same period in 2005, cost of sales increased by approximately $107,000 and $490,000, respectively. This was a result of increased revenues during the three and six months ended June 30, 2006 compared to the same period in 2005. The cost of sales as a percentage of revenue was 72% and 70% for the six months ended June 30, 2006 and 2005, respectively. The increase in cost of sales as a percentage of revenues is due in part to our refinement of our estimate and allocation of research and development costs. Also, our genotyping services have a lower gross profit margin than our consumer products. Because of our small sales volume, these results are not indicative of the margins that we expect to attain if our long-term goals are achieved. We anticipate that as we gain experience and can begin to take advantage of economies of scale benefits through increased revenues; our margins will stabilize and begin to track in line with other companies in similar industries. However, in the near term, while we continue to be a development stage enterprise, we expect that our margins will continue to fluctuate.

      Research and Development Expenses


      During the three and six months ended June 30, 2006 compared to the same period in the prior year research and development (R&D) expenses increased $765,388 and $2,413,493, respectively. The increase of approximately $765,000 in R&D during the second quarter of 2006 compared to the same quarter in the prior year resulted primarily from $249,000 of costs invested in our EPO project, $75,000 invested in our ADHD project, $234,000 invested in our diabetes project, $71,000 invested in post operative nausea and vomiting project and $2,000 invested in research samples used to expand our current products, and increase of labor costs of $57,000. The remaining increase of $77,000 was the cost of increased research performed on our other current products and allocation of administrative costs.

      The increase of approximately $2,413,000 in research and development expense for the first six months ended June 30, 2006 compared to the same period in 2005 resulted primarily from $852,000 of costs invested in our EPO project, $150,000 invested in our ADHD project, $20,000 invested in our Statinome project,


      -23-
      $599,000 invested in our diabetes project, $71,000 invested in post operative nausea and vomiting project and $108,000 invested in research samples used to expand our current products, and increase of labor costs of $183,000. The remaining increase of $430,000 was the cost of increased research performed on our other current products and allocation of administrative costs.

      Because we are in the development stage of our long-term business, it is not possible to directly correlate our current research and development costs to our future costs. Currently we do not manage on a project cost basis with respect to research and development. We are implementing revenue recognition and project status measures which will in the future disclose such information. Our revenue generation to date has not been substantial or steady enough to warrant segregation of time, costs and revenue. We are a development stage enterprise with new products that are not available through competitors for forensics and genealogy. For example, many of our products and services are in the development stage, and the segregation of each project by its particular cost, revenue and cash flow is currently not feasible.

      We continue to support research and development to attain our long-term business strategy, and it will remain a high priority and a necessary resource to sustain future growth. We will continue to hire research and development personnel and invest in the infrastructure required to support future innovation, including equipment, supplies and other asset purchases.

      In order to advance our pharmacogenomic products to commercialization, our development costs for these products will increase in 2006. We have the following commitments which will increase our research and developments costs in the future.

      We entered into a license agreement with Beth Israel for EPO. In exchange for the license, we agreed to make certain milestone payments linked to their progress in developing marketable products from the licensed technology. The total of payments, if all milestones are reached, is $2,150,000. The milestone payments are nonrefundable. Up to $200,000 of this amount is creditable against future royalties. In addition to the milestone payments, we must also pay Beth Israel an annual royalty of 4% of the net sales of all products developed from the licensed technology. A minimum royalty payment of $100,000 a year is due upon the commencement of commercial sales in any territory worldwide.

      We entered into a consulting agreement with Dr. Arthur Sytkowski, the Director of Beth Israel, to consult on the EPO project. In exchange for the services, we will pay Dr. Sytkowski $10,000 a month, five annual incentive payments of $25,000 each, and certain milestone payments totaling $125,000 linked to our progress under the Beth Israel license in developing marketable products from the licensed EPO technology. The milestone payments will be reduced - dollar for dollar - to the extent Dr. Sytkowski receives payments from Beth Israel relating to the same milestone events under the Beth Israel license.

      During late March 2006, we entered into a service agreement with KBI BioPharma for services to be provided totaling $2,840,000 of which $348,000 has been paid. KBI will provide us services for the production development of EPO.

      During July 2006, we entered into a collaborative research agreement with Beth Israel to provide four researchers to us to conduct certain research work related to our EPO research. This project will cost approximately $600,000.

      We entered into an exclusive licensing agreement with Dr. Mark Froimowitz to develop a series of compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, ADHD and depression. We are obligated to pay the licensor a two percent (2%) quarterly royalty fee on the net sales of products covered by the license. Minimum annual maintenance fees of $25,000 are required for the license term, but will be deducted from royalties. Additionally, the license requires progress payments of up to $275,000 upon the successful development and approval of licensed


      -24-
      products. The license's initial five-year term is supplemented by options capable of extending the license term for up to twenty years.

      We entered into an exclusive research sponsorship and license agreement (the "Harvard License") with Harvard College through the Laboratory for Translational Research at Harvard Medical School. The Harvard License provides for sponsored research and the clinical development and commercialization of a diagnostic test targeting early identification of the population at risk of developing vascular diabetic complications. The research will be conducted under the supervision of Dr. Jose Halperin. The remaining sponsored research payments total approximately $2.1 million and will be paid in quarterly installments of approximately $208,333 over approximately three years.

      Under the Harvard License, we have the exclusive right to develop, market and sell products and services derived from the research. We must pay the Licensor a six percent royalty on the net sales of products and services covered by the License and thirty percent of all non-royalty sublicense income. We are also required to pay escalating minimum annual license maintenance fees totaling $850,000 through January 1, 2012. We are obligated to make annual license maintenance fees of $250,000 through the Harvard License term, but, beginning January 1, 2013, the annual license fee of $250,000 is credited against royalty payments.

      We entered into a research sponsorship agreement with the Massachusetts College of Pharmacy and Health Sciences ("MCPHS"), under which Dr. Mark Froimowitz. We have $150,000 of payments to MCPHS remaining for this research work.

      We have begun development of our new licensed technology from Beth Israel Deaconess Hospital (BIDMC), known as 'Super' EPO, which we anticipate will be used to treat kidney dialysis, cancer patients and immune transplant patients . . .
      Avatar
      schrieb am 08.10.06 11:32:51
      Beitrag Nr. 194 ()
      Avatar
      schrieb am 10.10.06 16:13:06
      Beitrag Nr. 195 ()
      Avatar
      schrieb am 24.11.06 08:02:39
      Beitrag Nr. 196 ()
      Thread: Kein Titel für Thread 8155914035320777451616069681559

      Pressemitteilungen


      Presse
      Pressemitteilungen
      Pressematerial
      Pressekontakt
      Newsletter Archiv
      Newsletter An/Abmeldung
      RSS-Feeds Information



      29.09.2004
      Biofrontera erhält strategisches Investment von DNAPrint in Höhe von 20 Millionen Euro

      Leverkusen, Deutschland − Biofrontera AG gab heute bekannt, dass auf der Basis eines strategischen Investments von DNAPrint™ genomics, Inc., Sarasota, FL, USA eine Joint Venture Rahmenvereinbarung zwischen beiden Unternehmen geschlossen wurde. DNAPrint erwirbt von Biofrontera neu ausgegebene Vorzugsaktien der Serie B für 20 Mio Euro. Heidelberg Innovation, 3i Group, TechnoMedia Kapitalbeteiligungsgesellschaft Köln mbH sowie Herr Prof. Dr. Riesner erhöhen das Gesamtinvestitionsvolumen auf 21,2 Mio Euro.



      Biofrontera wird das aufgenommene Kapital zur Weiterentwicklung der klinischen und präklinischen Produktpipeline nutzen. DNAPrint werden zwei der sechs Aufsichtsratssitze der Biofrontera zugesprochen, und Prof. Dr. Hermann Lübbert, Vorstandsvorsitzender der Biofrontera AG, wird dem Board von DNAPrint beitreten.



      Durch die unterzeichnete Rahmenvereinbarung sollen beide Technologieplattformen zum gegenseitigem Nutzen der Unternehmen kombiniert werden. Biofronteras Forschungs- und Entwicklungsprojekte für neue Arzneimittel sollen durch DNAPrints einzigartigen Ansatz zur Entwicklung von Diagnostika ergänzt werden, der auf populationsgenetischen Analysen beruht. Patientengruppen können hierdurch besser ausgewählt werden, damit Wirksamkeit und Nebenwirkungen von potenziellen Medikamenten leichter nachweisbar werden. Das Management erwartet, dass die frühzeitige Einbindung geeigneter diagnostischer Tests den Prozess der Arzneimittelentwicklung vereinfachen und beschleunigen wird.



      Das Investment von DNAPrint ist gesichert durch die Zusage des Dutchess Private Equity Fonds, der auf Anforderung von DNAPrint neu ausgegebene DNAPrint Aktien für bis zu 35 Mio US$ innerhalb der kommenden beiden Jahre erwerben wird. Die Transaktion wird mit der Registrierung der neugeschaffenen Aktien am Aktienmarkt wirksam.



      „Der Abschluss einer derartigen Partnerschaft mit einem US Unternehmen ist ein bedeutender Meilenstein für unser Unternehmen. Die eingeworbenen Kapitalressourcen ermöglichen es uns unsere Produktkandidaten in der klinischen Entwicklung voranzutreiben und hierdurch den Wert der Firma drastisch zu steigern,“ kommentierte Prof. Hermann Lübbert. „Mit Hilfe des Investments wollen wir unser führendes Produkt BF-Derm1 zur Behandlung von chronischer Urtikaria und weitere Produktkandidaten in den nächsten drei Jahren zur Marktreife führen. Durch den Einsatz der DNAPrint Technologie wird die Entwicklung unserer Arzneimittel beschleunigt und weniger kostenintensiv. Die Möglichkeit, die Wirkung eines Medikaments in einem bestimmten Patienten vorherzusagen wird zur optimalen Versorgung der Patienten beitragen. Schnellere Entwicklungserfolge werden die Biofrontera einem angestrebten Börsengang näher bringen.“



      Richard Garbriel, Vorstandsvorsitzender und Präsident von DNAPrint genomics Inc, sagte: „Wir freuen uns, dass wir der erfolgsversprechenden Verbindung zwischen Biofrontera und DNAPrint eine zuverlässige Kapitalbasis bieten können. Wir sind überzeugt, dass diese Finanzierung nach der Registrierung der Aktien durch die SEC unseren Aktionären eine Wertsteigerung bringt, die deutlich über den eigentlichen Wert der Biofrontera Aktien hinausgeht. Durch die Kombination der Technologieplattformen hoffen wir die derzeitigen Umsatzchancen beider Unternehmen zu verbessern und dem Markt Lösungen für viele Probleme der Pharmaforschung und -entwicklung anzubieten.“


      Biofrontera AG

      Biofrontera’s strategisches Ziel ist der Aufbau eines Specialty-Pharmaunternehmens im Bereich Dermatologie bei Nutzung interner Forschungskapazitäten zur Erweiterung der bestehenden Produktpipeline.





      DNAPrint genomics Inc.

      DNAPrint genomics Inc. nutzt patentierte DNA-basierende Forschungsmethoden um daraus ihre Produkte und Services zu entwickeln. Die Firma hat 2003 die Produkte ANCESTRYbyDNA™ in den Verbrauchermarkt und DNAWitness™ in den forensischen Markt eingeführt und entwickelt derzeit Produkte im Pharmacogenomics-Markt. Die Firma ist am NASDAQ OTC Bulletin Board (DNAP) und der Berliner Börse (WKN-Nummer 940906) gelistet.
      Avatar
      schrieb am 26.01.07 01:35:53
      Beitrag Nr. 197 ()
      Hallo in die Runde. Beobachte DNA schon einige Jahre. Seit knapp einem Jahr auch investiert. Interessante Bewegung in den letzten Tagen. Konstant aufwärts. Gab es bei DNA schon lange nicht mehr. Gründe? Entweder Puscherblätter die aufmerksam geworden sind und ihre Lemminge aktivieren oder aber es kommt etwas substantielles. Weiß jemand irgendwas? Verfolgt überhaupt sonst noch jemand diesen Wert (mit einer lächerlichen Marktkapitalisierung von 5 Mio.)??
      grüße
      gp
      Avatar
      schrieb am 26.01.07 08:59:33
      Beitrag Nr. 198 ()
      Antwort auf Beitrag Nr.: 27.189.131 von gameplay am 26.01.07 01:35:53Hallo gp,

      natürlich verfolge ich diesen Wert noch!
      Zwischenzeitlich bin aus Frust über den Kursverlauf und das dröge Management fast komplett ausgestiegen, aber beim Stand von 0,0075 bin ich wieder rein (und jetzt nochmal ein wenig bei 0,017).

      Ich bin mir auch nicht sicher, ob der momentane Uptrend einen realen Hintergrund hat, den wir noch nicht kennen, oder ob es mal wieder die wohlbekannten Spielchen der MMs sind, die den Kurs hochtreiben, oben verkaufen, den Kurs wieder runterprügeln und sich dann ganz unten wieder eindecken.
      Haben wir ja gerade bei diesem Wert oft genug erlebt! :mad:

      Momentan bin ich mit 300.000 shares investiert und lass die erst mal liegen. Das Traden hat nämlich bisher für mich überhaupt nix gebracht.

      Gruß Michi
      Avatar
      schrieb am 26.01.07 15:02:06
      Beitrag Nr. 199 ()
      Michiko,

      ich glaube,daß wir beide wohl am längsten in dieser Aktie drin sind.Seit 2000.
      Ich habe noch keine einzige verkauft,was bestimmt nicht gut war.
      Aber ich halte bis die Firma ein Globalplayer oder pleite ist.

      Gruß hvs1

      Frage an alle anderen,ist noch jemand solange in dieser Aktie drin?
      Avatar
      schrieb am 26.01.07 15:38:47
      Beitrag Nr. 200 ()
      Antwort auf Beitrag Nr.: 27.199.436 von hvs1 am 26.01.07 15:02:06hvs1, eines ist Dir hoffentlich klar geworden (bei mir hat`s ne Weile gedauert): Wenn irgendwo am Horizont auch nur der Verdacht auf einen Resplit auftaucht, dann lauf, so schnell Du kannst!
      Avatar
      schrieb am 26.01.07 15:52:53
      Beitrag Nr. 201 ()
      Michiko,

      solltest Du diesbzeüglich etwas mitkriegen,hoffe ich,daß Du mich informierst.Danke im voraus.

      hvs1
      Avatar
      schrieb am 26.01.07 16:11:49
      Beitrag Nr. 202 ()
      Michiko,

      sollte es heute wieder dahinlaufen,wie auch sonst war?

      hvs1
      Avatar
      schrieb am 26.01.07 17:29:50
      Beitrag Nr. 203 ()
      Antwort auf Beitrag Nr.: 27.201.201 von hvs1 am 26.01.07 16:11:49hvs1, genau diese Befürchtung habe ich schon deutlich im Qork-Thread geäußert!
      Und auch schon hier im Posting #198.

      Mehr kann ich im Moment nicht sagen.

      Falls sich die Gerüchte über eine Zusammenarbeit mit Merck bestätigen sollten - möglichst durch eine offizielle PR - dann sähe das Ding schon gleich ganz anders aus.

      Falls sich das Management aber wieder einmal - wie schon so oft - völlig ausschweigt, befürchte ich einen abermaligen Rückgang zum Subpenny!

      Gruß
      Avatar
      schrieb am 26.01.07 18:06:49
      Beitrag Nr. 204 ()
      Vielleicht ist der Rückschlag ja schon ausgestanden!?! :confused:

      http://de.advfn.com/p.php?pid=staticchart&s=NB%5EDNAG&p=0&t=…
      Avatar
      schrieb am 26.01.07 18:07:33
      Beitrag Nr. 205 ()
      Antwort auf Beitrag Nr.: 27.203.566 von Michiko am 26.01.07 18:06:49Äh . . . ich meinte natürlich:

      Avatar
      schrieb am 30.01.07 16:35:47
      Beitrag Nr. 206 ()
      Hallo Michiko,

      es ist verdammt ruhig hier.
      Hoffentlich ist es die Ruhe vor dem bald beginnenden Sturm.

      hvs1
      Avatar
      schrieb am 30.01.07 16:46:50
      Beitrag Nr. 207 ()
      Antwort auf Beitrag Nr.: 27.199.436 von hvs1 am 26.01.07 15:02:06Hallo hvs1,

      bin auch noch einer der "Oldtimer" von 2000 und habe bisher (leider) auch noch keine Stücke verkauft.

      Habe letzte Woche wieder angefangen (nach langer Zeit) eine neue Position zu kaufen.Bei meinem heutigen Kauf hatte ich 3 Teilausführungen obwohl meine Kauforder über dem Ask lag.Es ist wirklich schwierig Stücke zu bekommen.

      Gruß

      BJ
      Avatar
      schrieb am 30.01.07 17:25:18
      Beitrag Nr. 208 ()
      Hallo Blackjack 2000,

      ich grüße Dich.
      Ich hatte vorgestern eine Order über 475500 Stck reingestellt zu
      0,016 und hatte zwei Teilausführungen.Eine über 160.000,- zu 0,015
      und eine über 315.500,- zu 0,0154
      Habe meine 1M zusammen.Ich hatte vor dem Resplit 3M im Depot und
      auch leider keine einzige verkauft.
      Die Hoffunung stirbt zuletzt.Allerdings bin ich von den Produkten der Firma überzeugt.

      Gruß hvs1
      Avatar
      schrieb am 30.01.07 17:32:52
      Beitrag Nr. 209 ()
      Hallo Ihr Beiden,

      was zahlt Ihr eigentlich für Teilausführungen Eurer Orders? Jedesmal die volle Gebühr oder bei den nächsten Teilausführungen nur noch ein bißchen?
      Avatar
      schrieb am 30.01.07 17:37:02
      Beitrag Nr. 210 ()
      Michiko,

      ich order über meine Hausbank und zahle für 315.500 Stck 37,93€ Provision und 16,66€ Fremdspesen.

      Gruß hvs1
      Avatar
      schrieb am 30.01.07 17:39:18
      Beitrag Nr. 211 ()
      Michiko,

      jedes Mal die volle Gebühr.

      hvs1
      Avatar
      schrieb am 30.01.07 17:44:33
      Beitrag Nr. 212 ()
      Antwort auf Beitrag Nr.: 27.300.454 von hvs1 am 30.01.07 17:39:18hvs1, ich habe bisher bei der comdreck geordert. Auch jedesmal die volle Gebühr von knapp 30 Euro (bei kleineren Aufträgen).

      Ich habe im Laufe des Jahres 2006 insgesamt 4mal geordert und jedesmal kam zuerst eine Teilausführung über 500 Stück und dann eine weitere Ausführung über den Rest (oder einen Teil des Restes).
      Reine Gebührenabzocke! :mad:
      Ich habe mich schriftlich darüber beschwert. Die Antwort: "Da können wir garnix machen. Wir geben den Auftrag nur weiter nach Amerika.

      Ich habe jetzt zu Consors gewechselt. Da kosten die weiteren Teilausführungen z.T. nur weniger als einen Euro, bei größeren Aufträgen auch mal bis zu höchstens 5 Euro.
      Auch wenn ich mich über coco schon geärgert habe; in dieser Beziehung sind sie Klasse!

      Gruß Michi
      Avatar
      schrieb am 30.01.07 17:45:27
      Beitrag Nr. 213 ()
      Antwort auf Beitrag Nr.: 27.300.307 von Michiko am 30.01.07 17:32:52Hallo Michiko,

      auch bei mir kostet es jedes mal die volle Gebühr.
      Hatte mal 7! Teilausführungen bei einer kleinen Verkaufsorder,Gebühren 175Euro :mad:

      Bin bei Consors.

      Wie sieht es bei Dir aus?


      Gruß

      BJ
      Avatar
      schrieb am 30.01.07 17:47:25
      Beitrag Nr. 214 ()
      Antwort auf Beitrag Nr.: 27.300.582 von Blackjack2000 am 30.01.07 17:45:27Hi Blacky, wie es bei mir momentan aussieht, habe ich ja gerade gepostet. Ist das bei Consors schon ne Weile her? Im Moment bin ich mit denen sehr zufrieden!
      Oder hast Du etwa in Deutschland geordert???
      Avatar
      schrieb am 30.01.07 17:49:53
      Beitrag Nr. 215 ()
      Michiko,

      habe eben gerade Deinen Beitrag gelesen.

      Bei meinen letzten Teilausführungen musste ich noch die volle Gebühr bezahlen,ist aber auch schon 2 Jahre her.Falls sich das jetzt wirklich geändert hat,bin ich positiv überrascht von Consors.Muss erst mal warten bis ich meine Abrechnung von heute bekomme.
      Avatar
      schrieb am 30.01.07 17:51:25
      Beitrag Nr. 216 ()
      Habe natürlich direkt in USA geordert:)
      Avatar
      schrieb am 30.01.07 18:05:54
      Beitrag Nr. 217 ()
      OLMP scheint ja im Moment draußen zu sein.

      Ein gutes Zeichen! :)
      Avatar
      schrieb am 30.01.07 18:13:58
      Beitrag Nr. 218 ()
      Antwort auf Beitrag Nr.: 27.192.440 von Michiko am 26.01.07 08:59:33Hi Michiko,
      ein paar Tage nicht reingeschaut - und schon lebt dieser Thread : )
      Danke für deine Antwort. Ich habe den Wert auch schon seit 2000 auf der Liste, immer mal wieder gekauft und verkauft, meist zum falschen Zeitpunkt. Jetzt seit über einem Jahr fest dabei. Wollte eigentlich bei 0.007 / 0.008 aufstocken, aber war zu langsam.
      Für mich macht die Aktien in den letzten 2-3 Wochen einen anderen Eindruck als vorher. Es ist einfach latentes Kaufinteresse da. Immer mal wieder Gewinnmitnahmen aber dann geht es gleich weiter. Dieses Muster kenne ich von DNA eigentlich gar nicht mehr.
      Natürlich ist das alles ein Bauchgefühl und so sollte man es auch bewerten. Und natürlich sind die Umsätze lächerlich gering. 15 % Kurssteigerung bei nichtmal 23.000 Dollar gewechselte Aktien ...
      Trotzdem. Ich bleibe positiv gestimmt - immer mit einem interessiert wachsamen Auge auf Biofrontera. Das ist sozusagen die zweite Chance bei DNA.
      gruß an alle
      gp
      Avatar
      schrieb am 30.01.07 18:15:53
      Beitrag Nr. 219 ()
      Antwort auf Beitrag Nr.: 27.200.330 von Michiko am 26.01.07 15:38:47zum Thema Reverse-Split. Ich verstehe nicht wirklich, warum das immer so negativ gesehen wird. Im Grunde ist daran ja nichts Schlechtes, oder? Brutal ist es natürlich, wenn man sich im Rahmen eines Reverse-Splits das genehmigte Kapitl deart erhöhen lässt, wie DNA beim letzten Mal. Das war schlicht unglaublich. Aber abgesehen davon... was ist schlecht am Reverse-Split?
      gp
      Avatar
      schrieb am 30.01.07 18:17:24
      Beitrag Nr. 220 ()
      Antwort auf Beitrag Nr.: 27.202.878 von Michiko am 26.01.07 17:29:50und zu Merck (letztes Posting ;): Woher kommen diese Gerüchte? Ist das reine Stille Post oder gibt es da irgendwo einen Ansatz in einer Meldung, einer Kooperation, einer dieser Börsenbriefe? Das Gerücht ist bisher vollkommen an mir vorbei gerauscht :look:
      Avatar
      schrieb am 30.01.07 18:31:12
      Beitrag Nr. 221 ()
      gameplay,

      im Ragingbull gibt es ein Message Board,dort stellen User Zeitungs-
      berichte aus den USA rein.
      Merk arbeitet mit dem Moffitt-Center zusammen und Moffitt mit DNAG.
      Könnte durchaus was werden.Außerdem hat Dr. Gomez bei Merk jahre-
      lang gearbeitet.
      Kommt Zeit,kommt Rat.

      Gruß hvs1
      Avatar
      schrieb am 30.01.07 19:01:26
      Beitrag Nr. 222 ()
      Antwort auf Beitrag Nr.: 27.301.423 von gameplay am 30.01.07 18:15:53. . . also zu diesem Reverse-Split zum x-ten mal meine Klage:

      Das a/s beträgt bei DNA-Print ca. 1,5 Milliarden shares (authorized).

      Das o/s (outstanding) betrug vor dem Resplit so ca. 1,4 Milliarden, d.h. es war fast das gesamte Tafelsilber verscherbelt, es standen der Company nur noch ca. 100 Millionen shares zur Verfügung.
      Also wurde ein Resplit 1 für 20 durchgeführt! Also ging das o/s auf 70 Millionen zurück, das a/s blieb aber bei 1,5 Milliarden.
      Die Firma hatte wieder shares in Hülle und Fülle; auf ein Neues!
      (Nebenbei: Die Anteile des Managements haben sich natürlich nicht vermindert!!)

      Nachteil: Ein hvs1 hat danach statt 3 Millionen nur noch 150.000 shares. Und da erfahrungsgemäß der Kurs binnen kurzem auf den alten Wert zurückgeht, haben die Alt-Aktionäre verloren auf Teufel-komm-raus. Es sei denn, sie hätten rechtzeitig verkauft.

      Ich kann Dir in dieser Beziehung noch viel extremere Beispiele anführen, die ich selbst erlebt habe, z.B. American Jewelry Corp.

      Fazit: Wenn ich was von einem neuen Resplit höre, laufe ich weg so schnell ich kann.
      Aber vielleicht ist das ja garnicht mehr nötig! :cool:
      Avatar
      schrieb am 30.01.07 23:05:21
      Beitrag Nr. 223 ()
      Na ja, wenigstens ein Bisserl hoch im Endeffekt.
      Wir sind ja schon mit Kleinigkeiten sehr zufrieden! :cry:

      Avatar
      schrieb am 31.01.07 17:02:47
      Beitrag Nr. 224 ()
      Leutz, ist schon jemandem aufgefallen, dass wir deutlich über 16 sind!?!
      Avatar
      schrieb am 31.01.07 17:15:28
      Beitrag Nr. 225 ()
      Ja:D
      Avatar
      schrieb am 31.01.07 18:16:41
      Beitrag Nr. 226 ()
      Und mir erst!:lick:

      hvs1
      Avatar
      schrieb am 31.01.07 18:21:40
      Beitrag Nr. 227 ()
      Antwort auf Beitrag Nr.: 27.327.202 von hvs1 am 31.01.07 18:16:41hvs1, lass mich mal ein wenig spötteln:
      Bis es Dir auffällt, ist es fast schon wieder vorbei :laugh:

      Nix für ungut! :keks:

      Michi
      Avatar
      schrieb am 31.01.07 18:30:44
      Beitrag Nr. 228 ()
      Stimmt,

      aber die 0,0165 stehen wie eine eins!:rolleyes:
      Avatar
      schrieb am 31.01.07 20:20:21
      Beitrag Nr. 229 ()
      Antwort auf Beitrag Nr.: 27.327.644 von hvs1 am 31.01.07 18:30:44Volumen bis jetzt ca. 6 Millionen.

      Wenn jetzt ne schöne PR käme . . . :cool:
      Avatar
      schrieb am 01.02.07 17:51:46
      Beitrag Nr. 230 ()
      17,5 hatten wir schon lange nicht mehr :lick:

      Avatar
      schrieb am 02.02.07 01:04:35
      Beitrag Nr. 231 ()
      Antwort auf Beitrag Nr.: 27.301.811 von hvs1 am 30.01.07 18:31:12@hvs1 - Danke für die Auskunft. Auf raging bull habe ich mich früher auch oft rumgetrieben. Aber seit die von Lycos übernommen wurden... schien es mir auszusterben. Gut zu hören, dass das DNA-Board dort noch aktiv ist :D
      @Michiko: Das meinte ich. Es ist ja nicht zwingend so, dass zwar das genehmigte Kapital nicht mitgeresplitet (tolles Wort) wird. In der Dreistigkeit war es mir zumindest zum ersten Mal untergekommen.

      solong
      es geht weiter steetig bergauf
      gp
      Avatar
      schrieb am 12.02.07 16:30:17
      Beitrag Nr. 232 ()
      Michiko,

      Haß oder Liebe,

      dann bin ich für Liebe.

      hvs1:laugh:


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      DNAG: Hass oder Liebe - dazwischen geht nichts!